WO2011014925A1 - Process for obtaining peptide fractions - Google Patents
Process for obtaining peptide fractions Download PDFInfo
- Publication number
- WO2011014925A1 WO2011014925A1 PCT/AU2010/000994 AU2010000994W WO2011014925A1 WO 2011014925 A1 WO2011014925 A1 WO 2011014925A1 AU 2010000994 W AU2010000994 W AU 2010000994W WO 2011014925 A1 WO2011014925 A1 WO 2011014925A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glutaminase
- trypsin
- subtilisin
- protein
- oryzin
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 190
- 238000000034 method Methods 0.000 title claims abstract description 133
- 230000008569 process Effects 0.000 title claims abstract description 78
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 134
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 134
- 239000000758 substrate Substances 0.000 claims abstract description 112
- 235000013305 food Nutrition 0.000 claims abstract description 43
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 230000006806 disease prevention Effects 0.000 claims abstract description 6
- 102000004190 Enzymes Human genes 0.000 claims description 68
- 108090000790 Enzymes Proteins 0.000 claims description 68
- 239000000047 product Substances 0.000 claims description 59
- 102000004142 Trypsin Human genes 0.000 claims description 55
- 108090000631 Trypsin Proteins 0.000 claims description 55
- 102000009127 Glutaminase Human genes 0.000 claims description 53
- 108010073324 Glutaminase Proteins 0.000 claims description 53
- 102000002704 Leucyl aminopeptidase Human genes 0.000 claims description 49
- 108010004098 Leucyl aminopeptidase Proteins 0.000 claims description 49
- 239000012588 trypsin Substances 0.000 claims description 49
- 108090000787 Subtilisin Proteins 0.000 claims description 48
- 108090000021 oryzin Proteins 0.000 claims description 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 47
- 239000000284 extract Substances 0.000 claims description 23
- 238000012360 testing method Methods 0.000 claims description 23
- 238000000502 dialysis Methods 0.000 claims description 18
- 230000004071 biological effect Effects 0.000 claims description 17
- 238000004255 ion exchange chromatography Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 150000001768 cations Chemical class 0.000 claims description 12
- 235000015872 dietary supplement Nutrition 0.000 claims description 12
- 230000007935 neutral effect Effects 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 208000012902 Nervous system disease Diseases 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 235000013372 meat Nutrition 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 150000001450 anions Chemical class 0.000 claims description 6
- 238000005341 cation exchange Methods 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 6
- 239000008267 milk Substances 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 238000005349 anion exchange Methods 0.000 claims description 5
- 238000005374 membrane filtration Methods 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 229940041514 candida albicans extract Drugs 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 239000012138 yeast extract Substances 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 3
- 201000002832 Lewy body dementia Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000009106 Shy-Drager Syndrome Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 201000000053 blastoma Diseases 0.000 claims description 3
- 201000008184 embryoma Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 description 124
- 230000005764 inhibitory process Effects 0.000 description 69
- 230000000694 effects Effects 0.000 description 66
- 229940088598 enzyme Drugs 0.000 description 65
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 56
- 238000003556 assay Methods 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- 238000006460 hydrolysis reaction Methods 0.000 description 44
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 42
- 230000007062 hydrolysis Effects 0.000 description 41
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 39
- 241000283690 Bos taurus Species 0.000 description 34
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 33
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 31
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 31
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 28
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 28
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 27
- 238000002360 preparation method Methods 0.000 description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 244000062793 Sorghum vulgare Species 0.000 description 23
- 239000012528 membrane Substances 0.000 description 23
- 235000019713 millet Nutrition 0.000 description 23
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 23
- 102000007544 Whey Proteins Human genes 0.000 description 22
- 108010046377 Whey Proteins Proteins 0.000 description 22
- 238000005194 fractionation Methods 0.000 description 21
- 108010009736 Protein Hydrolysates Proteins 0.000 description 19
- 239000011780 sodium chloride Substances 0.000 description 19
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 18
- 241000700159 Rattus Species 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 18
- 239000000463 material Substances 0.000 description 17
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 16
- 235000013365 dairy product Nutrition 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 239000000872 buffer Substances 0.000 description 15
- 239000003531 protein hydrolysate Substances 0.000 description 15
- 102000005158 Subtilisins Human genes 0.000 description 14
- 108010056079 Subtilisins Proteins 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 108010074328 Interferon-gamma Proteins 0.000 description 13
- 235000021245 dietary protein Nutrition 0.000 description 13
- 239000000413 hydrolysate Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 235000021119 whey protein Nutrition 0.000 description 13
- 102100037850 Interferon gamma Human genes 0.000 description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
- 230000003110 anti-inflammatory effect Effects 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 238000009739 binding Methods 0.000 description 12
- 239000006041 probiotic Substances 0.000 description 12
- 230000000529 probiotic effect Effects 0.000 description 12
- 235000018291 probiotics Nutrition 0.000 description 12
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 11
- 235000013330 chicken meat Nutrition 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 11
- -1 for example Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 241000287828 Gallus gallus Species 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 239000004627 regenerated cellulose Substances 0.000 description 10
- AAXWBCKQYLBQKY-IRXDYDNUSA-N (2s)-2-[[(2s)-2-[(2-benzamidoacetyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)C=1C=CC=CC=1)C1=CN=CN1 AAXWBCKQYLBQKY-IRXDYDNUSA-N 0.000 description 9
- 235000010469 Glycine max Nutrition 0.000 description 9
- 239000005862 Whey Substances 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 9
- 125000000129 anionic group Chemical group 0.000 description 9
- 125000002091 cationic group Chemical group 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 108010016268 hippuryl-histidyl-leucine Proteins 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 241000251468 Actinopterygii Species 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 108010076119 Caseins Proteins 0.000 description 8
- 102000011632 Caseins Human genes 0.000 description 8
- 108010068370 Glutens Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000000975 bioactive effect Effects 0.000 description 8
- 229940071162 caseinate Drugs 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 235000019688 fish Nutrition 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000009897 systematic effect Effects 0.000 description 8
- 102000035195 Peptidases Human genes 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 235000009337 Spinacia oleracea Nutrition 0.000 description 7
- 244000300264 Spinacia oleracea Species 0.000 description 7
- 235000021307 Triticum Nutrition 0.000 description 7
- 241000209140 Triticum Species 0.000 description 7
- 108010051873 alkaline protease Proteins 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 235000013339 cereals Nutrition 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000012465 retentate Substances 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 244000251953 Agaricus brunnescens Species 0.000 description 6
- 102000008873 Angiotensin II receptor Human genes 0.000 description 6
- 108050000824 Angiotensin II receptor Proteins 0.000 description 6
- 235000016425 Arthrospira platensis Nutrition 0.000 description 6
- 240000002900 Arthrospira platensis Species 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 230000003276 anti-hypertensive effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 235000020246 buffalo milk Nutrition 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 210000003746 feather Anatomy 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 108060006613 prolamin Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000011492 sheep wool Substances 0.000 description 6
- 229940082787 spirulina Drugs 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 5
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 235000019687 Lamb Nutrition 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 240000006394 Sorghum bicolor Species 0.000 description 5
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 5
- 238000013019 agitation Methods 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 235000015278 beef Nutrition 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 5
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 108010007119 flavourzyme Proteins 0.000 description 5
- 235000013312 flour Nutrition 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000005342 ion exchange Methods 0.000 description 5
- 239000003456 ion exchange resin Substances 0.000 description 5
- 229920003303 ion-exchange polymer Polymers 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000001338 self-assembly Methods 0.000 description 5
- 235000020254 sheep milk Nutrition 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 235000021246 κ-casein Nutrition 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 208000006168 Ewing Sarcoma Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000005905 Hydrolysed protein Substances 0.000 description 4
- 102000000704 Interleukin-7 Human genes 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 108010063045 Lactoferrin Proteins 0.000 description 4
- 102000010445 Lactoferrin Human genes 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- 235000021277 colostrum Nutrition 0.000 description 4
- 210000003022 colostrum Anatomy 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 4
- 229940078795 lactoferrin Drugs 0.000 description 4
- 235000021242 lactoferrin Nutrition 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 108010020132 microbial serine proteinases Proteins 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 235000015277 pork Nutrition 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 235000019833 protease Nutrition 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229960004418 trolamine Drugs 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 210000005253 yeast cell Anatomy 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- ZDLZKMDMBBMJLI-FDMDGMSGSA-N 2-[[2-[[(2s)-2-[[(e)-3-(furan-2-yl)prop-2-enoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]acetic acid Chemical compound C([C@@H](C(=O)NCC(=O)NCC(=O)O)NC(=O)\C=C\C=1OC=CC=1)C1=CC=CC=C1 ZDLZKMDMBBMJLI-FDMDGMSGSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 108010048632 2-furanacryloyl-phenylalanyl-glycyl-glycine Proteins 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 240000001592 Amaranthus caudatus Species 0.000 description 3
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 3
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 235000019733 Fish meal Nutrition 0.000 description 3
- 108010058643 Fungal Proteins Proteins 0.000 description 3
- 240000005979 Hordeum vulgare Species 0.000 description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 description 3
- 102000004157 Hydrolases Human genes 0.000 description 3
- 108090000604 Hydrolases Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 101710118538 Protease Proteins 0.000 description 3
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 3
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 3
- 102000003667 Serine Endopeptidases Human genes 0.000 description 3
- 108090000083 Serine Endopeptidases Proteins 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 235000012735 amaranth Nutrition 0.000 description 3
- 239000004178 amaranth Substances 0.000 description 3
- 230000003941 amyloidogenesis Effects 0.000 description 3
- 229950006323 angiotensin ii Drugs 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000008236 biological pathway Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940072440 bovine lactoferrin Drugs 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000021196 dietary intervention Nutrition 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000004467 fishmeal Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- XXRYFVCIMARHRS-UHFFFAOYSA-N propan-2-yl n-dimethoxyphosphorylcarbamate Chemical compound COP(=O)(OC)NC(=O)OC(C)C XXRYFVCIMARHRS-UHFFFAOYSA-N 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229940001941 soy protein Drugs 0.000 description 3
- 239000004458 spent grain Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- QSMRHXUZHXEHBK-AWEZNQCLSA-N (2s)-2-[3-(furan-2-yl)prop-2-enoylamino]-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)C=CC=1OC=CC=1)C1=CC=CC=C1 QSMRHXUZHXEHBK-AWEZNQCLSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 102000004400 Aminopeptidases Human genes 0.000 description 2
- 108090000915 Aminopeptidases Proteins 0.000 description 2
- 108010094108 Amyloid Proteins 0.000 description 2
- 102000001049 Amyloid Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000981399 Aspergillus melleus Species 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010073032 Grain Proteins Proteins 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000037276 Primitive Peripheral Neuroectodermal Tumors Diseases 0.000 description 2
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 2
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 229940100994 interleukin-7 Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 229960004773 losartan Drugs 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000009931 pascalization Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 208000016802 peripheral primitive neuroectodermal tumor Diseases 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 201000003804 salivary gland carcinoma Diseases 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000013300 spontaneous hypertensive rat model Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101710150620 Anionic peptide Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000131314 Aspergillus candidus Species 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 101001047738 Aspergillus oryzae (strain ATCC 42149 / RIB 40) probable leucine aminopeptidase 2 Proteins 0.000 description 1
- 241000981365 Aspergillus sulphureus Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 102100021257 Beta-secretase 1 Human genes 0.000 description 1
- 101710150192 Beta-secretase 1 Proteins 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- DWGWCWDDNTVOGF-UHFFFAOYSA-N Cl.Cl.Cl.Cl.Cl.Cl Chemical compound Cl.Cl.Cl.Cl.Cl.Cl DWGWCWDDNTVOGF-UHFFFAOYSA-N 0.000 description 1
- 101710140722 Cocoonase Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000160765 Erebia ligea Species 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101000757797 Geobacillus stearothermophilus Aminopeptidase 2 Proteins 0.000 description 1
- 102100025961 Glutaminase liver isoform, mitochondrial Human genes 0.000 description 1
- 101710138819 Glutaminase liver isoform, mitochondrial Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000000209 Isaacs syndrome Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FORGMRSGVSYZQR-YFKPBYRVSA-N L-leucinamide Chemical compound CC(C)C[C@H](N)C(N)=O FORGMRSGVSYZQR-YFKPBYRVSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 101001117478 Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) Aspergillopepsin-1 Proteins 0.000 description 1
- 206010072359 Neuromyotonia Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 101710180958 Putative aminoacrylate hydrolase RutD Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 101000733766 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Aminopeptidase 2, mitochondrial Proteins 0.000 description 1
- 108010083387 Saralasin Proteins 0.000 description 1
- 101000733770 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Aminopeptidase 1 Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 108010038346 Seaprose S Proteins 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710085616 Subtilisin BL Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 102100023634 Zona pellucida sperm-binding protein 3 Human genes 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000000584 angiotensin II type 2 receptor blocker Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000006937 anti-inflammatory bioactivity Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000027625 autoimmune inner ear disease Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 108010059677 colistinase Proteins 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000011188 deamidation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 108090000283 dipeptidyl peptidase III Proteins 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 108010043837 egg surface sperm receptor Proteins 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006529 extracellular process Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 235000020993 ground meat Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000009675 homeostatic proliferation Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 239000012500 ion exchange media Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000002655 kraft paper Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 108010003855 mesentericopeptidase Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000006959 non-competitive inhibition Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229950010534 promelase Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 108010043535 protease S Proteins 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- PFGWGEPQIUAZME-NXSMLHPHSA-N saralasin Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)C1=CC=C(O)C=C1 PFGWGEPQIUAZME-NXSMLHPHSA-N 0.000 description 1
- 229960004785 saralasin Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 108010004307 subtilisin J Proteins 0.000 description 1
- ACTRVOBWPAIOHC-XIXRPRMCSA-N succimer Chemical compound OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000006967 uncompetitive inhibition Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a process for isolating one or more peptide fractions from a protein substrate.
- the invention also relates to isolated peptide fractions and their use in food and drink products and for the treatment or prevention of disease.
- bioactive peptides and protein hydrolysates containing such bioactive peptides include hydrolysates obtained by incubation of protein substrates with probiotic bacteria or enzymes obtained from such bacteria as well as specific tripeptides obtained by fermentation of Lactobacillus which inhibit angiotensin-converting enzyme (ACE).
- ACE angiotensin-converting enzyme
- the present inventors have found that food proteins can be hydrolysed by safe and food grade enzymes in a food-compatible process to yield peptide products that are not otherwise released by digestion.
- peptide fractions are produced that are stable to intestinal digestion and which have biological activity.
- the present invention provides a process for obtaining a peptide fraction, the process comprising:
- the present invention provides a process for obtaining a peptides obtained from step i) which are less than about 11 kDa.
- the present invention provides a process for obtaining a peptides obtained from step i) which are less than about 11 kDa.
- step i) comprises contacting the protein substrate with a series
- the process further comprises: iii) separating the peptides which are less than about 11 kDa into one or more of cation, anion and/or neutral peptide fractions.
- the peptides are separated into one or more of cation, anion and/or neutral peptide fractions by ion- exchange chromatography.
- the ion-exchange chromatography is performed using cation and anion exchange columns in series.
- the ion-exchange chromatography may be performed at any suitable pH, preferably, the ion-exchange chromatography is performed at about pH 6.0 to about pH 8.0. In one particular embodiment, the ion-exchange chromatography is performed at about pH 7.4.
- the step ii) is performed by dialysis, membrane filtration or size-exclusion chromatography.
- the protein substrate may be any suitable substance that contains protein, for example a food or food protein including animal, plant or microbial proteins, or a non- food animal, plant or microbial protein, or a waste product or by-product from a process.
- the protein substrate is a protein-rich extract.
- the protein-rich extract is a milk extract, meat extract, plant extract, yeast extract and/or bacterial extract.
- the protein-rich extract is a protein hydrolysate.
- High pressure treatment exposes protein domains to hydrolysis that would not otherwise be exposed.
- the protein substrate may be high pressure treated prior to contacting the protein substrate with the series of enzymes.
- the protein substrate may be high pressure treated at about 400 MPa to about 800 MPa for about 15 minutes to about 1 hour.
- the protein substrate is high pressure treated at about 600 MPa for about 30 minutes.
- the protein substrate is contacted with the series of enzymes glutaminase, subtilisin, oryzin, leucyl aminopeptidase, and trypsin, wherein the protein substrate is selected from fish, soy flour, yeast, pork, beef, chicken, lamb, bovine caseinate, spinach, sheep milk, buffalo milk, spirulina, mushroom, bovine lactoferrin, bovine colostrum, millet, sheep wool, barley, sorghum, amaranth, probiotic microorganisms and bovine whey protein.
- the protein substrate is contacted with the series of enzymes glutaminase, oryzin, subtilisin, leucyl aminopeptidase, and trypsin, wherein the protein substrate is selected from bovine caseinate, bovine whey protein, fish, soy flour, yeast, pork, beef, chicken, lamb, spinach, sheep milk, buffalo milk, bovine lactoferrin, bovine colostrum, chicken feather, millet, probiotic organisms, and spirulina.
- the protein substrate is contacted with the series of enzymes glutaminase, leucyl aminopeptidase, oryzin, subtilisin, and trypsin, wherein the protein substrate is selected from bovine caseinate, bovine whey protein, lactoferrin, fish, soy flour, yeast, beef, chicken, lamb, spinach, spirulina, sheep wool, probiotic organisms, and buffalo milk.
- the process of the invention further comprises isolating one or more peptides from the peptide fraction.
- the process further comprises testing the peptide fraction and/or isolated peptide for biological activity.
- the process may comprise testing the peptide fraction and/or peptide for biological activity selected from angiotensin converting enzyme (ACE) inhibition activity, angiotensin II receptor inhibition activity, anti-inflammatory activity, fibril inhibition activity, beta-secretase I inhibition activity, and inhibition of receptor for advanced glycation endproduct-mediated inflammation activity.
- ACE angiotensin converting enzyme
- the protein substrate is selected from bovine caseinate, bovine whey protein, lactoferrin, fish, soy flour, yeast, pork, beef, chicken, and lamb, and the peptide fraction obtained by the process has angiotensin converting enzyme (ACE) inhibition activity.
- ACE angiotensin converting enzyme
- the protein substrate is selected from bovine caseinate, bovine whey protein, sheep milk, buffalo milk, spinach, and spirulina, and the peptide fraction obtained by the process of the invention has angiotensin II receptor inhibition activity.
- the protein substrate is selected from bovine whey protein and yeast, and the peptide fraction obtained by the process of the invention has anti-inflammatory activity.
- the protein substrate is selected from bovine caseinate, bovine lactoferrin, bovine colostrum, bovine whey protein, sheep milk, buffalo milk, millet, sheep wool, chicken feather, barley, sorghum, amaranth, mushroom, wheat, and wheat gluten, and the peptide fraction obtained by the process of the invention has fibril inhibition activity.
- the protein substrate is probiotic microorganisms, and the peptide fraction obtained by the process of the invention has beta-secretase I inhibition activity.
- the present invention provides a peptide fraction obtained by the process of the invention.
- the peptide fraction obtained by the process of the invention may be a mixture of charged and neutral peptides.
- the peptide fraction may be a cation or anion peptide fraction.
- the peptide fraction of the invention is a cation peptide fraction at about pH 7.4.
- the peptide fraction of the invention has biological activity.
- the biological activity is selected from angiotensin converting enzyme (ACE) inhibition activity, angiotensin II receptor inhibition activity anti-inflammatory activity, fibril inhibition activity, beta-secretase I inhibition activity, and inhibition of receptor for advanced glycation endproduct-mediated inflammation activity.
- ACE angiotensin converting enzyme
- the present invention provides a composition comprising the peptide fraction of the invention.
- the present invention provides use of the peptide fraction of the invention or the composition of the invention in the manufacture of a food or drink product.
- the food or drink product is a nutritional supplement.
- the present invention provides a food or drink product comprising the peptide fraction of the invention or the composition of the invention.
- the present invention further provides use of the peptide fraction of the invention or the composition of the invention in the manufacture of a medicament for the treatment or prevention of disease in a subject.
- the present invention provides a method for the treatment or prevention of disease in a subject, the method comprising administering to the subject the peptide fraction of the invention or the composition of the invention.
- the disease is selected from cardiovascular disease, cancer, inflammatory or autoimmune disease, and/or a neurological disorder.
- the disease is selected from cardiovascular disease and cancer.
- the cardiovascular disease that is treated or prevented is selected from hypertension, atherosclerosis and arteriosclerosis.
- the cancer is selected from carcinoma, lymphoma, blastoma, sarcoma, and leukemia.
- the cancer is selected from breast cancer, prostate cancer, colon cancer, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, liver cancer, bladder cancer, hepatoma, colorectal cancer, uterine cervical cancer, endometrial carcinoma, salivary gland carcinoma, mesothelioma, kidney cancer, vulval cancer, thyroid cancer, hepatic carcinoma, skin cancer, melanoma, brain cancer, neuroblastoma, myeloma, various types of head and neck cancer, acute lymphoblastic leukemia, acute myeloid leukemia, Ewing sarcoma and peripheral neuroepithelioma.
- the inflammatory or autoimmune disease is selected from asthma, rheumatoid arthritis, inflammatory bowel disease, psoriasis and multiple sclerosis.
- the neurological disorder is selected from Alzheimer's disease, Parkinson's disease, dementia, Huntington's disease, Shy-Drager syndrome, progressive supranuclear palsy, Lewy body disease and amyotrophic lateral sclerosis.
- the present invention further provides a peptide fraction of the invention, wherein the peptide fraction is a cation peptide fraction at about pH 7.4, and the peptide fraction was obtained by contacting bovine whey protein isolate with the series of enzymes glutaminase, oryzin, subtilisin, leucyl aminopeptidase, and trypsin.
- the present invention further provides a peptide fraction of the invention, wherein the peptide fraction was obtained from a protein substrate comprising mushroom, and the protein substrate was contacted with the series of enzymes glutaminase, subtilisin, oryzin, leucyl aminopeptidase, and trypsin.
- FIGURE 1 Effects of feeding Spontaneous Hypertensive rats with lead dairy anti-hypertensive product versus commercial hydrolysate DH 17, showing (a) rat body masses and (b) tailcuff systolic blood pressures measured at fortnightly intervals over treatment period, starting with rats at 2 weeks of age.
- FIGURE 2 Effects of feeding Spontaneous Hypertensive rats with PO 147 at 200 mg/kg/day, showing (a) rat body masses and (b) tailcuff systolic blood pressures measured at fortnightly intervals over treatment period, starting with rats at 2 weeks of age.
- FIGURE 3 Inhibition kinetics by Lineweaver-Burk plot for control and lead products: (a) NaCl, (b) P0148 from bovine whey, (c) P0147 from bovine whey and (d) P0052 from bovine caseinate; (e) P0609 from sheep whey and (f) P0498 from soy protein, after concentration of the active fraction by Cl 8 Solid Phase Extraction (SPE).
- SPE Solid Phase Extraction
- FIGURE 4 Transmission Electron microscopic imaging of effects of A ⁇ 42 in the absence (a: A ⁇ 42 control incubated for 80 hr at minus 18 0 C; b: A ⁇ 42 control incubated for 80 hr (48 h at 37 0 C, then to 80 hr at 2O 0 C)) or presence (c: A ⁇ 42 +
- BM0263-SPE40 incubated for 80 hr at minus 18 0 C (note scale difference from other images); d: A ⁇ 42 + BM0263-SPE40 incubated for 80 hr (48 h at 37 0 C, then to 80 hr at
- FIGURE 5 ThT fluorescence monitoring showing effects of selected inhibitors on further fibril growth, in the presence of pre-formed fibrils of A ⁇ 42 (0.043 mg/ml, after 52 hr at 37 0 C) and similar pre-formed fibrils of A ⁇ 42 in the presence of (a)
- P0263-SPE40 (millet at 0.17 mg/ml) and (b) BM0263-SPE40 (button mushroom at 0.17 mg/ml).
- FIGURE 6 Reverse Phase HPLC profiles of SPE40 and SPElOO sub-fractions of P0147.
- FIGURE 7 Modulation of RCM-kCn fibrils by SPE fractions of PO 147, as monitored by RCM-kCn fibril inhibition assay.
- FIGURE 8 Concentration-dependent modulation of A ⁇ 42 toxicity to yeast by
- FIGURE 9 CD profiles of human A ⁇ 42 (sample subtracted) in the absence and presence of (a) SPE40 and (b) SPElOO fractions of PO 147 after incubation at 3O 0 C for 2O h.
- FIGURE 10 Western Blot analysis of A ⁇ 42+P0147 mixtures after incubation at 3O 0 C for 20 h. Freshly prepared A ⁇ 42 (10 ⁇ M final) was incubated at with increasing concentrations of P0147-SPE40+SPE100 (Lanes 1-4: 0.1, 0.05, 0.01 and 0 mg/ml, respectively), and visualized by 6E10 antibody immunoblotting.
- FIGURE 11 Transmission Electron microscopy of (a) A ⁇ 42 alone; (b) A ⁇ 42 and P0147-SPE total and (c) P0147-SPE total alone, each incubated at 3O 0 C for 20 hr.
- the recombinant protein, cell culture, and immunological techniques utilized in the present invention are standard procedures, well known to those skilled in the art. Such techniques are described and explained throughout the literature in sources such as, J. Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons (1984), J. Sambrook et al, Molecular Cloning: A Laboratory Manual, 3 rd edn, Cold Spring Harbour Laboratory Press (2001), R. Scopes, Protein Purification - Principals and Practice, 3 edn, Springer (1994), T. A. Brown (editor), Essential Molecular Biology: A Practical Approach, Volumes 1 and 2, IRL Press (1991), D.M. Glover and B.D.
- protein substrate refers to any substance which comprises protein.
- the protein substrate may be, for example, food or may contain food proteins, for example animal, plant or microbial proteins, or the protein substrate may be a non-food substrate such as, for example, a non-food animal, plant or microbial protein, or a waste product or by-product from a process.
- the protein substrate may include proteins from dairy, for example milk or milk protein, or from meat, vegetable, grain, yeast or bacteria.
- peptide as used herein is typically used to refer to chains of amino acids which are not large, for instance 100 or less residues in length.
- peptide fraction will be understood to indicate a fraction of a hydro lysed protein substrate that contains peptides that may be of different lengths.
- the "peptide fraction” may also include non-peptide components such as, for example, free amino acids, carbohydrates or lipids.
- the term "subject" relates to an animal.
- the subject is a mammal such as a human, or a companion animal such as a dog or cat, or a livestock animal such as horse, cow, pig or sheep.
- the subject may be avian, for example, poultry such as a chicken, turkey or duck.
- the subject is a human.
- administering as used herein is to be construed broadly and includes administering a peptide fraction as described herein to a subject as well as providing a peptide fraction as described herein to a cell.
- treating include administering a therapeutically effective amount of a peptide fraction as described herein sufficient to reduce or delay the onset or progression of specified disease, or to reduce or eliminate at least one symptom of the disease.
- preventing include administering a therapeutically effective amount of a peptide fraction sufficient to stop or hinder the development of at least one symptom of the specified condition.
- a substance comprising protein may be desirable to process protein substrates that have relatively low protein content, such as plant materials, to form a protein-rich extract.
- plant materials may first be homogenized and treated to remove or reduce the amount of non-protein constituents such as cellulose.
- Seed grains may optionally be homogenized and proteins such as albumins, glutelins and prolamins extracted by known techniques prior to use as a protein substrate.
- proteins such as albumins, glutelins and prolamins extracted by known techniques prior to use as a protein substrate.
- probiotic microorganisms it is preferred that they are lysed prior to use as a protein substrate in the process of the invention.
- the probiotic microorganisms may be lysed using known techniques, for example, by French pressing.
- a substance such as a food containing protein may first be minced or chopped and then finely ground to form a protein substrate.
- Other additional or alternative treatments include high pressure treatment, oven drying and/or freeze drying prior to use of the substance as a protein substrate in the process of the invention.
- the protein-rich extract may also be a protein hydrolysate.
- protein hydrolysates suitable for use in the process of the invention include hydrolysates of native food proteins, such as soy proteins, dairy proteins (e.g., whey, casein), wheat proteins, canola proteins, corn proteins, vegetable proteins, grain proteins, animal proteins, yeast proteins, including those available from commercial sources, for example, hydrolysates such as wheat hydrolysate (Gempr HiQ) from Manildra Group, NSW, Australia, hydrolysates such as bovine whey hydrolysate (DH 17) from Myopure, NSW, Australia, and hydrolysates such as rice protein hydrolysate (Hyprol 8115) from Quest International, the Netherlands. Although these protein hydrolysates have been at last partially broken down or digested either by processing or enzymatic cleavage, they still serve as substrates for the enzymes used in the process of the present invention.
- the hydrolysates may be desalted using known techniques such as dialysis prior to use as a protein substrate in the process of the invention. If desired, other substances, for example, milk or skim milk, may also be desalted prior to use as a protein substrate.
- Non-limiting examples of protein substrates suitable for use in the process of the invention include bovine proteins such as bovine caseinate, bovine casein hydrolysate bovine whey protein, wheat, wheat hydrolysate, wheat gluten hydrolysate, soy, soy hydrolysate, soy flour, rice protein hydrolysate, pea protein hydrolysate, milk including cow, buffalo and sheep milk, lactoferrin, fishmeal, fish meat, yeast, yeast extract, pork, beef, chicken meat, chicken feathers, egg or egg proteins, lamb, spinach, spirulina, millet, barley, brewer's spent grain, sheep wool, sorghum, amaranth, mushroom, or probiotic cultures of microorganisms.
- bovine proteins such as bovine caseinate, bovine casein hydrolysate bovine whey protein, wheat, wheat hydrolysate, wheat gluten hydrolysate, soy, soy hydrolysate, soy flour, rice protein hydrolysate, pea protein hydrolysate, milk
- the protein substrate need only contain protein to be useful in the process of the invention, preferably the protein substrate comprises at least 5% protein, or more preferably at least 10%, 20%, 30%, 40%, or 50% or more protein.
- the present inventors have advantageously identified a combination of food- compatible enzymes that yield peptide fractions that may not otherwise be released by digestion.
- the enzymes the protein substrate is processed with are glutaminase, subtilisin, oryzin, leucyl aminopeptidase and trypsin.
- Use of these exo and endo proteases and peptidases in different sequential combinations generates peptides fractions with variation of terminal amino acids.
- These peptide fractions, that are produced by hydrolysis of the protein substrate in series advantageously have anti-disease, nutritional or other desirable properties.
- Glutaminase is a hydrolase which acts on carbon nitrogen bonds other than peptide bonds. When reacted with a protein substrate, glutaminase converts glutamine residues to glutamic acid in a deamidation reaction. Enzymes with this activity have been classified as EC 3.5.1.2. Synonyms for glutaminase include glutaminase I, L- glutaminase, and glutamine aminohydrolase. Glutaminase is commercially available and can be obtained, for example, from Daiwa Kasei K.K. Shiga, Japan.
- Subtilisin is a serine endopeptidase with broad specificity for peptide bonds, but with a preference for cleavage at glutamic acid residues and also hydrolyses peptide amides. Enzymes with this activity have been classified as EC 3.4.21.62.
- subtilisin alternatives names for subtilisin include alcalase, alcalase 0.6L, alcalase 2.5L, alcalase 2.4 L FG, ALK-enzyme, bacillopeptidase A, bacillopeptidase B, Bacillus subtilis alkaline proteinase, bioprase AL 15, bioprase APL 30, colistinase, subtilisin J, subtilisin S41, subtilisin Sendai, subtilisin GX, subtilisin E, subtilisin BL, genease I, esperase, maxatase, thermoase PC 10, protease XXVII, superase, subtilisin DY, subtilopeptidase, SP 266, savinase 8.0L, savinase 4.0T, kazusase, protease VIII, opticlean, protin A 3L, savinase 16.0L, savinase 32.0L EX, orient
- Oryzin is a serine endopeptidase which acts on peptide bonds and hydrolyses proteins with broad specificity. Enzymes with this activity have been classified as EC 3.4.21.63.
- Alternative names for oryzin include Aspergillus alkaline proteinase, aspergillopeptidase B, API 21, aspergillopepsin B, aspergillopepsin F, Aspergillus candidus alkaline proteinase, Aspergillus flavus alkaline proteinase, Aspergillus melleus semi-alkaline proteinase, Aspergillus oryzae alkaline proteinase, Aspergillus serine proteinase, Aspergillus sydowi alkaline proteinase, Aspergillus soya alkaline proteinase, Aspergillus melleus alkaline proteinase, Aspergillus sulphureus alkaline proteinase, prozyme,
- Leucyl aminopeptidase is a hydrolase that acts on peptide bonds to release an N- terminal amino acid from XaaYaa in which Xaa is preferably Leu, but may be other amino acids including Pro, although not Arg or Lys, and Yaa may be proline. Enzymes with this activity are classified as EC 3.4.11.1.
- leucyl aminopeptidase examples include leucine aminopeptidase, leucyl peptidase, peptidase S, cytosol aminopeptidase, cathepsin III, L-Leucine aminopeptidase, leucinamide aminopeptidase, FTBL proteins, proteinates FBTL, aminopeptidase I, aminopeptidase II, aminopeptidase III.
- Leucyl aminopeptidase is commercially available and can be obtained from, for example, Novozymes, Bagsvaerd, Denmark under the tradename Flavourzyme.
- Trypsin is a serine endopeptidase which acts on peptide bonds and preferentially cleaves arginine and lysine. Enzymes with this activity are classified as EC 3.4.21.4. Alternative names for trypsin include alpha-trypsin, beta-trypsin, cocoonase, parenzyme, parenzymol, tryptar, trypure, pseudotrypsin, tripcellim and sperm receptor hydrolase. Trypsin is commercially available and can be obtained, for example, from Novozymes.
- the protein substrate may be completely hydrolysed by a given enzyme, the person skilled in the art would understand that in some instances a given enzyme may only at least partially hydrolyse the protein substrate.
- the protein substrate is first contacted with glutaminase to achieve conversion of glutamine residues to glutamic acid, thereby increasing the anionic character of peptides at physiological pH.
- Contacting a protein substrate with glutaminase also allows for the production of peptides having potentially enhanced biological activity.
- the protein substrate that has been at least partially hydrolysed by glutaminase is then contacted with the other hydrolytic enzymes in series.
- the final enzyme with which the partially hydrolysed protein substrate is contacted is trypsin.
- trypsin as a final enzyme advantageously achieves digestive stability of the peptide fraction produced by the process of the invention and which contains a heterogeneous mixture of peptides.
- subtilisin, oryzin and leucyl aminopeptidase may be used in any order so as to produce heterogeneity in peptide length, sequence and biological activity.
- the protein substrate is contacted with the enzymes in a series selected from:
- glutaminase, subtilisin, oryzin, leucyl aminopeptidase, and trypsin b) glutaminase, oryzin, subtilisin, leucyl aminopeptidase, and trypsin, and c) glutaminase, leucyl aminopeptidase, oryzin, subtilisin, and trypsin.
- a suitable buffer for hydrolysis with the aforementioned enzymes, protein substrates or processed products thereof are dissolved or suspended in a suitable buffer.
- buffers that are suitable for hydrolysis are well known to those skilled in the art and include Tris, triethanolamine (TEA), sodium borate, PBS, HEPES amongst other well known buffers. Determining a suitable buffer, its concentration and pH for performing hydrolysis is a matter of routine for the person skilled in the art.
- the pH of the buffer will fall within the range of pH 6.0 to pH 9.0, but preferably will be about pH 6.0 to about pH 8.0, and in one embodiment is about pH 7.4.
- the buffer may also comprise other components such as cofactors or small quantities of organic solvent to increase the solubility of the protein substrate.
- a buffer suitable for use in the process of the present invention is 10 mM TEA, 10% ethanol, pH 7.4.
- the amount of protein in the protein substrate suspension or solution may vary.
- the solution or suspension may contain about 5% to about 25% protein (w/w), or preferably about 10% to about 20% protein (w/w).
- Other reaction conditions such as reaction time and incubation temperature can be readily determined by the skilled person.
- a protein substrate may be reacted with each enzyme for a period from about 5 minutes to about 24 hours, preferably about 30 minutes to 2 hours. In one embodiment, the protein substrate is reacted with each enzyme for about 1 hour.
- the temperature of the hydrolysis reaction will depend on the particular enzyme that is being reacted with the protein substrate.
- glutaminase, leucyl aminopeptidase, subtilisin and oryzin may be reacted with the protein substrate at about 45°C to about 55 0 C, preferably at about 50 0 C.
- the temperature of the reaction is preferably about 37°C and the reaction is an hour or more, or alternatively at least 2, 3, 5, 10 or more hours.
- An exemplary hydrolysis reaction suitable for use in the process of the present invention involves dissolving or suspending a protein substrate or processed product thereof at about 10% total protein (w/w) in 10 mM TEA, 10% EtOH, pH 7.4 and maintained at pH 7.4 throughout the hydrolysis process.
- the first enzyme for example, Glutaminase may be added to a final concentration of 0.5% (w/w) and incubated with agitation at 50 0 C for 1 hour.
- subtilisin (Alcalase) (0.5%, w/w), oryzin (Corolase) (0.5%, w/w) and leucyl aminopeptidase (Flavourzyme) (0.5%, w/w) may be subsequently introduced sequentially at 1 hr intervals at 50 0 C, according to one of 3 possible sequences.
- trypsin (0.5%, w/w) may be introduced to the mixture and incubated at 37°C for 17 hours (overnight). Following hydrolysis, the enzymes may be inactivated, for example, by heating at 90 0 C for 30 min.
- each of the enzymes is added to the reaction mixture sequentially, with each enzyme at least partially hydrolysing the protein substrate prior to the addition of the next enzyme.
- the enzymes are not heat inactivated before the addition of the next enzyme in the series.
- the partially hydrolysed protein substrate is not isolated or purified between each reaction with a different enzyme. The skilled person would understand, however, that following the at least partial hydrolysis of the protein substrate with an enzyme, the enzyme could be heat inactivated prior to the addition of the next enzyme in the series. Alternatively, if desired, the at least partially hydrolysed protein substrate could be isolated or purified prior to contacting the substrate with the next enzyme in the series.
- peptides of about 11 kDa or less are selected.
- the process of the invention involves selecting peptides about 8 kDa or less.
- peptides of about 11 kDa or less may be selected by dialysis, membrane filtration or size-exclusion chromatography.
- Recovery of a peptide fraction by dialysis may be achieved by performing dialysis of the hydrolysate with a suitable dialysis membrane such as a regenerated cellulose or cellulose ester dialysis tubing with an appropriate molecular weight cut-off.
- Membrane filtration is a process for separating small particles and dissolved molecules from fluids and is suited to the selection of peptides about 11 kDa or less.
- a membrane's pore size rating typically given as a micron value, indicates that peptides, proteins or other molecules larger than the rating will be retained.
- Ultrafiltration membranes which are particularly suited to selecting peptides are rated according to the nominal molecular weight limit (NMWL), also sometimes referred to as molecular weight cut-off (MWCO).
- NMWL nominal molecular weight limit
- MWCO molecular weight cut-off
- membranes are made of materials such as regenerated cellulose and microporous PVDF.
- the retention and recovery of peptides by membrane filtration may be affected by other factors, including the molecular shape and size of the molecule; electrical characteristics; sample concentration and composition; operating conditions; and device or system configuration.
- Two membranes may have the same NMWL but will exhibit different retention of molecules within a relatively narrow range of sizes.
- slender, linear molecules may find their way through pores that will retain a globular species of the same weight. Retention can also be affected by hydration with counter-ions.
- the person skilled in the art would routinely be able to determine an appropriate membrane for use in the process of the invention to select peptides about 11 kDa or less.
- the process of the invention may optionally include the step of separating the peptides into one or more of a cation, anion and/or neutral peptide fraction.
- Ion-exchange Chromatography relies on charge -charge interactions between the proteins in a sample and the charges immobilized on a chosen resin. Ion exchange chromatography can be subdivided into cation exchange chromatography, in which positively charged ions bind to a negatively charged resin; and anion exchange chromatography, in which the binding ions are negative, and the immobilized functional group is positive.
- neutral peptide fraction refers to a peptide fraction which has no net charge and does not bind to either a cation exchange resin or anion exchange resin at a given pH.
- ion exchange resins can be cationic, anionic, mixtures of cation and anionic, or biologically related.
- ion exchange resins useful in this invention include, but are not limited to, those made of cross-linked polyvinylpyrolodone and polystyrene, and those having ion exchange functional groups such as, but not limited to, halogen ions, sulfonic acid, carboxylic acid, iminodiacetic acid, and tertiary and quaternary amines.
- biologically related resins examples include, but are not limited to, SephadexTM, CM C-25, CM C-50, DEAE A-25, DEAE A-50, QAE A-25, QAE A-50, SP C-25, and SP C-50.
- SephadexTM CM C-25, CM C-50, DEAE A-25, DEAE A-50, QAE A-25, QAE A-50, SP C-25, and SP C-50.
- cationic, anionic, mixed cationic and anionic, and biologically related ion exchange resins are commercially available.
- a variety of buffers at different pH values can be used to tailor charge distribution.
- a linear or step gradient of pH or salt can be used to elute peptide fractions from ion-exchange media.
- Peptides may contain ionizable groups on the side chains of their amino acids as well as their amino- and carboxyl-termini. These include basic groups on the side chains of lysine, arginine and histidine and acidic groups on the side chains or glutamate, aspartate, cysteine and tyrosine.
- the pH of the solution, the pK of the side chain and the side chain's environment influence the charge on each side chain.
- cation exchange (SP Sepharose BB) and anion exchange (Q Sepharose BB) columns may be connected in series. Batches of size selected peptides may be loaded onto the columns with non-binding neutral peptide fractions collected. The columns may then be uncoupled and the fraction bound to the cation exchange column eluted with a 1 M NaCl solution for the recovery of a cationic peptide fraction. The fraction bound to the anion exchange column may be eluted with 1 M NaCl to recovery an anionic peptide fraction.
- a size selected peptide fraction may be further fractionated into non-binding (neutral), cationic and anionic fractions. Testing the peptide fractions for biological activity
- peptide fractions of the invention may exhibit biological activity and be useful for the modulation of biological pathways associated with disease.
- a "biologically active" peptide or peptide fraction, or a peptide or peptide fraction having “biological activity” may be one which is capable of regulating or modulating for example, the cardiovascular system such as by modulating blood pressure, the immunohemopoietic system, or which may affect the viability, growth and differentiation of a variety of normal or neoplastic cells in the body, or which modulates immune-mediated inflammatory or autoimmune disorders, or neurological disorders.
- the biologically active peptide may be one which is capable of affecting immune regulation or which is capable of enhancing or inducing resistance to infection of cells and tissues, or which modulates energy metabolism as relevant to diabetes and metabolic disease.
- Non-health related biological activity includes anti-fibril chaperone activity useful for the stabilisation of proteins during thermal processing.
- assays There are many assays known to those skilled in the art for determining whether a peptide fraction of the invention has a particular biological activity. Such assays include, by way of non-limiting example, assays for determining whether a peptide fraction of the invention has angiotensin converting enzyme (ACE) inhibition activity, angiotensin II receptor inhibition activity, anti-inflammatory activity or fibril inhibition activity.
- ACE angiotensin converting enzyme
- ACE inhibition activity may be determined, for example, by monitoring the decrease in absorbance at 340 nm as a result of ACE-mediated hydrolysis of the substrate 3-(2-furylacryloyl)-L-phenylalanylglyclglycine (FAPGG) (Sigma-Aldrich, Sydney, Australia) to 3-(2-furylacryloylphenylalanine (FAP) and glyclglycine (GG) (Harjanne, 1984) in the presence of a peptide fraction of the invention.
- FAP 2-furylacryloylphenylalanine
- GG glyclglycine
- Anti-inflammatory activity may be determined, for example, by generating a ThI response in human peripheral blood mononuclear cells culture by the addition of IL-7 and IL- 12.
- the stimulation of na ⁇ ve T-cells to mature into ThI cells causes the production of ThI associated cytokines including IFN- ⁇ (Gutcher and Becher, 2007).
- a decrease in the level of IFN- ⁇ in a sample comprising a peptide fraction of the invention relative to a control culture is indicative of anti-inflammatory biological activity.
- One example of an assay for determining fibril inhibition activity of a peptide fraction utilises reduced and carboxymethylated ⁇ -casein (RCM-K-CN) which forms amyloid fibrils under physiological conditions.
- the RCM-K-CN is incubated in the presence and absence of test peptide fractions and the formation of amyloid fibrils monitored.
- a peptide fraction obtained by the process of the invention is included in a food or drink product.
- Food or drink products according to the invention can be prepared by the skilled person using known techniques. Non-limiting examples of such food or drink products are baked goods, dairy type foods and drinks, snacks, etc.
- the amount of the peptide fraction of the invention to be used in a food or drink product can be variable as the peptides themselves are nutrients.
- the food or drink product is a nutritional supplement.
- a "nutritional supplement” is an orally ingestible product consumed to improve overall nutrition, health, well-being, or performance of a subject in an activity and/or an orally ingestible product which provides additional perceived nutritional or biological benefit to a subject.
- the nutritional supplement may be provided in a concentrated form, thus allowing for the addition of the nutritional supplement to a food or drink product to allow for the consumption of a desired quantity of a peptide fraction of the invention in a reasonable serving size.
- the food or drink product of the present invention can include additional ingredients including an orally ingestible diluent or carrier.
- an orally ingestible diluent or carrier are known in the food sciences. These include, but are not limited to, manufactured cereals, fruit or vegetable products, beverages or beverage concentrates, ground meat products or vegetable analogues thereof, and any inert diluent, carrier, or excipient known in the pharmaceutical art.
- the peptide fractions of the current invention constitute from about 0.0001 to about 10.0% by weight of the food or drink product.
- the nutritional supplement of the current invention can include additional ingredients.
- more than one of the peptide fractions of the current invention can be included in the same nutritional supplement formulation.
- Other additional ingredients include any ingestible product.
- Preferred additional ingredients include, but are not limited to, other active food supplement ingredients such as vitamins and minerals.
- the food additive may also include acceptable dispersing and suspending agents, and water.
- Other conventional nutritional supplements can also be included if desired.
- the nutritional supplement can take many forms including, but not limited to, powders, tablets, capsules, solutions, concentrates, syrups, suspensions, or dispersions.
- the peptide fractions obtained by the methods of the invention are of use for the inhibition of biological pathways associated with disease including cardiovascular disease, cancer, inflammatory or autoimmune disease, or neurological disorders.
- the present invention provides methods of treating or preventing disease by administering to a subject a peptide fraction of the invention or a composition of the invention.
- a peptide fraction of the invention may be used in the treatment or prevention of cardiovascular disease in a subject, such as for example, for lowering blood pressure in a subject.
- Using the peptide fractions of the invention to lower blood pressure in a subject may decrease the risk of, for example, heart failure, kidney failure, and the harmful effects of diabetes.
- the peptide fraction of the invention may be used for the treatment or prevention of cardiovascular diseases including, but not limited to hypertension, atherosclerosis and arteriosclerosis.
- the peptide fractions of the invention may be useful in the treatment or prevention of cancer in a subject, including, but not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More particular examples of such cancers include breast cancer, prostate cancer, colon cancer, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, liver cancer, bladder cancer, hepatoma, colorectal cancer, uterine cervical cancer, endometrial carcinoma, salivary gland carcinoma, mesothelioma, kidney cancer, vulval cancer, thyroid cancer, hepatic carcinoma, skin cancer, melanoma, brain cancer, neuroblastoma, myeloma, various types of head and neck cancer, acute lymphoblastic leukemia, acute myeloid leukemia, Ewing sarcoma and peripheral neuroepithelioma.
- the peptide fractions obtained by the methods of the invention are of use for the inhibition of biological pathways associated with disease including inflammatory and autoimmune disease and/or neurological disorders.
- Inflammatory disorders and autoimmune diseases which may be treated with peptide fractions of the invention include asthma, rheumatoid arthritis, inflammatory bowel disease, psoriasis and multiple sclerosis.
- Autoimmune diseases arise from an overactive immune response of the body against substances and tissues normally present in the body.
- autoimmune diseases include Addison's disease, alopecia areata, ankylosing spondylitis, antiphospholipid antibody syndrome (APS), autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, bullous pemphigoid, coeliac disease, chagas disease , chronic obstructive pulmonary disease, Crohns disease (one of two types of idiopathic inflammatory bowel disease "IBD”), dermatomyositis, diabetes mellitus type 1, endometriosis, goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome (GBS), Hashimoto's disease, hidradenitis suppurativa, Kawasaki disease, IgA nephropathy, idiopathic thrombocytopenic purpura, Interstitial cystitis, lupus erythematosus, mixed connective tissue disease, morphea, multiple sclerosis (MS), myasthenia
- the peptide fractions of the present invention may also be used for the treatment or prevention of a neurological disorder, such as, but not limited to Alzheimer's disease, Parkinson's disease, dementia, Huntington's disease, Shy-Drager syndrome, progressive supranuclear palsy, Lewy body disease or amyotrophic lateral sclerosis.
- a neurological disorder such as, but not limited to Alzheimer's disease, Parkinson's disease, dementia, Huntington's disease, Shy-Drager syndrome, progressive supranuclear palsy, Lewy body disease or amyotrophic lateral sclerosis.
- compositions and administration are provided.
- the present invention provides compositions comprising a peptide fraction of the invention and a suitable carrier or excipient.
- the composition is a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
- the peptide fractions are incorporated into pharmaceutical compositions suitable for administration to a mammalian subject, e.g., a human.
- Such compositions typically comprise the "active" compound (i.e. the peptide fraction) and a "pharmaceutically acceptable carrier".
- pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- a pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration.
- routes of administration include parenteral (e.g., intravenous, intradermal, subcutaneous, intramuscular, intraperitoneal, intrathecal), mucosal (e.g., oral, rectal, intranasal, buccal, vaginal, respiratory), enteral (e.g., orally, such as by tablets, capsules or drops, rectally) and transdermal (topical, e.g., epicutaneous, inhalational, intranasal, eyedrops, vaginal).
- parenteral e.g., intravenous, intradermal, subcutaneous, intramuscular, intraperitoneal, intrathecal
- mucosal e.g., oral, rectal, intranasal, buccal, vaginal, respiratory
- enteral e.g., orally, such as by tablets, capsules or drops, rectally
- transdermal topical, e.g.,
- Solutions or suspensions used for parenteral, intradermal, enteral or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- suitable carriers include physiological saline, bacteriostatic water, CremophorTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
- the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier is a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity is maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms is achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid and the like.
- isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition.
- Prolonged absorption of the injectable compositions is brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions may be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound is incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions are also prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate or Sterotes
- a glidant such as colloidal silicon dioxide
- the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
- a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
- Systemic administration can also be by mucosal or transdermal means.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art, and include, for example, for mucosal administration, detergents, bile salts, and fusidic acid derivatives. Mucosal administration is accomplished through the use of nasal sprays or suppositories.
- the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
- a pharmaceutically acceptable vehicle is understood to designate a compound or a combination of compounds entering into a pharmaceutical composition which does not cause side effects and which makes it possible, for example, to facilitate the administration of the active compound, to increase its life and/or its efficacy in the body, to increase its solubility in solution or alternatively to enhance its preservation.
- These pharmaceutically acceptable vehicles are well known and will be adapted by persons skilled in the art according to the nature and the mode of administration of the active compound chosen.
- Chlorhexidine gluconate (20%) and Tris-Hydrochloride (Tris-HCl) were from ICN Biomedicals, Aurora, Ohio.
- MWCO 6000-8000 Daltons were obtained from Spectrum Laboratories, Inc., Dominguez, CA.
- Ethanol was from CSR Distilleries, Victoria, Australia.
- Triethanolamine (TEA), Phosphate buffered saline (PBS) tablets, Sodium bicarbonate (NaHCO3), Ethylenediaminetetraacetic acid (EDTA), L-cysteine, polyvinylpyrrolidone (PVP) and Sodium acetate were from Sigma Chemical Co., St. Louis, MO, USA.
- Sodium Chloride (NaCl) and Magnesium chloride (MgC ⁇ ) were obtained from Univar, NSW, Australia.
- IP Isopropanol
- SDS sodium dodecyl sulphate
- Ammonium Hydroxide (25%) was from BASF, Singapore.
- SPI extraction buffer 20 mM Tris-HCl, pH 8.0, 10 mM NaHCO3, 10 mM MgC12, 1 mM EDTA, 1 mM L-Cysteine, 1% insoluble PVP.
- Water soluble protein extractant 0.5 M NaCl.
- Prolamins extractant 50% IP containing 1% acetic acid and 1% L-Cysteine.
- Glutelins extractant 4 M urea, 1% ammonium hydroxide, 1% L-Cysteine dissolved in water. Protocol 1. No further processing
- Substrate reconstituted to 10% total solids in milliQ water and placed in regenerated cellulose dialysis tubing (6-8 KDa MWCO). Dialysis was conducted against 2 changes of 0.001% Chlorhexidine gluconate and 3 changes of distilled water over 48 hours. The resulting substrate free of minerals and salts was freeze-dried and stored at -20 0 C pending hydrolysis.
- Substrate reconstituted to 1% total protein (w/w) in 10% ethanol and subjected to 600 MPa pressure in HPP unit (QFP 35L, Flow Pressure Systems, S-72166 Vasteras, Sweden) for 15 minutes at 22°C.
- HPP unit QFP 35L, Flow Pressure Systems, S-72166 Vasteras, Sweden
- Protocol 5 Commercially available probiotic cells lysed by French pressing
- DSM DELVO Pro LAFTI-L26 Direct Set Lyophilized starter culture (DSL);
- the mixture was centrifuged (4200rpm /30 min, J6-HC, Beckman Coulter, Inc.,
- the substrate was washed using distilled water and excess moisture was removed by shaking and blotting in absorbent paper.
- the clean wool/feathers were chopped into pieces (2 - 6mm) with the help of sharp scissors.
- Protocol 10 Preparation of lactoferrin-enriched bovine colostral whey
- bovine colostrum The pH of bovine colostrum was adjusted to 4.6 with 5.0 M acetic acid and the mixture was warmed to 40 0 C for 30 min (to melt fat) in a water bath. Fat was removed by centrifugation (3000g /30 min, J6-HC, Beckman Coulter, Inc.Fullerton, CA, USA) at 10 0 C. After discarding fat, the supernatants (colostral whey) were pooled and diluted by 1/3 using distilled water. The pH was readjusted to 5.2 using 5.0 M sodium acetate and the whey was processed through 5 m 2 UF plant (30 K membrane).
- Retentate was diafiltered 1 fold with distilled water. The retentate was collected; spray dried and stored at -20 0 C pending hydrolysis.
- Seeds were cleaned of any extraneous matter and milled using a blender (Semak Australia, Victoria, Australia) or hammer mill (> 2kg, Ernest Fleming Pty Ltd, New South Wales, Australia) to a particle size range of 0.5 mm- 1.2 mm.
- Alcohol soluble proteins were extracted by adding 2 litres of prolamin extractant to the millet solid fraction from Protocol 12 and mixing vigorously by overhead stirring at RT for 1.0 hr. The soluble proteins were recovered by centrifugation (4200rpm /30 min, J6-HC, Beckman Coulter, Inc.Fullerton, CA, USA) at RT and the process was repeated with 3 litres of prolamin extractant. The supernatants (pellet was saved for protocol 14) were pooled and 2 volumes of 1.5 M NaCl was added to allow protein fraction to precipitate overnight at 4°C. The precipitate was recovered and placed in regenerated cellulose dialysis tubing (6-8 KDa MWCO). Dialysis was conducted against 2 changes of 0.001% Chlorhexidine gluconate and 3 changes of distilled water over 48 hours. The resulting desalted protein solution was freeze-dried and stored at -20 0 C pending hydrolysis.
- Alkali soluble proteins were extracted by adding 2 litres of glutelin extractant to the millet solid fraction from Protocol 13 and mixing vigorously by overhead stirring at RT for 1.0 hr. The soluble proteins were recovered by centrifugation (4200rpm /30 min, J6-HC, Beckman Coulter, Inc., Fullerton, CA, USA) at RT and the process was repeated with 3 litres of glutelin extractant. The supernatants were pooled and placed in regenerated cellulose dialysis tubing (6-8 KDa MWCO). Dialysis was conducted against 2 changes of 0.001% Chlorhexidine gluconate and 3 changes of distilled water over 48 hours. The resulting desalted protein solution was freeze-dried and stored at -20 0 C pending hydrolysis.
- Triethanolamine was from Sigma Chemical Co., St. Louis, MO, USA.
- Ethanol was from CSR Distilleries, Victoria, Australia.
- Sodium Chloride NaCl was obtained from Univar, NSW, Australia.
- Alcalase 2.4L, Flavourzyme IOOOL and Trypsin enzymes were obtained from Novozymes, Bagsvaerd, Denmark.
- Corolase PN-L was obtained from AB Enzymes GmbH, Darmstadt, Germany.
- Glutaminase was obtained from Daiwa Kasei K.K., Shiga, Japan.
- Dialysis membrane Spectra/Por regenerated cellulose, molecular weight cut-off (MWCO) 6000-8000 Daltons
- MWCO molecular weight cut-off
- SP and Q Sepharose Big Beads ion exchange resins were obtained from GE Healthcare, Uppsala, Sweden.
- Food source refers to the original material from which a protein-rich 'substrate' was prepared, where necessary.
- the food source and substrate e.g., dairy whey protein isolate
- a protein-rich substrate was prepared from the original food source. If not available in a powder form, all food sources were washed and ground or milled to a particle size range of 0.5 to 1.2 mm before further processing. Methods for preparation of protein-rich substrates from specific food sources are described for specific 'leads' in tables below.
- Substrates were dissolved or suspended at 10% total protein (w/w) in 10 mM TEA, 10% EtOH, pH 7.4 and maintained at pH 7.4 throughout the hydrolysis process.
- the first enzyme Glutaminase was added to a final concentration of 0.5% (w/w) and incubated with agitation at 50 0 C for 1 hour.
- the enzymes Alcalase (0.5%, w/w), Corolase (0.5%, w/w) and Flavourzyme (0.5%, w/w) were subsequently introduced sequentially at 1 hr intervals at 50 0 C, according in one of 3 possible sequences (Table 1).
- the final enzyme Trypsin (0.5%, w/w) was introduced to the mixture and incubated at 37°C for 17 hours (overnight).
- the enzymes were inactivated by heating at 90 0 C for 30 min, and the product cooled to 22 0 C for at least 15 mins.
- the molecular size fraction ⁇ 8 KDa was recovered by dialysis using regenerated cellulose membrane (6-8 KDa MWCO). Each dialysate was subjected to ion exchange chromatographic fractionation, as follows. Peptide fractionation was performed using 2 columns (4.6 x 10 cm) connected in series. Column 1 was packed with cation exchange resin (SP Sepharose BB) and Column 2 was packed with anion exchange resin (Q Sepharose BB) The eluant was monitored by UV detection at 280 nm (Shimadzu SPD-10AV, Kyoto, Japan).
- each dialysate was fractionated into 3 products, yielding a total of 9 distinct products from each protein substrate (Table 2) or 6 different products where the substrates were commercially available hydrolysates (Table 3). All products were freeze dried and stored at -20 0 C pending bioactivity testing and other methods of characterisation.
- the assay for the determination of pig kidney ACE (EC 3.4.15.1) (Sigma- Aldrich, Sydney, Australia) employed a COBAS BIO autoanalyser (Roche Diagnostics Ltd, Rotnch, Switzerland) which monitored the decrease in absorbance at 340 nm as a result of ACE-mediated hydrolysis of the substrate 3-(2-furylacryloyl)-L- phenylalanylglyclglycine (FAPGG) (Sigma-Aldrich, Sydney, Australia) to 3-(2- furylacryloylphenylalanine (FAP) and glyclglycine (GG) (Harjanne, 1984).
- reagent buffer as 100 mM Tris-HCl pH 8.3, 300 mM NaCl, 10 ⁇ M ZnCl 2 containing ACE at 0.032 U/ml was loaded from a buffer boat and 20 ⁇ L of test sample (10-50 mg/ml) or known ACE inhibitors such as captopril (1-100 nM) or the tripeptide valinealanineproline (VAP, 0.1-20 ⁇ M) (Auspep Pty Ltd, Melbourne, Australia) found in as 1 -casein from the sample carousel are transferred into the multiple cuvette and spun in 2 minutes to warm to 37°C.
- test sample 10-50 mg/ml
- known ACE inhibitors such as captopril (1-100 nM) or the tripeptide valinealanineproline (VAP, 0.1-20 ⁇ M) (Auspep Pty Ltd, Melbourne, Australia) found in as 1 -casein from the sample carousel are transferred into the multiple cuvette and spun in 2 minutes to warm to 37
- a broad range of substrates yielded peptide products with significant capacity for inhibition of ACE (Table 4).
- Rat livers or pig hearts were snap frozen in liquid nitrogen and coarsely ground in a pestle and mortar and membranes prepared by differential centrifugation (Leifert et al., 2009).
- To 1 g of frozen tissue was added 10 ml of ice cold isolation medium containing (in mM) 250 sucrose, 50 mM Tris, 1 MgCl 2 , 1 EDTA, pH 7.4 and homogenised with an Ultra-Tarrax (Jankee & Riversidel GmbH, Staufen, Germany) on setting 4 for 3 bursts of 10 seconds with a short rest in between bursts.
- the solution was filtered through two pieces of nylon mesh and washed through with 5 ml of isolation media and centrifuged at 3,000 x g for rat liver or 6,000 x g for pig heart in a J2-21 centrifuge (Beckman Instrument Co., Palo Alto, CA) for 30 min at 4°C.
- the supernatant was decanted and retained and the pellet resuspended in isolation medium and centrifuged as before.
- the supernatants were combined and centrifuged at 46,000 x g for 30 min.
- the final pellet was suspended (in mM) 50 Tris, 10 MgCl 2 , 1 EGTA, pH 7.4 assay buffer with 5 stokes of a dounce glass/Teflon homogeniser that contained protease inhibitors diluted into the buffer at 1: 1000 (vol/vol).
- the stock protease inhibitor concentrations were (mg/ml, solvent) phenylmethylsulfonyl fluoride 17.4, DMSA; aprotinin 1, H 2 O; iodoacetate 184, H 2 O; and pepstatin A 1.37, DMSO.
- the final stock concentration of liver or heart membrane preparations was 1-2 mg/ml and stored in aliquots at -80 0 C.
- Receptor radioligand binding activity was determined for rat liver membrane fraction (3,000-46,000 x g) with the All antagonist [ ⁇ IHSar'-Ile ⁇ -angiotensin II (2200 Ci/mmol, 10 ⁇ Ci in 200 ⁇ l assay buffer diluted to 1 nM stock) (Perkin Elmer, MA, USA) which is specific for the ATi receptor at sub Ka concentration of 0.1 nM (Del Carmen Caro et al., 1998; Leifert et al., 2009).
- the assay final volume of 75 ⁇ l in a 4 ml plastic tube contained (in mM) 90 Tris, 10 MgCl 2 , 1 EGTA, pH with 0.2% BSA with buffer or the antagonists losartan (10-1000 nM), saralasin (1-100 nM), PD12319 (10-10,000 nM, AT 2 antagonist) or agonist angiotensin II (1-100 nM) (all Sigma- Aldrich, Sydney, Australia) or the prepared library fractions or products.
- Peptides or plant products were dissolved in 10% ethanol (v/v) in (mM) 90 Tris, 10 MgCl 2 , 1 EGTA adjusted to pH 7.4 with 2 N NaOH, centrifuged at 8,000 x g (Sigma 113 Laborzentrifugen, Ostrode am Harz, Germany) and added at 0.01-10 mg/mL final in the assay.
- the assay contents were pre-incubated with of 7 ⁇ l of rat liver membrane preparation containing approximately 7 ⁇ g protein for at least 10 min.
- the assay is commenced by the addition of 7.5 ⁇ l 1 nM [ 125 I]-[Sar 1 -Ile 8 ]-Angiotensin II (0.1 nM final) and the binding reaction allowed to proceed for 50 min while shaking at 25°C (Del Carmen Caro et al., 1998). Non specific binding was determined in the presence of unlabelled All or losartan and did not exceed 5%.
- Table 5 Summary of Angiotensin I receptor inhibition bioactivity of food protein- derived peptide fractions generated using systematic method of hydrolysis and chromatographic fractionation.
- Example 5 In vivo testing protocol in spontaneous hypertensive rat study 1
- the lead anti-hypertensive products were tested in the Spontaneous Hypertensive rat model by dietary intervention over 20 weeks of feeding.
- the test feed was given as a mixture of leads comprising P0147+P0148+P0052 (1 : 1: 1).
- Rats were randomised into 4 treatment groups based on the following dietary interventions (control, dairy lead mixture at 20 mg/kg, dairy lead mixture at 200 mg/kg and a commercial whey protein hydrolysate (Myopure) at 200 mg/kg.
- Tailcuff blood pressures and body weights were monitored every 14 days with peripheral blood flow and activity of plasma ACE measured at completion of study.
- Example 7 Inhibition kinetics of angiotensin converting enzyme
- HPLC-based method described was adapted from that of Cushman and Cheung (1971).
- hippuric acid (HA) is released from a substrate hippuryl-L- histidyl-L-leucine (HHL) in the presence of Angiotensin I-converting enzyme (ACE) and HA is isolated by extraction into ethyl acetate and measured by absorbance at 228 nm.
- ACE Angiotensin I-converting enzyme
- the concentration of the HA released from HHL is directly related to ACE activity or its inhibition.
- the concentration of HA and HHL was quantified by HPLC.
- Hippuryl-L-histidyl-L-leucine (4 mM, St. Louis, MO, USA) and angiotensin I- converting enzyme (25 ⁇ L, 0.05 unit/mL, rabbit lung, St. Louis, MO, USA) were dissolved in reaction buffer (0.1 M dipotassium hydrogen phosphate, 0.3 M NaCl, pH 8.3).
- HHL 50 ⁇ L, St. Louis, MO, USA was prepared in 4 different concentrations (4, 2, 1 and 0.5 mM).
- Test inhibitor samples were dissolved in MQ water and tested each at 0, 0.1, 0.5, 1.0 and 2.0 mg/mL for each concentration of substrate.
- reaction mixture was incubated at 37°C for 30 min using an Eppendorf Thermomixer (Brinkmann Instruments, New York, USA) with continuous agitation (500 rpm) before inactivation of the enzyme by addition of 1 M HCl (50 ⁇ L).
- Eppendorf Thermomixer Boppendorf Instruments, New York, USA
- continuous agitation 500 rpm
- 1 M HCl 50 ⁇ L
- the HHL concentration corresponding to zero enzyme activity i.e., 100% inhibition
- Inhibition was expressed as the percentage of inhibition of ACE activity compared with the control. Data were analysed using MS Excel XP and Prism (V4.0, GraphPad Software Inc., CA, USA).
- HA and HHL analysis was performed by HPLC (ThermoFinnigan HPLC system, with diode-array detection, a MS pump, and Xcalibur Version 1.4 SRl software, ThermoFinnigan USA).
- Samples (10 ⁇ L) were injected onto C18 reverse phase column (Vydac 238 EV52, monomeric column, 2.1 x 250 mm, 5 ⁇ m).
- HA and HHL were detected at 228 nm. Column temperature was 35 0 C.
- Test samples were fractionated using solid phase extraction cartridge media in order to isolate the active peptide fraction and eliminate salts. Samples were dissolved in MQ water 0.1 to 0.5 g total solids loaded per SPE column (Strata-X reversed phase polymeric sorbent, 500 mg/6 ml, particle size 33 ⁇ m, pore size 85 A, surface area 800 m /g, Phenomenex Australia). A 12-position SPE vacuum manifold set (AHO-60230) was used for loading, washing and elution cycles (Phenomenex Australia).
- ThI response in a human Peripheral Blood Mononuclear Cell (PMBC) culture system was generated by the addition of interleukin 7 (IL7), for homeostatic proliferation and survival of na ⁇ ve T-cells (Rathmell et al., 2001); and interleukin 12 (IL12) to promote the stimulation of na ⁇ ve T- cells to mature into ThI cells.
- IL7 interleukin 7
- IL12 interleukin 12
- APCs antigen presenting cells
- the stimulation of na ⁇ ve T- cells to mature into ThI cells causes the production of ThI associated cytokines including IFN- ⁇ (Gutcher and Becher, 2007).
- Anti-inflammatory effects of a food extract, protein, or peptide were demonstrated by introducing the test substance into a culture containing PBMC, IL- 12 and IL-7 and monitoring levels of IFN- ⁇ . A decrease in the levels of IFN- ⁇ relative to a control culture, where the extract, protein, or peptide was not present, was taken as indicating an anti-inflammatory effect while an increase in the level of IFN- ⁇ relative to control was taken to indicate a pro-inflammatory response.
- T Helper cell Type 1-mediated inflammation A small selection of substrates yielded peptide products with significant capacity for inhibition of T Helper cell Type 1-mediated inflammation (Table 6). Substrates included bovine whey protein after high pressure denaturation and several sources of yeast protein including commercial hydro lysates (i.e., Vegemite) and both Brewers and Bakers yeast sources. In vitro activity was significantly associated with IE+ chromatographic fractions and enzyme sequence codes 1, 2 or 4 were represented. Table 6. Summary of inhibition of T Helper Cell Type 1 receptor inhibition bioactivity of food protein-derived peptide fractions generated using systematic method of hydrolysis and chromatographic fractionation.
- RCM-K-CN which forms amyloid fibrils under physiological conditions
- RCM-K-CN was used in a primary high throughput microtitre plate screen for potential inhibitors of amyloid formation (Carver et al., 2010).
- RCM-K-CN was incubated at 37°C in 50 mM phosphate buffer, pH 7.4 at 0.5 mg/mL. Screened samples were prepared by weighing out appropriate quantities and diluted to double final concentration in the assay using MiIIiQ water as solvent for peptide samples and 10% ethanol for plant samples.
- ⁇ I and ⁇ I S represents the change in ThT fluorescence after 1000 mins for RCM-K-CN in the absence and presence of the tested sample respectively.
- Table 7 Summary of inhibition of reduced carboxymethylated kappa casein fibril assembly bioactivity of food protein-derived peptide fractions generated using systematic method of hydrolysis and chromatographic fractionation.
- Beta-Amyloid (1-42), A ⁇ l-42 was purchased from Anaspec Company (San Jose, CA, USA) and then dissolved with 60 ⁇ L 1.0% NH 4 OH. MiIIiQ water was added to make a 250 ⁇ M stock solution, which was aliquoted and stored at - 80 0 C until use.
- Amyloid fibril formation by A ⁇ l-42 was monitored using an adapted in situ ThT binding assay similar to that described above for RCM-K-CN. 25 ⁇ M A ⁇ l-42 in 50 mM phosphate buffer (pH 7.4) with 100 mM NaCl was incubated at 37°C in black ⁇ clear 96-microwell plates (Greiner Bio-One, Stonehouse, UK) either in the presence or absence of tested samples. The percent protection afforded by each sample was calculated from the ThT fluorescence data at 200 mins by the same equation as used for the RCM-K-CN ThT assay (see above).
- Table 8 Summary of inhibition of Amyloid beta 1-42 peptide fibril assembly bioactivity of food protein-derived peptide fractions generated using systematic method of hydrolysis and chromatographic fractionation.
- Saccharomyces cerevisiae assay system employs an A ⁇ 42-MRF fusion with functional MRF being required for growth of yeast (Bagrianstev et al., 2006).
- a ⁇ 42-MRF fusion readily aggregates into non-functional high n-oligomers due to A ⁇ 42-induced oligomerisation.
- several compounds that decrease the oligomerisation allow growth.
- Growth assays are convenient and can be performed on solid or liquid media.
- Our system is a hybrid of the above two in that it uses a GFP-A ⁇ fusion in yeast.
- GFP-A ⁇ fusion in yeast.
- plasmids pASIN.GFP and pAS IN. GFP-A ⁇ direct the constitutive synthesis of GFP and GFP-A ⁇ , respectively.
- Standard yeast strains transformed with these plasmids have been previously described (Bayly et al., 2001). Cells were spread at 10 7 cells per plate of solidified media and incubated for 16 hours. Plates of 90 mm diameter contained 20 ml solidified media. Cells were re-suspended from the surface of the plate into water immediately before flow cytometry analyses.
- LCYl [pASlN.GFP-A ⁇ ] and LCYl [pASIN.GFP] cells were grown in solidified minimal media (with tryptophan but lacking leucine) supplemented with folinic acid at 50, 100, 200, and 300 ⁇ g/ml concentrations.
- Propidium iodide (PI) was used to identify dead cells.
- GFP fluorescence was assessed using a flow cytometer (FACSCalibur, BD Biosciences). Data were analyzed using CellQuest analysis software. Cell population gated on a forward and side scatter dot plot was analyzed for PI staining. GFP fluorescence was estimated in the population of Pi-negative (live) cells. Fifteen thousand cells per sample were analyzed. Results
- Bioactivity of a selection of leads from Table 7 were also tested in the yeast expression system of GDP-tagged amyloid beta 1-42. In this assay fluorescence increases >10% represent significant anti-fibril activity and the assay also confirms cellular uptake of samples associated with positive results. As for previous fibril- specific assays, millet and related grains following 1-NIE processing exhibited significant anti-fibril assay in this cell system. Some additional bioactive peptides were identified from dairy and Spirulina. Bioactivity was associated with IEO fractions indicating that low net charge was required for cell uptake (Table 9). Table 9. Summary of inhibition of A ⁇ 1-42 oligomerisation as indicated by increase in GFP fluorescence, by food protein-derived peptide fractions generated using systematic method of hydrolysis and chromatographic fractionation.
- Dried plant samples were dispersed in 10% ethanol at approximately 50 mg/mL total solids by vortexing and extracted for 30 mins using gentle agitation, at room temperature. Supernatants containing extractable solids were freeze dried before reconstitution at 20 mg/mL in 10% ethanol.
- the stock solution was diluted by 1/100 into sodium acetate buffer (0.1 M, pH 4.5) to a final concentration of 200 ⁇ g/mLH.
- a working sample aliquot (25 ⁇ l) was pre-incubated (15 mins at room temperature) with BACEl enzyme (25 ⁇ L at 4 ⁇ g/mL, Calbiochem) before adding the fluorescent substrate (50 ⁇ L at 25 ⁇ M, Calbiochem) and commencing monitoring of the reaction.
- the enzyme inhibition assay was adapted to a high-throughput format using 96-well plate format and microplate fluorescence reader (Biotek FL600, Bio-Tek Instruments Inc, VT, USA), monitoring for 2 hours at room temperature, at excitation and emission wavelength settings of 360 and 485 nm, respectively. Enzyme activity was detected as a linear increase in florescence over the 2 hour monitoring timeframe, and inhibition was measured as the percentage reduction in the fluorescence increase, compared to the control reaction. For dose response experiments, the concentration of extracts was the only variable altered, with all other conditions remaining constant.
- Capacity for inhibition of beta secretase was associated with protein substrates from bovine dairy and egg protein sources.
- a peptides product prepared from a probiotic cell biomass was bioactive following high pressure denaturation and hydrolysis (3 -IEO) (Table 10).
- Table 10 Summary of inhibition of Beta Secretase Type 1 enzyme bioactivity of food protein-derived peptide fractions generated using systematic method of hydrolysis and chromatographic fractionation.
- RAW264.7 cells obtained from Ian Cassidy, University of Queensland, Australia
- Ni l microglia obtained from the University of Tublingen, Germany
- DMEM Dulbecco's Modified Eagle's Medium
- FCS fetal calf serum
- penicillin 200 U/ml
- streptomycin 200 ⁇ g/ml
- Fungizone 2.6 ⁇ g/ml
- Samples to be tested were dissolved in DMSO, 95% ethanol or ddH 2 O to concentrations of 100 mg/ml. Dilutions were then made in media from these concentrates, so that the maximum solvent content did not exceed 0.05% of the final well volume. All stock solutions were stored at -20 0 C and dilutions in media were stored at 4°C for no longer than one week.
- the media was removed by aspiration.
- the dilutions in media were added one hour prior to addition of the activation mixture containing 25 ⁇ g/ml LPS and 10 U/ml IFN- ⁇ (Shanmugam et al, 2008, Berbaum et al, 2008). Plates were incubated at 37°C (5% CO 2 ) for 24 hours. Every plate contained three wells that only contained media as a negative control, while 10 ⁇ g/ml LPS was used as a positive control. Vehicle controls were initially present, where all solvents used were tested alone at 0.05% of total volume, but did not have a significant effect on cells in terms of activating ability or effect on viability.
- Nitric oxide production was monitored by measuring the concentration of nitrite in the media using the 'Griess reagent' (Fox et al., 1982).
- Conditioned media (50 ⁇ l) from each well was transferred to a fresh 96-well plate and 25 ⁇ l of Reagent 1 (1% w/v sulfanilamide in ddH 2 O) and 25 ⁇ l of Reagent 2 (0.1% w/v naphthyethylene-diamine in 5% HCl) were added and the absorbance at 540nm determined using a plate reader (Multiskan Ascent with Ascent software v2.4, Labsystems). Determination of TNF in cell culture supernatant by ELISA
- TNF concentration of TNF, following 24 hours of incubation of cells with LPS was determined by a Sandwich Enzyme -Linked Immunosorbent Assay (ELISA), according to the manufacturer's manual (Peprotech). Briefly, capture antibody was used at a concentration of 1 ⁇ g/ml in PBS (1.9 mM NaH 2 PO 4 , 8.1 mM Na 2 HPO 4 , 154 mM NaCl) (pH 7.4). Serial dilutions of TNF standard from 0 to 10000 pg/ml in diluent (0.05% Tween-20, 0.1% BSA in PBS) were used as internal standard. TNF was detected with a biotinylated second antibody and an Avidin peroxidase conjugate with ABTS as detection reagent. Colour was determined at 405nm in a 96 well plate reader. Cell viability assays
- MTT 3-(4,5-dimethylthiazol-2-yl)2,5- diphenyl tetrazolium bromide
- Bioactivity associated with IEO fractions may indicate cell uptake but anti- inflammatory effects were also possible by inhibition of extra-cellular processes IE- and IE+ fractions.
- BM0263 was prepared according to the method applied for millet 'P0263' as per Table 8, with the exception that the button mushroom was processed without prior concentration of protein fraction and dispersed initially at a stock concentration of 10% total solids on a dry weight basis, before addition of enzymes.
- BM0263-spe40 sub- fraction was prepared by recovering the fraction that eluted from C18 Solid Phase Extraction cartridges in 40% acetonitrile after elution of the non-binding fraction with water.
- Amyloid beta 1-42 (Ab 1-42, Rpeptides, USA ) was dissolved in DMSO (1 mg/ml) and immediately stored in aliquots (100 ⁇ l) at -18 0 C. An aliquot of Ab 1-42 was diluted by 1/10 in water producing a stock solution of 0.1 mg/ml in 10% DMSO. The mushroom product stock solution was 10 mg/ml in water.
- Ab 1-42 and mushrooms stock solutions were mixed 1 : 1 (v/v) and divided in half with one set of samples (including Ab 1-42 only controls) incubated at -18 0 C and the other set of samples incubated at 37 0 C, each for 48 hr.
- the final concentrations were 0.05 and 10 mg/ml for Ab 1-42 and mushroom solids, in 5% DMSO.
- Carbon-coated 300-mesh copper grids were glow-discharged in nitrogen to render the carbon film hydrophilic.
- a sample aliquot (4 ⁇ l) was pipetted onto each grid with excess liquid drawn off using filter paper, after 30 seconds adsorption time, before staining with 2% aqueous potassium phosphotungstate at pH 7.2, for 10 seconds.
- Grids were air-dried pending analysis.
- the samples were examined using a Tecnai 12 Transmission Electron Microscope (FEI, Eindhoven, The Netherlands) at an operating voltage of 120 KV. Images were recorded using a Megaview III CCD camera and AnalySIS camera control software (Olympus, Tokyo, Japan). Each grid was systematically examined and imaged to reflect a representative view of the sample.
- the 'P0263' analogue prepared from button mushroom exhibited significant anti-fibril activity in the RCM-kCn assay and this activity was supported by the suppression of progression of self-assembly of human Ab42 peptide, as monitored by TEM (Table 12; Figure 4).
- Table 12 Summary of inhibition of reduced carboxymethylated kappa casein fibril assembly bioactivity of food protein-derived peptide fractions, generated using systematic method of enzyme hydrolysis and chromatographic fractionation.
- Example 15 Dissolution of Ab42 fibrils by P0263 and BM0263
- Freshly prepared A ⁇ 42 was dissolved in MQ water and sonicated for 10 min and then placed in 37 0 C oven for 52 hr before being used for dissolution study.
- P0263- SPE40 from Panorama millet
- BM0263-SPE40 from Button mushroom were dissolved in MQ water, respectively.
- Equal volumes of A ⁇ 42 and P0263-SPE40 or BM0263-SPE40 (100 ⁇ l each) and 30 ⁇ l 20 ⁇ M ThT were added to a 96 microplate (OptiPlate-96F, PerkinElmer Inc., MA, USA), each in triplicate.
- the final concentrations for fibrillar A ⁇ 42 was 0.043 mg/ml, and for PP0263SPE40 or BM0263SPE40 were 0.17 mg/ml, respectively. They were incubated at 37 0 C for 66 hr with fluorescence intensity readings at 10 min intervals (Varioskan Flash, Thermo Scientific, USA and 442/482 nm excitation and Emission wavelengths, respectively.
- PO 147 hydrolysate was prepared from bovine whey protein isolate using confidential project methods and contained 77.6% protein (w/w).
- P0147 was sub- fractionated using Cl 8 solid phase cartridges (Phenomenex, California, USA). The void and unbound species (LW) were eluted with water and bound fractions sequentially eluted with 40% and 100% acetonitrile (Aj ax Fine Chem, NSW, Australia, SPE40, and SPElOO respectively).
- Synthetic human A ⁇ 42 was purchased from the W. M. Keck Laboratory (Yale University, New Haven, CT). Solutions of A ⁇ were prepared according to the method of Bharadwaj et al. (2008) with some modifications. A ⁇ was dissolved in l,l,l,3,3,3-hexafluoro-2-propanol (HFIP) and incubated overnight at RT. The HFIP solution was centrifuged at 14000 rpm for 10 min and the supernatant removed. The HFIP was then evaporated and the resulting peptide film dissolved in sterile double- distilled water. The solution was sonicated on ice for 5 min and centrifuged for 10 min at 14000 rpm.
- HFIP l,l,l,3,3,3-hexafluoro-2-propanol
- the supernatant contained soluble oligomers and was used for the toxicity experiments.
- the RCM-kCn was used as a model for protein fibril self assembly as follows.
- RCM-kCn 0.5 mg/mL
- test peptide samples for 24 h at 37 0 C in black Clear 96-microwell plates that were sealed to prevent evaporation.
- ThT Thioflavin T
- the ThT fluorescence intensity of each sample was recorded every 5 min using a FLUOstar
- a ⁇ 42 toxicity assay in yeast was done according to the method of Bharadwaj et al. (2008).
- the prototrophic yeast strain Candida glabrata ATCC 90030 was used in this study. Cultures of yeast cells were grown in YEPD (1% yeast extract; 2% peptone,
- a ⁇ 42 peptide solutions pre-incubated with different concentrations of PO 147 were analysed by Jasco J-810 CD Spectropolarimeter (JASCO Inc., Easton, MD, USA) with computerised data collection.
- Ab 1-42 Oligomer solution was prepared as described in the methods. Oligomeric Abl-42 (0.05mg/ml) was incubated with P0147 sub-fractions spe40 and spelOO, at 0.005, 0.05 & 0.25 mg/ml, respectively in MiIIiQ water. The mean residue ellipticities of samples were recorded across the far UV range of 190-260 nm wavelength using a 0.1 cm path-length quartz cuvette, at room temperature, monitoring at 0.1 nm intervals.
- the acquisition parameters were 100 nm/min with 1 sec response times, 1.0 nm bandwidth, and 0.1 nm data pitch, and data sets were averaged over 3 scans. Spectra of P0147 fractions alone at the appropriate experimental concentration were subtracted from respective profiles of Ab 1-42 +P0147, but were otherwise unsmoothed.
- the instrument was calibrated with deionised water (MiIIiQ).
- a ⁇ 42 peptide solutions pre-incubated with different concentrations of PO 147 fractions.
- the samples were fractionated on a 4-12% Bis-Tris NuPage gel in a MES buffering system and visualized by 6E10 immunoblotting followed by TMB development.
- ThT -binding assay Figure 7
- yeast toxicity results Figure 8 revealed interesting dose-dependent capacity for modulation of A ⁇ fibril morphology and toxicity, respectively, by SPE40 and SPElOO (see Reverse Phase HPLC profiles of respective hydrolysate fractions, Figure 6), apparently driving self-assembly progressively from relatively more toxic to less toxic forms of A ⁇ 42.
- the suppression of ThT binding by dairy peptides correlated with: loss of beta sheet absorbance by CD ( Figure 9); suppression of oligomeric A ⁇ 42 by Western blot with 6E10 antibody
- Peptide hydrolysates of brewer's and baker's yeasts were prepared as follows.
- Dried Brewers yeast (Lotus Foods Pty Ltd, Cheltenham, Victoria, Australia) and dried Bakers yeast (Lowan Whole Foods, Glendenning, New South Wales, Australia) were dissolved or suspended at 10% total protein (w/w) in 10 mM tri-ethanolamine, 10% EtOH, pH 7.4 and maintained at pH 7.4 throughout the hydrolysis process. After rehydration, Glutaminase was added to a final concentration of 0.5% (w/w) and incubated with agitation at 50 0 C for 1 hour.
- the enzymes Alcalase (0.5%, w/w), Corolase (0.5%, w/w) and Flavourzyme (0.5%, w/w) were subsequently introduced sequentially at 1 hr intervals at 50 0 C.
- the final enzyme Trypsin (0.5%, w/w) was introduced to the mixture and incubated at 37°C for 17 hours (overnight).
- the enzymes were inactivated heating at 90 0 C for 30 min, and the product cooled to 22 0 C for at least 15 mins.
- the hydrolysates were dialysed and the permeate (regenerated cellulose membrane, 6-8 KDa MWCO) recovered and freeze dried.
- VegemiteTM Kertial Foods, Port Melbourne, Victoria, Australia
- MarmiteTM Australian Health and Nutrition Association Ltd, Berkley Vale, NSW, Australia
- Epicor® was purchased on-line (Vitamin research products, Carson City, USA).
- SPE fractions of the hydrolysate products and the yeast derived foods were obtained by dispersing the samples in water at a concentration of 100 mg/mL then centrifuging to remove insoluble matter. Supernatants were fractionated using Strata-X
- test compound / concentration point was tested in two culture wells, each well being assayed in triplicate.
- Interleukin 10 IL-10, 250 pg/mL
- Hydrocortisone HC, 200 ng/mL
- Supernatants were removed at the conclusion of the culture period and stored at -80 0 C until tested.
- Supernatants were tested for IFN- ⁇ by ELISA using the Human IFN- ⁇ DuoSet; DY28E (R&D systems, USA) as per instructions with a standard curve from 5000 to 5 pg/ml prepared by serial 1:2 dilutions of the supplied standard.
- Results for ELISAs were read at absorbance wavelengths 460 nm and 590 nm in an FL600 Fluorescence Microplate Reader (BioTek, USA) and the KC4 software (version 3.1, BioTek, USA).
- the assay was also revised from that used to test the P0613 and P0713 products.
- LPS activates the Toll Like Receptor 4 present on macrophages and monocytes and PHA activates phosphorylation of mitogen activated protein kinases (MAPK), stimulating the release of inflammatory cytokines including Tumour necrosis Factor-alpha (TNF-a) and Interferon -gamma (IFN- ⁇ ).
- MAPK mitogen activated protein kinases
- TNF-a Tumour necrosis Factor-alpha
- IFN- ⁇ Interferon -gamma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Abstract
The present invention relates to a process for isolating one or more peptide fractions from a protein substrate. The invention also relates to peptide fractions obtained by the process and their use in food and drink products and for the treatment and prevention of disease.
Description
PROCESS FOR OBTAINING PEPTIDE FRACTIONS
FIELD OF THE INVENTION
The present invention relates to a process for isolating one or more peptide fractions from a protein substrate. The invention also relates to isolated peptide fractions and their use in food and drink products and for the treatment or prevention of disease.
BACKGROUND OF THE INVENTION
There is increasing interest in the use of protein hydrolysates for both medical and non-medical applications. In both applications, an easily assimilable diet featuring facilitated gastrointestinal uptake of peptides is a factor of prime importance. Peptides from partial enzymatic hydrolysates of food proteins have been shown to provide health benefits such as, for example, antihypertensive activity. These peptides are hidden in a latent state within the sequence of the parent protein and may be released by proteolytic processes during hydrolysis or during food processing.
The commercialisation of various protein hydrolysates claiming antihypertensive effects emphasize the increased scope of use of protein hydrolysates containing bioactive peptides in medical and non-medical applications. Examples of these bioactive peptides and protein hydrolysates containing such bioactive peptides include hydrolysates obtained by incubation of protein substrates with probiotic bacteria or enzymes obtained from such bacteria as well as specific tripeptides obtained by fermentation of Lactobacillus which inhibit angiotensin-converting enzyme (ACE). Products containing antihypertensive peptides by fermenting casein with lactic acid bacteria, as well as the use of highly purified or chemically synthesized peptides for reducing blood pressure or treating diabetes, renal impairment or obesity, have also been described.
Processes aimed at optimising protein hydrolysate characteristics, for example biological activity useful for therapeutic or nutritional purposes, have used single or mixed endoproteases such as animal-derived endoproteases like trypsin, chymotrypsin and pancreatin. However, there remains a need for processes to derive peptides from hydrolysed food proteins that would be useful in the development of novel food additives and for therapeutic uses.
SUMMARY OF THE INVENTION
The present inventors have found that food proteins can be hydrolysed by safe and food grade enzymes in a food-compatible process to yield peptide products that are not otherwise released by digestion. By using a strategic combination of enzymes with complementary specificities to normal digestive enzymes, peptide fractions are produced that are stable to intestinal digestion and which have biological activity.
Accordingly, in one aspect, the present invention provides a process for obtaining a peptide fraction, the process comprising:
i) contacting a protein substrate with a series of enzymes selected from:
a) glutaminase, subtilisin, oryzin, leucyl aminopeptidase, and trypsin, b) glutaminase, oryzin, subtilisin, leucyl aminopeptidase, and trypsin, c) glutaminase, subtilisin, leucyl aminopeptidase, oryzin, and trypsin, d) glutaminase, oryzin, leucyl aminopeptidase, subtilisin, and trypsin, e) glutaminase, leucyl aminopeptidase, oryzin, subtilisin, and trypsin, and f) glutaminase, leucyl aminopeptidase, subtilisin, oryzin, and trypsin, ii) selecting peptides obtained from step i) which are less than about 11 kDa. In another aspect, the present invention provides a process for obtaining a peptide fraction, the process comprising:
i) contacting a protein substrate with a series of enzymes selected from:
a) trypsin, subtilisin, oryzin, leucyl aminopeptidase, and glutaminase, b) trypsin, subtilisin, leucyl aminopeptidase, oryzin, and glutaminase, c) trypsin, oryzin, subtilisin, leucyl aminopeptidase, and glutaminase, d) trypsin, oryzin, leucyl aminopeptidase, subtilisin, and glutaminase, e) trypsin, leucyl aminopeptidase, oryzin, subtilisin, and glutaminase, and f) trypsin, leucyl aminopeptidase, subtilisin, oryzin, and glutaminase, ii) selecting peptides obtained from step i) which are less than about 11 kDa. In one embodiment, step i) comprises contacting the protein substrate with a series of enzymes selected from:
a) glutaminase, subtilisin, oryzin, leucyl aminopeptidase, and trypsin, b) glutaminase, oryzin, subtilisin, leucyl aminopeptidase, and trypsin, and c) glutaminase, leucyl aminopeptidase, oryzin, subtilisin, and trypsin. The enrichment for peptide fractions of like physicochemical properties, i.e., neutral, cationic and anionic fractions, reflecting the systematic fractionation of related peptides, permits the concentration of a key physicochemical property required for biological activity. Thus, in one embodiment, the process further comprises:
iii) separating the peptides which are less than about 11 kDa into one or more of cation, anion and/or neutral peptide fractions. In an embodiment, the peptides are separated into one or more of cation, anion and/or neutral peptide fractions by ion- exchange chromatography.
In one embodiment the ion-exchange chromatography is performed using cation and anion exchange columns in series.
Although the ion-exchange chromatography may be performed at any suitable pH, preferably, the ion-exchange chromatography is performed at about pH 6.0 to about pH 8.0. In one particular embodiment, the ion-exchange chromatography is performed at about pH 7.4.
In one embodiment, the step ii) is performed by dialysis, membrane filtration or size-exclusion chromatography.
The protein substrate may be any suitable substance that contains protein, for example a food or food protein including animal, plant or microbial proteins, or a non- food animal, plant or microbial protein, or a waste product or by-product from a process. In one embodiment, the protein substrate is a protein-rich extract.
In one particular embodiment, the protein-rich extract is a milk extract, meat extract, plant extract, yeast extract and/or bacterial extract.
In yet another embodiment, the protein-rich extract is a protein hydrolysate. High pressure treatment exposes protein domains to hydrolysis that would not otherwise be exposed. Thus, in one embodiment, the protein substrate may be high pressure treated prior to contacting the protein substrate with the series of enzymes. For example, the protein substrate may be high pressure treated at about 400 MPa to about 800 MPa for about 15 minutes to about 1 hour. In one embodiment, the protein substrate is high pressure treated at about 600 MPa for about 30 minutes.
In another embodiment, the protein substrate is contacted with the series of enzymes glutaminase, subtilisin, oryzin, leucyl aminopeptidase, and trypsin, wherein the protein substrate is selected from fish, soy flour, yeast, pork, beef, chicken, lamb, bovine caseinate, spinach, sheep milk, buffalo milk, spirulina, mushroom, bovine lactoferrin, bovine colostrum, millet, sheep wool, barley, sorghum, amaranth, probiotic microorganisms and bovine whey protein.
In another embodiment, the protein substrate is contacted with the series of enzymes glutaminase, oryzin, subtilisin, leucyl aminopeptidase, and trypsin, wherein the protein substrate is selected from bovine caseinate, bovine whey protein, fish, soy flour, yeast, pork, beef, chicken, lamb, spinach, sheep milk, buffalo milk, bovine
lactoferrin, bovine colostrum, chicken feather, millet, probiotic organisms, and spirulina.
In yet another embodiment, the protein substrate is contacted with the series of enzymes glutaminase, leucyl aminopeptidase, oryzin, subtilisin, and trypsin, wherein the protein substrate is selected from bovine caseinate, bovine whey protein, lactoferrin, fish, soy flour, yeast, beef, chicken, lamb, spinach, spirulina, sheep wool, probiotic organisms, and buffalo milk.
In another embodiment, the process of the invention further comprises isolating one or more peptides from the peptide fraction.
Once a peptide fraction has been obtained by performing the method of the invention, the person skilled in the art may test the peptide fraction and/or isolated peptide for biological activity using any suitable known assay. Thus, in one embodiment, the process further comprises testing the peptide fraction and/or isolated peptide for biological activity. For example, the process may comprise testing the peptide fraction and/or peptide for biological activity selected from angiotensin converting enzyme (ACE) inhibition activity, angiotensin II receptor inhibition activity, anti-inflammatory activity, fibril inhibition activity, beta-secretase I inhibition activity, and inhibition of receptor for advanced glycation endproduct-mediated inflammation activity.
In one embodiment of the process of the invention, the protein substrate is selected from bovine caseinate, bovine whey protein, lactoferrin, fish, soy flour, yeast, pork, beef, chicken, and lamb, and the peptide fraction obtained by the process has angiotensin converting enzyme (ACE) inhibition activity.
In another embodiment, the protein substrate is selected from bovine caseinate, bovine whey protein, sheep milk, buffalo milk, spinach, and spirulina, and the peptide fraction obtained by the process of the invention has angiotensin II receptor inhibition activity.
In yet another embodiment, the protein substrate is selected from bovine whey protein and yeast, and the peptide fraction obtained by the process of the invention has anti-inflammatory activity.
In another embodiment, the protein substrate is selected from bovine caseinate, bovine lactoferrin, bovine colostrum, bovine whey protein, sheep milk, buffalo milk, millet, sheep wool, chicken feather, barley, sorghum, amaranth, mushroom, wheat, and wheat gluten, and the peptide fraction obtained by the process of the invention has fibril inhibition activity.
In yet another embodiment, the protein substrate is probiotic microorganisms, and the peptide fraction obtained by the process of the invention has beta-secretase I inhibition activity.
In another aspect, the present invention provides a peptide fraction obtained by the process of the invention.
The peptide fraction obtained by the process of the invention may be a mixture of charged and neutral peptides. Alternatively, the peptide fraction may be a cation or anion peptide fraction. In one embodiment, the peptide fraction of the invention is a cation peptide fraction at about pH 7.4.
In one embodiment, the peptide fraction of the invention has biological activity.
In one particular embodiment, the biological activity is selected from angiotensin converting enzyme (ACE) inhibition activity, angiotensin II receptor inhibition activity anti-inflammatory activity, fibril inhibition activity, beta-secretase I inhibition activity, and inhibition of receptor for advanced glycation endproduct-mediated inflammation activity.
In another aspect, the present invention provides a composition comprising the peptide fraction of the invention.
In yet another aspect, the present invention provides use of the peptide fraction of the invention or the composition of the invention in the manufacture of a food or drink product. In one embodiment, the food or drink product is a nutritional supplement.
In one aspect, the present invention provides a food or drink product comprising the peptide fraction of the invention or the composition of the invention.
In another aspect, the present invention further provides use of the peptide fraction of the invention or the composition of the invention in the manufacture of a medicament for the treatment or prevention of disease in a subject.
In yet another aspect, the present invention provides a method for the treatment or prevention of disease in a subject, the method comprising administering to the subject the peptide fraction of the invention or the composition of the invention.
In one embodiment of the use or method of the invention, the disease is selected from cardiovascular disease, cancer, inflammatory or autoimmune disease, and/or a neurological disorder.
In another embodiment, the disease is selected from cardiovascular disease and cancer. In one embodiment, the cardiovascular disease that is treated or prevented is selected from hypertension, atherosclerosis and arteriosclerosis.
In another embodiment, the cancer is selected from carcinoma, lymphoma, blastoma, sarcoma, and leukemia.
In yet another embodiment, the cancer is selected from breast cancer, prostate cancer, colon cancer, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, liver cancer, bladder cancer, hepatoma, colorectal cancer, uterine cervical cancer, endometrial carcinoma, salivary gland carcinoma, mesothelioma, kidney cancer, vulval cancer, thyroid cancer, hepatic carcinoma, skin cancer, melanoma, brain cancer, neuroblastoma, myeloma, various types of head and neck cancer, acute lymphoblastic leukemia, acute myeloid leukemia, Ewing sarcoma and peripheral neuroepithelioma.
In one embodiment, the inflammatory or autoimmune disease is selected from asthma, rheumatoid arthritis, inflammatory bowel disease, psoriasis and multiple sclerosis.
In another embodiment, the neurological disorder is selected from Alzheimer's disease, Parkinson's disease, dementia, Huntington's disease, Shy-Drager syndrome, progressive supranuclear palsy, Lewy body disease and amyotrophic lateral sclerosis.
The present invention further provides a peptide fraction of the invention, wherein the peptide fraction is a cation peptide fraction at about pH 7.4, and the peptide fraction was obtained by contacting bovine whey protein isolate with the series of enzymes glutaminase, oryzin, subtilisin, leucyl aminopeptidase, and trypsin.
The present invention further provides a peptide fraction of the invention, wherein the peptide fraction was obtained from a protein substrate comprising mushroom, and the protein substrate was contacted with the series of enzymes glutaminase, subtilisin, oryzin, leucyl aminopeptidase, and trypsin.
As will be apparent, preferred features and characteristics of one aspect of the invention are applicable to many other aspects of the invention.
Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
The invention is hereinafter described by way of the following non-limiting Examples and with reference to the accompanying figures.
BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS
FIGURE 1. Effects of feeding Spontaneous Hypertensive rats with lead dairy anti-hypertensive product versus commercial hydrolysate DH 17, showing (a) rat body masses and (b) tailcuff systolic blood pressures measured at fortnightly intervals over treatment period, starting with rats at 2 weeks of age.
FIGURE 2. Effects of feeding Spontaneous Hypertensive rats with PO 147 at 200 mg/kg/day, showing (a) rat body masses and (b) tailcuff systolic blood pressures measured at fortnightly intervals over treatment period, starting with rats at 2 weeks of age.
FIGURE 3. Inhibition kinetics by Lineweaver-Burk plot for control and lead products: (a) NaCl, (b) P0148 from bovine whey, (c) P0147 from bovine whey and (d) P0052 from bovine caseinate; (e) P0609 from sheep whey and (f) P0498 from soy protein, after concentration of the active fraction by Cl 8 Solid Phase Extraction (SPE).
FIGURE 4. Transmission Electron microscopic imaging of effects of Aβ42 in the absence (a: Aβ42 control incubated for 80 hr at minus 180C; b: Aβ42 control incubated for 80 hr (48 h at 370C, then to 80 hr at 2O0C)) or presence (c: Aβ42 +
BM0263-SPE40 incubated for 80 hr at minus 180C (note scale difference from other images); d: Aβ42 + BM0263-SPE40 incubated for 80 hr (48 h at 370C, then to 80 hr at
2O0C)) of BM0263-SPE40 showing significant suppression of fibril assembly at either minus 180C or 37/2O0C, following incubation for 80 hr.
FIGURE 5. ThT fluorescence monitoring showing effects of selected inhibitors on further fibril growth, in the presence of pre-formed fibrils of Aβ42 (0.043 mg/ml, after 52 hr at 370C) and similar pre-formed fibrils of Aβ42 in the presence of (a)
P0263-SPE40 (millet at 0.17 mg/ml) and (b) BM0263-SPE40 (button mushroom at 0.17 mg/ml).
FIGURE 6. Reverse Phase HPLC profiles of SPE40 and SPElOO sub-fractions of P0147.
FIGURE 7. Modulation of RCM-kCn fibrils by SPE fractions of PO 147, as monitored by RCM-kCn fibril inhibition assay.
FIGURE 8. Concentration-dependent modulation of Aβ42 toxicity to yeast by
SPE fractions of PO 147 after 20 h at 3O0C.
FIGURE 9. CD profiles of human Aβ42 (sample subtracted) in the absence and presence of (a) SPE40 and (b) SPElOO fractions of PO 147 after incubation at 3O0C for 2O h.
FIGURE 10. Western Blot analysis of Aβ42+P0147 mixtures after incubation at 3O0C for 20 h. Freshly prepared Aβ42 (10 μM final) was incubated at with increasing
concentrations of P0147-SPE40+SPE100 (Lanes 1-4: 0.1, 0.05, 0.01 and 0 mg/ml, respectively), and visualized by 6E10 antibody immunoblotting.
FIGURE 11. Transmission Electron microscopy of (a) Aβ42 alone; (b) Aβ42 and P0147-SPE total and (c) P0147-SPE total alone, each incubated at 3O0C for 20 hr.
FIGURE 12. Whole blood inflammation assay results showing (a) SPE non- binding and binding fractions eluting in 40% and 100% acetonitrile tested at 200 μg/ml, • Vegemite, I Marmite, AEpiCor, with IL-10 and hydrocortisone included as positive controls, and (b) untreated Vegemite, reference (Epicor) and total SPE bound fractions of BR0263 and BA0263. Each point is an average of data from four donors with results also shown for individual donors (OΔVO), error bars indicate one SD. 100% = no change, <100% indicates an anti-inflammatory effect.
FIGURE 13. Dose response curve for total SPE bound fractions of: (a) Vegemite, (b) Bakers yeast hydrolysate, BA0263-SPE, (c) Brewers yeast hydrolysate, BR0263-SPE and (d) Epicor-SPE. Results are expressed by representing the average for four donors, error bars indicate 1 SD, and also results for individual donors (OΔVO). 100% = no change, <100% indicates an anti-inflammatory effect based on reduction in level of IFNγ relative to stimulated control in the absence of sample.
DETAILED DESCRIPTION OF THE INVENTION
General techniques and definitions
Unless specifically defined otherwise, all technical and scientific terms used herein shall be taken to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in protein chemistry, biochemistry, food science, cell culture, molecular genetics, microbiology, and immunology).
Unless otherwise indicated, the recombinant protein, cell culture, and immunological techniques utilized in the present invention are standard procedures, well known to those skilled in the art. Such techniques are described and explained throughout the literature in sources such as, J. Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons (1984), J. Sambrook et al, Molecular Cloning: A Laboratory Manual, 3rd edn, Cold Spring Harbour Laboratory Press (2001), R. Scopes, Protein Purification - Principals and Practice, 3 edn, Springer (1994), T. A. Brown (editor), Essential Molecular Biology: A Practical Approach, Volumes 1 and 2, IRL Press (1991), D.M. Glover and B.D. Hames (editors), DNA Cloning: A Practical Approach, Volumes 1-4, IRL Press (1995 and 1996), and F. M. Ausubel et al. (editors), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-
Interscience (1988, including all updates until present), Ed Harlow and David Lane
(editors) Antibodies: A Laboratory Manual, Cold Spring Harbour Laboratory, (1988), and J.E. Coligan et al. (editors) Current Protocols in Immunology, John Wiley & Sons
(including all updates until present).
As used herein the term "protein substrate" refers to any substance which comprises protein. The protein substrate may be, for example, food or may contain food proteins, for example animal, plant or microbial proteins, or the protein substrate may be a non-food substrate such as, for example, a non-food animal, plant or microbial protein, or a waste product or by-product from a process. By way of non- limiting example, the protein substrate may include proteins from dairy, for example milk or milk protein, or from meat, vegetable, grain, yeast or bacteria.
The term "peptide" as used herein is typically used to refer to chains of amino acids which are not large, for instance 100 or less residues in length.
As used herein, the term "peptide fraction" will be understood to indicate a fraction of a hydro lysed protein substrate that contains peptides that may be of different lengths. The "peptide fraction" may also include non-peptide components such as, for example, free amino acids, carbohydrates or lipids.
As used herein, the term "subject" relates to an animal. Preferably, the subject is a mammal such as a human, or a companion animal such as a dog or cat, or a livestock animal such as horse, cow, pig or sheep. Alternatively, the subject may be avian, for example, poultry such as a chicken, turkey or duck. Most preferably, the subject is a human.
"Administering" as used herein is to be construed broadly and includes administering a peptide fraction as described herein to a subject as well as providing a peptide fraction as described herein to a cell.
As used herein, the terms "treating", "treat" or "treatment" include administering a therapeutically effective amount of a peptide fraction as described herein sufficient to reduce or delay the onset or progression of specified disease, or to reduce or eliminate at least one symptom of the disease.
As used herein, the terms "preventing", "prevent" or "prevention" include administering a therapeutically effective amount of a peptide fraction sufficient to stop or hinder the development of at least one symptom of the specified condition.
The term "about" as used herein refers to a range of +1-5% of the specified value.
Process for obtaining peptide fractions
Protein substrate
In some embodiments, it may desirable to first process a substance comprising protein to form a protein-rich extract which is then used as a protein substrate in the process of the invention. For example, it may be desirable to process protein substrates that have relatively low protein content, such as plant materials, to form a protein-rich extract.
If desired plant materials may first be homogenized and treated to remove or reduce the amount of non-protein constituents such as cellulose. Seed grains may optionally be homogenized and proteins such as albumins, glutelins and prolamins extracted by known techniques prior to use as a protein substrate. When probiotic microorganisms are used it is preferred that they are lysed prior to use as a protein substrate in the process of the invention. The probiotic microorganisms may be lysed using known techniques, for example, by French pressing.
In some instances, a substance such as a food containing protein may first be minced or chopped and then finely ground to form a protein substrate. Other additional or alternative treatments include high pressure treatment, oven drying and/or freeze drying prior to use of the substance as a protein substrate in the process of the invention.
The protein-rich extract may also be a protein hydrolysate. Examples of protein hydrolysates suitable for use in the process of the invention include hydrolysates of native food proteins, such as soy proteins, dairy proteins (e.g., whey, casein), wheat proteins, canola proteins, corn proteins, vegetable proteins, grain proteins, animal proteins, yeast proteins, including those available from commercial sources, for example, hydrolysates such as wheat hydrolysate (Gempr HiQ) from Manildra Group, NSW, Australia, hydrolysates such as bovine whey hydrolysate (DH 17) from Myopure, NSW, Australia, and hydrolysates such as rice protein hydrolysate (Hyprol 8115) from Quest International, the Netherlands. Although these protein hydrolysates have been at last partially broken down or digested either by processing or enzymatic cleavage, they still serve as substrates for the enzymes used in the process of the present invention.
In the case of protein hydrolysates, the hydrolysates may be desalted using known techniques such as dialysis prior to use as a protein substrate in the process of the invention. If desired, other substances, for example, milk or skim milk, may also be desalted prior to use as a protein substrate.
Non-limiting examples of protein substrates suitable for use in the process of the invention include bovine proteins such as bovine caseinate, bovine casein hydrolysate
bovine whey protein, wheat, wheat hydrolysate, wheat gluten hydrolysate, soy, soy hydrolysate, soy flour, rice protein hydrolysate, pea protein hydrolysate, milk including cow, buffalo and sheep milk, lactoferrin, fishmeal, fish meat, yeast, yeast extract, pork, beef, chicken meat, chicken feathers, egg or egg proteins, lamb, spinach, spirulina, millet, barley, brewer's spent grain, sheep wool, sorghum, amaranth, mushroom, or probiotic cultures of microorganisms.
Although the protein substrate need only contain protein to be useful in the process of the invention, preferably the protein substrate comprises at least 5% protein, or more preferably at least 10%, 20%, 30%, 40%, or 50% or more protein.
Enzymes
The present inventors have advantageously identified a combination of food- compatible enzymes that yield peptide fractions that may not otherwise be released by digestion. In the process of the invention, the enzymes the protein substrate is processed with are glutaminase, subtilisin, oryzin, leucyl aminopeptidase and trypsin. Use of these exo and endo proteases and peptidases in different sequential combinations generates peptides fractions with variation of terminal amino acids. These peptide fractions, that are produced by hydrolysis of the protein substrate in series, advantageously have anti-disease, nutritional or other desirable properties.
Glutaminase is a hydrolase which acts on carbon nitrogen bonds other than peptide bonds. When reacted with a protein substrate, glutaminase converts glutamine residues to glutamic acid in a deamidation reaction. Enzymes with this activity have been classified as EC 3.5.1.2. Synonyms for glutaminase include glutaminase I, L- glutaminase, and glutamine aminohydrolase. Glutaminase is commercially available and can be obtained, for example, from Daiwa Kasei K.K. Shiga, Japan.
Subtilisin is a serine endopeptidase with broad specificity for peptide bonds, but with a preference for cleavage at glutamic acid residues and also hydrolyses peptide amides. Enzymes with this activity have been classified as EC 3.4.21.62. Alternative names for subtilisin include alcalase, alcalase 0.6L, alcalase 2.5L, alcalase 2.4 L FG, ALK-enzyme, bacillopeptidase A, bacillopeptidase B, Bacillus subtilis alkaline proteinase, bioprase AL 15, bioprase APL 30, colistinase, subtilisin J, subtilisin S41, subtilisin Sendai, subtilisin GX, subtilisin E, subtilisin BL, genease I, esperase, maxatase, thermoase PC 10, protease XXVII, superase, subtilisin DY, subtilopeptidase, SP 266, savinase 8.0L, savinase 4.0T, kazusase, protease VIII, opticlean, protin A 3L, savinase 16.0L, savinase 32.0L EX, orientase 1OB and protease S. Subtilisin is
commercially available and can be obtained, for example, from Novozymes, Bagsvaerd, Denmark under the tradename Alcalase® 2.4 L FG.
Oryzin is a serine endopeptidase which acts on peptide bonds and hydrolyses proteins with broad specificity. Enzymes with this activity have been classified as EC 3.4.21.63. Alternative names for oryzin include Aspergillus alkaline proteinase, aspergillopeptidase B, API 21, aspergillopepsin B, aspergillopepsin F, Aspergillus candidus alkaline proteinase, Aspergillus flavus alkaline proteinase, Aspergillus melleus semi-alkaline proteinase, Aspergillus oryzae alkaline proteinase, Aspergillus serine proteinase, Aspergillus sydowi alkaline proteinase, Aspergillus soya alkaline proteinase, Aspergillus melleus alkaline proteinase, Aspergillus sulphureus alkaline proteinase, prozyme, P 5380, kyorinase, seaprose S, semi-alkaline proteinase, sumizyme MP, prozyme 10, onoprose, onoprose SA, protease P, and promelase. Oryzin is commercially available and can be obtained from, for example, AB Enzymes, Darmstadt, Germany under the tradename Corolase PN-L.
Leucyl aminopeptidase is a hydrolase that acts on peptide bonds to release an N- terminal amino acid from XaaYaa in which Xaa is preferably Leu, but may be other amino acids including Pro, although not Arg or Lys, and Yaa may be proline. Enzymes with this activity are classified as EC 3.4.11.1. Alternative names for leucyl aminopeptidase include leucine aminopeptidase, leucyl peptidase, peptidase S, cytosol aminopeptidase, cathepsin III, L-Leucine aminopeptidase, leucinamide aminopeptidase, FTBL proteins, proteinates FBTL, aminopeptidase I, aminopeptidase II, aminopeptidase III. Leucyl aminopeptidase is commercially available and can be obtained from, for example, Novozymes, Bagsvaerd, Denmark under the tradename Flavourzyme.
Trypsin is a serine endopeptidase which acts on peptide bonds and preferentially cleaves arginine and lysine. Enzymes with this activity are classified as EC 3.4.21.4. Alternative names for trypsin include alpha-trypsin, beta-trypsin, cocoonase, parenzyme, parenzymol, tryptar, trypure, pseudotrypsin, tripcellim and sperm receptor hydrolase. Trypsin is commercially available and can be obtained, for example, from Novozymes.
Although the protein substrate may be completely hydrolysed by a given enzyme, the person skilled in the art would understand that in some instances a given enzyme may only at least partially hydrolyse the protein substrate.
In one embodiment of the process of the invention, the protein substrate is first contacted with glutaminase to achieve conversion of glutamine residues to glutamic acid, thereby increasing the anionic character of peptides at physiological pH.
Contacting a protein substrate with glutaminase also allows for the production of peptides having potentially enhanced biological activity. The protein substrate that has been at least partially hydrolysed by glutaminase is then contacted with the other hydrolytic enzymes in series.
In another embodiment, the final enzyme with which the partially hydrolysed protein substrate is contacted is trypsin. The use of trypsin as a final enzyme advantageously achieves digestive stability of the peptide fraction produced by the process of the invention and which contains a heterogeneous mixture of peptides.
In the process of the invention, subtilisin, oryzin and leucyl aminopeptidase may be used in any order so as to produce heterogeneity in peptide length, sequence and biological activity. Preferably, however, the protein substrate is contacted with the enzymes in a series selected from:
a) glutaminase, subtilisin, oryzin, leucyl aminopeptidase, and trypsin, b) glutaminase, oryzin, subtilisin, leucyl aminopeptidase, and trypsin, and c) glutaminase, leucyl aminopeptidase, oryzin, subtilisin, and trypsin.
For hydrolysis with the aforementioned enzymes, protein substrates or processed products thereof are dissolved or suspended in a suitable buffer. Such buffers that are suitable for hydrolysis are well known to those skilled in the art and include Tris, triethanolamine (TEA), sodium borate, PBS, HEPES amongst other well known buffers. Determining a suitable buffer, its concentration and pH for performing hydrolysis is a matter of routine for the person skilled in the art. Typically the pH of the buffer will fall within the range of pH 6.0 to pH 9.0, but preferably will be about pH 6.0 to about pH 8.0, and in one embodiment is about pH 7.4. The buffer may also comprise other components such as cofactors or small quantities of organic solvent to increase the solubility of the protein substrate. One example of a buffer suitable for use in the process of the present invention is 10 mM TEA, 10% ethanol, pH 7.4.
The amount of protein in the protein substrate suspension or solution may vary. For example, the solution or suspension may contain about 5% to about 25% protein (w/w), or preferably about 10% to about 20% protein (w/w). Other reaction conditions such as reaction time and incubation temperature can be readily determined by the skilled person. For example, a protein substrate may be reacted with each enzyme for a period from about 5 minutes to about 24 hours, preferably about 30 minutes to 2 hours. In one embodiment, the protein substrate is reacted with each enzyme for about 1 hour. The temperature of the hydrolysis reaction will depend on the particular enzyme that is being reacted with the protein substrate. For example, glutaminase, leucyl aminopeptidase, subtilisin and oryzin may be reacted with the protein substrate at about
45°C to about 55 0C, preferably at about 500C. For trypsin, the temperature of the reaction is preferably about 37°C and the reaction is an hour or more, or alternatively at least 2, 3, 5, 10 or more hours.
An exemplary hydrolysis reaction suitable for use in the process of the present invention involves dissolving or suspending a protein substrate or processed product thereof at about 10% total protein (w/w) in 10 mM TEA, 10% EtOH, pH 7.4 and maintained at pH 7.4 throughout the hydrolysis process. After rehydration, the first enzyme, for example, Glutaminase may be added to a final concentration of 0.5% (w/w) and incubated with agitation at 500C for 1 hour. The enzymes subtilisin (Alcalase) (0.5%, w/w), oryzin (Corolase) (0.5%, w/w) and leucyl aminopeptidase (Flavourzyme) (0.5%, w/w) may be subsequently introduced sequentially at 1 hr intervals at 500C, according to one of 3 possible sequences. When used as the final enzyme, trypsin (0.5%, w/w) may be introduced to the mixture and incubated at 37°C for 17 hours (overnight). Following hydrolysis, the enzymes may be inactivated, for example, by heating at 900C for 30 min.
In the exemplary hydrolysis reaction, each of the enzymes is added to the reaction mixture sequentially, with each enzyme at least partially hydrolysing the protein substrate prior to the addition of the next enzyme. In this exemplary reaction, the enzymes are not heat inactivated before the addition of the next enzyme in the series. Further, the partially hydrolysed protein substrate is not isolated or purified between each reaction with a different enzyme. The skilled person would understand, however, that following the at least partial hydrolysis of the protein substrate with an enzyme, the enzyme could be heat inactivated prior to the addition of the next enzyme in the series. Alternatively, if desired, the at least partially hydrolysed protein substrate could be isolated or purified prior to contacting the substrate with the next enzyme in the series.
Size fractionation
Following hydrolysis of the protein substrate, peptides of about 11 kDa or less are selected. In one embodiment, the process of the invention involves selecting peptides about 8 kDa or less. There are several techniques known in the art for separating peptides based on size. By way of non-limiting example, peptides of about 11 kDa or less may be selected by dialysis, membrane filtration or size-exclusion chromatography.
Recovery of a peptide fraction by dialysis may be achieved by performing dialysis of the hydrolysate with a suitable dialysis membrane such as a regenerated cellulose or cellulose ester dialysis tubing with an appropriate molecular weight cut-off.
Membrane filtration is a process for separating small particles and dissolved molecules from fluids and is suited to the selection of peptides about 11 kDa or less. A membrane's pore size rating, typically given as a micron value, indicates that peptides, proteins or other molecules larger than the rating will be retained. Ultrafiltration membranes which are particularly suited to selecting peptides are rated according to the nominal molecular weight limit (NMWL), also sometimes referred to as molecular weight cut-off (MWCO). The NMWL indicates that most dissolved macromolecules with molecular weights higher than the NMWL will be retained. Typically membranes are made of materials such as regenerated cellulose and microporous PVDF.
As would be understood by one of skill in the art, the retention and recovery of peptides by membrane filtration may be affected by other factors, including the molecular shape and size of the molecule; electrical characteristics; sample concentration and composition; operating conditions; and device or system configuration. Two membranes may have the same NMWL but will exhibit different retention of molecules within a relatively narrow range of sizes. In addition, slender, linear molecules may find their way through pores that will retain a globular species of the same weight. Retention can also be affected by hydration with counter-ions. The person skilled in the art would routinely be able to determine an appropriate membrane for use in the process of the invention to select peptides about 11 kDa or less.
Charge fractionation
The present inventors found that the fractionation of the selected peptides at physiological pH to resolve neutral, cationic and anionic fractions further permits the enrichment of fractions with bioactivity as may be required in a particular physiological setting. Thus in one embodiment, the process of the invention may optionally include the step of separating the peptides into one or more of a cation, anion and/or neutral peptide fraction.
Techniques for separating peptides based on charge are known to those skilled in the art. One technique that is suited to the process of the invention is ion-exchange, for example ion-exchange chromatography. As is known to the person skilled in the art, Ion Exchange Chromatography relies on charge -charge interactions between the proteins in a sample and the charges immobilized on a chosen resin. Ion exchange
chromatography can be subdivided into cation exchange chromatography, in which positively charged ions bind to a negatively charged resin; and anion exchange chromatography, in which the binding ions are negative, and the immobilized functional group is positive. As used herein, the term "neutral peptide fraction" refers to a peptide fraction which has no net charge and does not bind to either a cation exchange resin or anion exchange resin at a given pH.
Any type of ion-exchange material can be used. For example, ion exchange resins can be cationic, anionic, mixtures of cation and anionic, or biologically related. Examples of ion exchange resins useful in this invention include, but are not limited to, those made of cross-linked polyvinylpyrolodone and polystyrene, and those having ion exchange functional groups such as, but not limited to, halogen ions, sulfonic acid, carboxylic acid, iminodiacetic acid, and tertiary and quaternary amines. Examples of biologically related resins that can be used in the process of the invention include, but are not limited to, Sephadex™, CM C-25, CM C-50, DEAE A-25, DEAE A-50, QAE A-25, QAE A-50, SP C-25, and SP C-50. These cationic, anionic, mixed cationic and anionic, and biologically related ion exchange resins are commercially available.
A variety of buffers at different pH values (e.g., Tris-HCL, HEPES, and multi- pH phosphate buffers) can be used to tailor charge distribution. A linear or step gradient of pH or salt can be used to elute peptide fractions from ion-exchange media.
As would be understood in the art, the charge on a peptide affects its behaviour in ion-exchange chromatography. Peptides may contain ionizable groups on the side chains of their amino acids as well as their amino- and carboxyl-termini. These include basic groups on the side chains of lysine, arginine and histidine and acidic groups on the side chains or glutamate, aspartate, cysteine and tyrosine. The pH of the solution, the pK of the side chain and the side chain's environment influence the charge on each side chain.
In one exemplary method of ion-exchange chromatography suitable for use in the process of the invention, cation exchange (SP Sepharose BB) and anion exchange (Q Sepharose BB) columns may be connected in series. Batches of size selected peptides may be loaded onto the columns with non-binding neutral peptide fractions collected. The columns may then be uncoupled and the fraction bound to the cation exchange column eluted with a 1 M NaCl solution for the recovery of a cationic peptide fraction. The fraction bound to the anion exchange column may be eluted with 1 M NaCl to recovery an anionic peptide fraction. Using such an exemplary method, a size selected peptide fraction may be further fractionated into non-binding (neutral), cationic and anionic fractions.
Testing the peptide fractions for biological activity
The present inventors have found that the peptide fractions of the invention may exhibit biological activity and be useful for the modulation of biological pathways associated with disease. As used herein, a "biologically active" peptide or peptide fraction, or a peptide or peptide fraction having "biological activity" may be one which is capable of regulating or modulating for example, the cardiovascular system such as by modulating blood pressure, the immunohemopoietic system, or which may affect the viability, growth and differentiation of a variety of normal or neoplastic cells in the body, or which modulates immune-mediated inflammatory or autoimmune disorders, or neurological disorders. Alternatively, the biologically active peptide may be one which is capable of affecting immune regulation or which is capable of enhancing or inducing resistance to infection of cells and tissues, or which modulates energy metabolism as relevant to diabetes and metabolic disease. Non-health related biological activity includes anti-fibril chaperone activity useful for the stabilisation of proteins during thermal processing.
There are many assays known to those skilled in the art for determining whether a peptide fraction of the invention has a particular biological activity. Such assays include, by way of non-limiting example, assays for determining whether a peptide fraction of the invention has angiotensin converting enzyme (ACE) inhibition activity, angiotensin II receptor inhibition activity, anti-inflammatory activity or fibril inhibition activity.
ACE inhibition activity may be determined, for example, by monitoring the decrease in absorbance at 340 nm as a result of ACE-mediated hydrolysis of the substrate 3-(2-furylacryloyl)-L-phenylalanylglyclglycine (FAPGG) (Sigma-Aldrich, Sydney, Australia) to 3-(2-furylacryloylphenylalanine (FAP) and glyclglycine (GG) (Harjanne, 1984) in the presence of a peptide fraction of the invention.
Anti-inflammatory activity may be determined, for example, by generating a ThI response in human peripheral blood mononuclear cells culture by the addition of IL-7 and IL- 12. The stimulation of naϊve T-cells to mature into ThI cells causes the production of ThI associated cytokines including IFN-γ (Gutcher and Becher, 2007). A decrease in the level of IFN-γ in a sample comprising a peptide fraction of the invention relative to a control culture is indicative of anti-inflammatory biological activity.
One example of an assay for determining fibril inhibition activity of a peptide fraction utilises reduced and carboxymethylated κ-casein (RCM-K-CN) which forms amyloid fibrils under physiological conditions. The RCM-K-CN is incubated in the presence and absence of test peptide fractions and the formation of amyloid fibrils monitored.
Other suitable assays for determining a biological activity of a peptide fraction of the invention would be know to those of skill in the art.
Food and drink products and nutritional supplements
In one embodiment of the invention, a peptide fraction obtained by the process of the invention is included in a food or drink product. Food or drink products according to the invention can be prepared by the skilled person using known techniques. Non-limiting examples of such food or drink products are baked goods, dairy type foods and drinks, snacks, etc. The amount of the peptide fraction of the invention to be used in a food or drink product can be variable as the peptides themselves are nutrients.
In one embodiment, the food or drink product is a nutritional supplement. As used herein, a "nutritional supplement" is an orally ingestible product consumed to improve overall nutrition, health, well-being, or performance of a subject in an activity and/or an orally ingestible product which provides additional perceived nutritional or biological benefit to a subject. As would be understood, the nutritional supplement may be provided in a concentrated form, thus allowing for the addition of the nutritional supplement to a food or drink product to allow for the consumption of a desired quantity of a peptide fraction of the invention in a reasonable serving size.
The food or drink product of the present invention can include additional ingredients including an orally ingestible diluent or carrier. Many orally ingestible diluents or carriers are known in the food sciences. These include, but are not limited to, manufactured cereals, fruit or vegetable products, beverages or beverage concentrates, ground meat products or vegetable analogues thereof, and any inert diluent, carrier, or excipient known in the pharmaceutical art. Preferably, the peptide fractions of the current invention constitute from about 0.0001 to about 10.0% by weight of the food or drink product.
The nutritional supplement of the current invention can include additional ingredients. In some embodiments, more than one of the peptide fractions of the current invention can be included in the same nutritional supplement formulation. Other
additional ingredients include any ingestible product. Preferred additional ingredients include, but are not limited to, other active food supplement ingredients such as vitamins and minerals. The food additive may also include acceptable dispersing and suspending agents, and water. Other conventional nutritional supplements can also be included if desired. The nutritional supplement can take many forms including, but not limited to, powders, tablets, capsules, solutions, concentrates, syrups, suspensions, or dispersions.
Therapeutic methods
The peptide fractions obtained by the methods of the invention are of use for the inhibition of biological pathways associated with disease including cardiovascular disease, cancer, inflammatory or autoimmune disease, or neurological disorders. Thus, in one aspect, the present invention provides methods of treating or preventing disease by administering to a subject a peptide fraction of the invention or a composition of the invention.
In one embodiment, a peptide fraction of the invention may be used in the treatment or prevention of cardiovascular disease in a subject, such as for example, for lowering blood pressure in a subject. Using the peptide fractions of the invention to lower blood pressure in a subject may decrease the risk of, for example, heart failure, kidney failure, and the harmful effects of diabetes. In addition, the peptide fraction of the invention may be used for the treatment or prevention of cardiovascular diseases including, but not limited to hypertension, atherosclerosis and arteriosclerosis.
The peptide fractions of the invention may be useful in the treatment or prevention of cancer in a subject, including, but not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More particular examples of such cancers include breast cancer, prostate cancer, colon cancer, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, liver cancer, bladder cancer, hepatoma, colorectal cancer, uterine cervical cancer, endometrial carcinoma, salivary gland carcinoma, mesothelioma, kidney cancer, vulval cancer, thyroid cancer, hepatic carcinoma, skin cancer, melanoma, brain cancer, neuroblastoma, myeloma, various types of head and neck cancer, acute lymphoblastic leukemia, acute myeloid leukemia, Ewing sarcoma and peripheral neuroepithelioma.
The peptide fractions obtained by the methods of the invention are of use for the inhibition of biological pathways associated with disease including inflammatory and
autoimmune disease and/or neurological disorders. Inflammatory disorders and autoimmune diseases which may be treated with peptide fractions of the invention include asthma, rheumatoid arthritis, inflammatory bowel disease, psoriasis and multiple sclerosis. Autoimmune diseases arise from an overactive immune response of the body against substances and tissues normally present in the body. Examples of autoimmune diseases include Addison's disease, alopecia areata, ankylosing spondylitis, antiphospholipid antibody syndrome (APS), autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, bullous pemphigoid, coeliac disease, chagas disease , chronic obstructive pulmonary disease, Crohns disease (one of two types of idiopathic inflammatory bowel disease "IBD"), dermatomyositis, diabetes mellitus type 1, endometriosis, goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome (GBS), Hashimoto's disease, hidradenitis suppurativa, Kawasaki disease, IgA nephropathy, idiopathic thrombocytopenic purpura, Interstitial cystitis, lupus erythematosus, mixed connective tissue disease, morphea, multiple sclerosis (MS), myasthenia gravis, narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anaemia, psoriasis, psoriatic arthritis, polymyositis, primary biliary cirrhosis, rheumatoid arthritis, scleroderma, Sjogren's syndrome, ulcerative colitis, vasculitis, vitiligo and Wegener's granulomatosis.
The peptide fractions of the present invention may also be used for the treatment or prevention of a neurological disorder, such as, but not limited to Alzheimer's disease, Parkinson's disease, dementia, Huntington's disease, Shy-Drager syndrome, progressive supranuclear palsy, Lewy body disease or amyotrophic lateral sclerosis.
Compositions and administration
In certain embodiments, the present invention provides compositions comprising a peptide fraction of the invention and a suitable carrier or excipient. In one embodiment, the composition is a pharmaceutical composition comprising a pharmaceutically acceptable carrier. The peptide fractions are incorporated into pharmaceutical compositions suitable for administration to a mammalian subject, e.g., a human. Such compositions typically comprise the "active" compound (i.e. the peptide fraction) and a "pharmaceutically acceptable carrier". As used hereinafter the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the
art. Except insofar as any conventional media or agent is incompatible with the active compound, such media can be used in the compositions of the invention. Supplementary active compounds can also be incorporated into the compositions.
A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral (e.g., intravenous, intradermal, subcutaneous, intramuscular, intraperitoneal, intrathecal), mucosal (e.g., oral, rectal, intranasal, buccal, vaginal, respiratory), enteral (e.g., orally, such as by tablets, capsules or drops, rectally) and transdermal (topical, e.g., epicutaneous, inhalational, intranasal, eyedrops, vaginal). Solutions or suspensions used for parenteral, intradermal, enteral or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier is a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity is maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms is achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid and the like. In many cases, it is preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged
absorption of the injectable compositions is brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions may be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound is incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions are also prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. Systemic administration can also be by mucosal or transdermal means. For mucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for mucosal administration, detergents, bile salts, and fusidic acid derivatives. Mucosal administration is accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
A pharmaceutically acceptable vehicle is understood to designate a compound or a combination of compounds entering into a pharmaceutical composition which does not cause side effects and which makes it possible, for example, to facilitate the administration of the active compound, to increase its life and/or its efficacy in the body, to increase its solubility in solution or alternatively to enhance its preservation. These pharmaceutically acceptable vehicles are well known and will be adapted by persons skilled in the art according to the nature and the mode of administration of the active compound chosen. EXAMPLES
Example 1. Protocols for preparation of protein substrates
Materials
Chlorhexidine gluconate (20%) and Tris-Hydrochloride (Tris-HCl) were from ICN Biomedicals, Aurora, Ohio.
Spectra/Por regenerated cellulose membranes with molecular weight cut-off
(MWCO) 6000-8000 Daltons were obtained from Spectrum Laboratories, Inc., Dominguez, CA.
Ethanol (EtOH) was from CSR Distilleries, Victoria, Australia.
Triethanolamine (TEA), Phosphate buffered saline (PBS) tablets, Sodium bicarbonate (NaHCO3), Ethylenediaminetetraacetic acid (EDTA), L-cysteine, polyvinylpyrrolidone (PVP) and Sodium acetate were from Sigma Chemical Co., St. Louis, MO, USA.
Sodium Chloride (NaCl) and Magnesium chloride (MgC^) were obtained from Univar, NSW, Australia.
Isopropanol (IP) and sodium dodecyl sulphate (SDS) were from BDH, VWR
International Ltd., Poole, England.
Urea and Acetic acid were from Merk, Darmstadt, Germany.
Ammonium Hydroxide (25%) was from BASF, Singapore.
SPI extraction buffer: 20 mM Tris-HCl, pH 8.0, 10 mM NaHCO3, 10 mM MgC12, 1 mM EDTA, 1 mM L-Cysteine, 1% insoluble PVP.
5.0 M acetic acid.
Water soluble protein extractant: 0.5 M NaCl.
Prolamins extractant: 50% IP containing 1% acetic acid and 1% L-Cysteine. Glutelins extractant: 4 M urea, 1% ammonium hydroxide, 1% L-Cysteine dissolved in water.
Protocol 1. No further processing
Substrates purchased from commercial sources were hydrolysed without further processing.
Protocol 2. Commercial substrates desalted prior to hydrolysis
Substrate reconstituted to 10% total solids in milliQ water and placed in regenerated cellulose dialysis tubing (6-8 KDa MWCO). Dialysis was conducted against 2 changes of 0.001% Chlorhexidine gluconate and 3 changes of distilled water over 48 hours. The resulting substrate free of minerals and salts was freeze-dried and stored at -200C pending hydrolysis.
Protocol 3. Desalting of skimmed milk by ultra- filtration
10 litres of fresh milk was skimmed by centrifugation (3000g /30 min, J6-HC, Beckman Coulter, Inc. Fullerton, CA, USA) at 100C. The skimmed milk was processed through a 1OK (SlYlO, Millipore, Billerica, MA, USA) membrane to concentrate to
500 ml and diafiltered with 5 volumes of distilled water. The concentrated purified retentate was freeze dried and stored at -200C pending hydrolysis. Protocol 4. Substrate denaturation by high pressure processing (HPP)
Substrate reconstituted to 1% total protein (w/w) in 10% ethanol and subjected to 600 MPa pressure in HPP unit (QFP 35L, Flow Pressure Systems, S-72166 Vasteras, Sweden) for 15 minutes at 22°C. The resulting denatured substrate was freeze-dried and stored at -200C pending hydrolysis.
Protocol 5. Commercially available probiotic cells lysed by French pressing
Materials
CHR-HANSEN La-5: (Direct Vat Set (DVS)) Thermophilic Lactic Culture nu- trish. Lot 264795; DOM 28.10.2005; BBD 29.10.2007.
DSM DELVO Pro LAFTI-L26: Direct Set Lyophilized starter culture (DSL);
Lot 129338/10; BBD 14./01.2007; 10 units/bag.
Method
45 g of freeze dried probiotic cell culture was washed 3 times with phosphate buffered saline (PBS) by suspension and centrifugation (14,000rpm/30,100g for 20
mins at 40C (J2-MC centrifuge, JA- 14 rotor, Beckman Coulter, Inc., Fullerton, CA, USA)) in 205 g of PBS. The washed cell pellet was re-suspended in equal mass of hydrolysis buffer (10 mM TEA in 10% ethanol) and lysed by three consecutive passes through the French press (manufactured at Melbourne University, Victoria, Australia as described in Vanderheiden et al. (1970). The cells were cooled on ice between passes to prevent over heating. The lysed cell slurry preparations were stored at -200C pending hydrolysis.
Protocol 6. Fresh fish fillet purchased from local fish-monger/supermarket and freeze- dried
500 g of fish fillet (deboned and skin removed) were cut into 2 cm3 pieces and freeze-dried. The freeze-dried pieces were ground to fine powder in a blender (Semak Australia, Victoria, Australia) and stored at -200C pending hydrolysis. Protocol 7. Fresh meat portions purchased from local butcher/supermarket and oven- dried
1 kg of fat-free meat portions were cut into 2 cm pieces and minced using a meat grinder (HV6, Moulinex, France). The minced meat was oven dried (Rational combi-Dampfer oven, Comcater, Victoria, Australia) at 1200C for 2 hours. The dried mince was ground to fine powder in a blender (Semak Australia, Victoria, Australia) and stored at -200C pending hydrolysis.
Protocol 8. Preparation of spinach protein isolate (SPI) for hydrolysis
12 kg of spinach (roots discarded) was washed and chopped coarsely. The leaves were blanched in 2 litres of boiling water to inactivate enzymes and soften cellulosic structures and chilled immediately. 5 volumes of SPI extraction buffer was added and leaves homogenised using a blender (Semak Australia, Victoria, Australia).
The mixture was centrifuged (4200rpm /30 min, J6-HC, Beckman Coulter, Inc.,
Fullerton, CA, USA) and supernatant strained through a sieve (50 μm) to remove solids. The clear filtrate was processed through UF membrane (10 K- SlYlO,
Millipore, Billerica, MA, USA) to remove salts, using 5 volumes of 10% ethanol, before concentrating to 5 litres. 2.5 litres of retentate was processed as per Protocol 4 to denature the proteins and freeze-dried and stored at -200C pending hydrolysis.
Remaining portion of retentate was Freeze dried (native SPI) and stored at-20°C pending hydrolysis.
Protocol 9. Preparation of sheep wool and chicken feathers
The substrate was washed using distilled water and excess moisture was removed by shaking and blotting in absorbent paper. The clean wool/feathers were chopped into pieces (2 - 6mm) with the help of sharp scissors.
Protocol 10. Preparation of lactoferrin-enriched bovine colostral whey
The pH of bovine colostrum was adjusted to 4.6 with 5.0 M acetic acid and the mixture was warmed to 400C for 30 min (to melt fat) in a water bath. Fat was removed by centrifugation (3000g /30 min, J6-HC, Beckman Coulter, Inc.Fullerton, CA, USA) at 100C. After discarding fat, the supernatants (colostral whey) were pooled and diluted by 1/3 using distilled water. The pH was readjusted to 5.2 using 5.0 M sodium acetate and the whey was processed through 5 m2 UF plant (30 K membrane).
Retentate was diafiltered 1 fold with distilled water. The retentate was collected; spray dried and stored at -200C pending hydrolysis.
Protocol 11. Milling of seed grains
Seeds were cleaned of any extraneous matter and milled using a blender (Semak Australia, Victoria, Australia) or hammer mill (> 2kg, Ernest Fleming Pty Ltd, New South Wales, Australia) to a particle size range of 0.5 mm- 1.2 mm.
Protocol 12. Preparation of albumin extract from seed grains
2 kg of millet was prepared as per Protocol 11. Water-soluble proteins (albumin) were extracted by adding 2 litres of 0.5 M NaCl to the millet sample and mixing vigorously by overhead stirring at room temperature (RT) for 1.0 hr. The soluble proteins were recovered by centrifugation (4200rpm /30 min, J6-HC, Beckman Coulter, Inc., Fullerton, CA, USA) at RT and the process was repeated with 3 litres of 0.5 M NaCl. The supernatants (pellet was saved for protocol 12) were pooled and processed through a IK (Prep scale TFF, Millipore, Billerica, MA, USA) membrane to concentrate to 200 ml and diafiltered with 5 volumes of distilled water. The concentrated desalted retentate was freeze dried and stored at -200C pending hydrolysis.
Protocol 13. Preparation of prolamin extract from panorama millet
Alcohol soluble proteins (Prolamins) were extracted by adding 2 litres of prolamin extractant to the millet solid fraction from Protocol 12 and mixing vigorously
by overhead stirring at RT for 1.0 hr. The soluble proteins were recovered by centrifugation (4200rpm /30 min, J6-HC, Beckman Coulter, Inc.Fullerton, CA, USA) at RT and the process was repeated with 3 litres of prolamin extractant. The supernatants (pellet was saved for protocol 14) were pooled and 2 volumes of 1.5 M NaCl was added to allow protein fraction to precipitate overnight at 4°C. The precipitate was recovered and placed in regenerated cellulose dialysis tubing (6-8 KDa MWCO). Dialysis was conducted against 2 changes of 0.001% Chlorhexidine gluconate and 3 changes of distilled water over 48 hours. The resulting desalted protein solution was freeze-dried and stored at -200C pending hydrolysis.
Protocol 14. Preparation of glutelin extract from panorama millet
Alkali soluble proteins (Glutelins) were extracted by adding 2 litres of glutelin extractant to the millet solid fraction from Protocol 13 and mixing vigorously by overhead stirring at RT for 1.0 hr. The soluble proteins were recovered by centrifugation (4200rpm /30 min, J6-HC, Beckman Coulter, Inc., Fullerton, CA, USA) at RT and the process was repeated with 3 litres of glutelin extractant. The supernatants were pooled and placed in regenerated cellulose dialysis tubing (6-8 KDa MWCO). Dialysis was conducted against 2 changes of 0.001% Chlorhexidine gluconate and 3 changes of distilled water over 48 hours. The resulting desalted protein solution was freeze-dried and stored at -200C pending hydrolysis.
Protocol 15. Preparation of total protein extract from panorama millet
The wet extracts from Protocol 12, 13 and 14 were pooled together and mixed thoroughly before placing in regenerated cellulose dialysis tubing (6-8 KDa MWCO). Dialysis was conducted against 2 changes of 0.001% Chlorhexidine gluconate and 3 changes of distilled water over 48 hours. The resulting desalted protein solution was freeze-dried and stored at -200C pending hydrolysis.
Protocol 16. Preparation of fish meal protein isolate (FMPI)
A 10% solution of fishmeal in 5% SDS was homogenised using Ultra-turrax
(T25, Crown Scientific P/L, NSW, Australia) for 5 minutes at 13500 rpm and heated to 800C for 1 hour. The mixture was cooled to room temperature and centrifuged (RC5C Sorvall Instruments, Minnesota, USA) at 8000 rpm for 20 minutes. The supernatant was filtered and processed through a 3K (S1Y3, Millipore, Billerica, MA, USA) membrane to concentrate to 200 ml and diafiltered with 3 volumes of distilled water.
The concentrated purified retentate was freeze dried and stored at -200C pending hydrolysis.
Example 2. Preparation of peptide library products
Materials
All reagents are approved for use in food processing according to Standard 1.3.3 describing the use of processing aids (Food Standards Australia New Zealand). All laboratory-scale processing involved reagent or better grade reagents whereas all materials used in the pilot plant were food grade.
Triethanolamine (TEA) was from Sigma Chemical Co., St. Louis, MO, USA.
Ethanol (EtOH) was from CSR Distilleries, Victoria, Australia. Sodium Chloride (NaCl) was obtained from Univar, NSW, Australia.
Alcalase 2.4L, Flavourzyme IOOOL and Trypsin enzymes were obtained from Novozymes, Bagsvaerd, Denmark. Corolase PN-L was obtained from AB Enzymes GmbH, Darmstadt, Germany. Glutaminase was obtained from Daiwa Kasei K.K., Shiga, Japan.
Dialysis membrane (Spectra/Por regenerated cellulose, molecular weight cut-off (MWCO) 6000-8000 Daltons) were from Spectrum Laboratories, Inc., Dominguez, CA. SP and Q Sepharose Big Beads ion exchange resins (BB) were obtained from GE Healthcare, Uppsala, Sweden.
Substrate hydrolysis
Food source refers to the original material from which a protein-rich 'substrate' was prepared, where necessary. In some cases, the food source and substrate, e.g., dairy whey protein isolate, were one and the same material. In other cases, e.g., Panorama millet, a protein-rich substrate was prepared from the original food source. If not available in a powder form, all food sources were washed and ground or milled to a particle size range of 0.5 to 1.2 mm before further processing. Methods for preparation of protein-rich substrates from specific food sources are described for specific 'leads' in tables below.
Substrates were dissolved or suspended at 10% total protein (w/w) in 10 mM TEA, 10% EtOH, pH 7.4 and maintained at pH 7.4 throughout the hydrolysis process. After rehydration, the first enzyme Glutaminase was added to a final concentration of 0.5% (w/w) and incubated with agitation at 500C for 1 hour. The enzymes Alcalase (0.5%, w/w), Corolase (0.5%, w/w) and Flavourzyme (0.5%, w/w) were subsequently
introduced sequentially at 1 hr intervals at 500C, according in one of 3 possible sequences (Table 1). The final enzyme Trypsin (0.5%, w/w) was introduced to the mixture and incubated at 37°C for 17 hours (overnight). The enzymes were inactivated by heating at 900C for 30 min, and the product cooled to 220C for at least 15 mins.
Table 1. Use of enzyme sequence to generate molecular heterogeneity for bioactivity discovery.
Fractionation of substrate hydro lysates
For each hydrolysate product, the molecular size fraction <8 KDa was recovered by dialysis using regenerated cellulose membrane (6-8 KDa MWCO). Each dialysate was subjected to ion exchange chromatographic fractionation, as follows. Peptide fractionation was performed using 2 columns (4.6 x 10 cm) connected in series. Column 1 was packed with cation exchange resin (SP Sepharose BB) and Column 2 was packed with anion exchange resin (Q Sepharose BB) The eluant was monitored by UV detection at 280 nm (Shimadzu SPD-10AV, Kyoto, Japan).
Batches of dialysate (400 ml) were loaded onto the two columns with 400 ml of dialysate collected containing non-binding species (designated 'IEO' fraction), corresponding to recovery of non-binding species absorbing at 280 nm. The columns were uncoupled and the fraction bound to the cation exchange column was eluted in 200 ml of 1 M NaCl solution (designated 'IE+' ), corresponding to recovery of cationic species absorbing at 280 nm. Finally, the fraction bound to the anion exchange column was eluted in 200 ml of 1 M NaCl solution (designated 'IE-' ), corresponding to recovery of anionic species absorbing at 280 nm. Thus, each dialysate was fractionated into 3 products, yielding a total of 9 distinct products from each protein substrate (Table 2) or 6 different products where the substrates were commercially available
hydrolysates (Table 3). All products were freeze dried and stored at -200C pending bioactivity testing and other methods of characterisation.
Table 2. Use of enzyme sequence and chromatographic fractionation to generate molecular heterogeneity for bioactivity discovery, yielding 9 distinct products from each protein substrate, as used in unhydrolysed form. When required, ion-exchange fractionation of the hydrolysate was omitted (NIE).
Table 3. Use of enzyme sequence and chromatographic fractionation to generate molecular heterogeneity for bioactivity discovery, yielding 6 distinct products from each substrate, where substrates were commercially available hydrolysates.
Assay protocol
The assay for the determination of pig kidney ACE (EC 3.4.15.1) (Sigma- Aldrich, Sydney, Australia) employed a COBAS BIO autoanalyser (Roche Diagnostics Ltd, Rotkreuz, Switzerland) which monitored the decrease in absorbance at 340 nm as a result of ACE-mediated hydrolysis of the substrate 3-(2-furylacryloyl)-L- phenylalanylglyclglycine (FAPGG) (Sigma-Aldrich, Sydney, Australia) to 3-(2- furylacryloylphenylalanine (FAP) and glyclglycine (GG) (Harjanne, 1984). Initially 250 μL reagent buffer as 100 mM Tris-HCl pH 8.3, 300 mM NaCl, 10 μM ZnCl2 containing ACE at 0.032 U/ml was loaded from a buffer boat and 20 μL of test sample (10-50 mg/ml) or known ACE inhibitors such as captopril (1-100 nM) or the tripeptide valinealanineproline (VAP, 0.1-20 μM) (Auspep Pty Ltd, Melbourne, Australia) found in as 1 -casein from the sample carousel are transferred into the multiple cuvette and spun in 2 minutes to warm to 37°C. At that time 50 μL of substrate FAPGG at final concentration 0.5 mM is transferred to the plastic multiple cuvette and quickly mixed and spun with the decrease in OD monitored from zero time every two minutes for 16 minutes which was in the linear range of the assay. The final ACE concentration was 0.025U/ml. Results
A broad range of substrates yielded peptide products with significant capacity for inhibition of ACE (Table 4). Substrates included several classes of dairy protein, vegetable, grain, yeast and meat protein sources. In vitro activity was significantly associated with IEO chromatographic fractions and all enzyme sequence codes were represented. In vivo bioactivity appeared to be associated with IE+ fractions.
Table 4. Angiotensin converting enzyme inhibition bioactivity of food protein-derived peptide fractions.
Example 4. Angiotensin II receptor inhibition activity
Assay protocol
Rat livers or pig hearts were snap frozen in liquid nitrogen and coarsely ground in a pestle and mortar and membranes prepared by differential centrifugation (Leifert et
al., 2009). To 1 g of frozen tissue was added 10 ml of ice cold isolation medium containing (in mM) 250 sucrose, 50 mM Tris, 1 MgCl2, 1 EDTA, pH 7.4 and homogenised with an Ultra-Tarrax (Jankee & Kundel GmbH, Staufen, Germany) on setting 4 for 3 bursts of 10 seconds with a short rest in between bursts. The solution was filtered through two pieces of nylon mesh and washed through with 5 ml of isolation media and centrifuged at 3,000 x g for rat liver or 6,000 x g for pig heart in a J2-21 centrifuge (Beckman Instrument Co., Palo Alto, CA) for 30 min at 4°C. The supernatant was decanted and retained and the pellet resuspended in isolation medium and centrifuged as before. The supernatants were combined and centrifuged at 46,000 x g for 30 min. The final pellet was suspended (in mM) 50 Tris, 10 MgCl2, 1 EGTA, pH 7.4 assay buffer with 5 stokes of a dounce glass/Teflon homogeniser that contained protease inhibitors diluted into the buffer at 1: 1000 (vol/vol). The stock protease inhibitor concentrations were (mg/ml, solvent) phenylmethylsulfonyl fluoride 17.4, DMSA; aprotinin 1, H2O; iodoacetate 184, H2O; and pepstatin A 1.37, DMSO. The final stock concentration of liver or heart membrane preparations was 1-2 mg/ml and stored in aliquots at -800C.
Assay of [125I-Sa^-IIe8I angiotensin II receptor binding to rat liver membrane
Receptor radioligand binding activity was determined for rat liver membrane fraction (3,000-46,000 x g) with the All antagonist [^IHSar'-Ile^-angiotensin II (2200 Ci/mmol, 10 μCi in 200 μl assay buffer diluted to 1 nM stock) (Perkin Elmer, MA, USA) which is specific for the ATi receptor at sub Ka concentration of 0.1 nM (Del Carmen Caro et al., 1998; Leifert et al., 2009). The assay final volume of 75 μl in a 4 ml plastic tube contained (in mM) 90 Tris, 10 MgCl2, 1 EGTA, pH with 0.2% BSA with buffer or the antagonists losartan (10-1000 nM), saralasin (1-100 nM), PD12319 (10-10,000 nM, AT2 antagonist) or agonist angiotensin II (1-100 nM) (all Sigma- Aldrich, Sydney, Australia) or the prepared library fractions or products. Peptides or plant products were dissolved in 10% ethanol (v/v) in (mM) 90 Tris, 10 MgCl2, 1 EGTA adjusted to pH 7.4 with 2 N NaOH, centrifuged at 8,000 x g (Sigma 113 Laborzentrifugen, Ostrode am Harz, Germany) and added at 0.01-10 mg/mL final in the assay. The assay contents were pre-incubated with of 7 μl of rat liver membrane preparation containing approximately 7 μg protein for at least 10 min. The assay is commenced by the addition of 7.5 μl 1 nM [125I]-[Sar1-Ile8]-Angiotensin II (0.1 nM final) and the binding reaction allowed to proceed for 50 min while shaking at 25°C (Del Carmen Caro et al., 1998). Non specific binding was determined in the presence of
unlabelled All or losartan and did not exceed 5%. To separate bound radioligand from free unbound radioligand, 3 ml of ice cold was buffer (mM) 90 Tris, 10 MgCl2, 1 EGTA, pH 7.4 was added to the assay tube and the contents rapidly filtered over GF/C filters (Whatman International Ltd, Maidstone, England) that were pre-soaked in wash buffer containing 1% polyethylenimine (Sigma- Al drich, Sydney, Australia) and washed 3 more times. Total counts on the GF/C filters were measured in a gamma counter (LKB Wallac Multigamma, Stockholm, Sweden).
Results
A range of substrates yielded peptide products with significant capacity for inhibition of angiotensin 1 receptor. Substrates included several classes of dairy protein, vegetable and cellular sources. In vitro activity was significantly associated with IE+ chromatographic fractions and only enzyme sequence codes 1-3 were represented indicating that commercial hydrolysates tested were not bioactive in this assay. A selection of substrates, required non-thermal, high pressure protein denaturation to release bioactive peptides.
Table 5. Summary of Angiotensin I receptor inhibition bioactivity of food protein- derived peptide fractions generated using systematic method of hydrolysis and chromatographic fractionation.
Example 5. In vivo testing protocol in spontaneous hypertensive rat study 1
The lead anti-hypertensive products were tested in the Spontaneous Hypertensive rat model by dietary intervention over 20 weeks of feeding. The test feed was given as a mixture of leads comprising P0147+P0148+P0052 (1 : 1: 1). Rats were randomised into 4 treatment groups based on the following dietary interventions (control, dairy lead mixture at 20 mg/kg, dairy lead mixture at 200 mg/kg and a commercial whey protein hydrolysate (Myopure) at 200 mg/kg. Tailcuff blood pressures and body weights were monitored every 14 days with peripheral blood flow and activity of plasma ACE measured at completion of study.
The results from the SH Rat Study 1 are shown as effects on body weight (Figure Ia) and tailcuff blood pressures (Figure Ib). The experimental feeds did not significantly alter weight gain in intervention compared groups with the control group. However, the P0147/P0148/P0052 mixture included in solid feeds significantly attenuated development of blood pressure in a dose-dependent manner. The reference hydrolysate (unfractionated commercial hydrolysate, Myopure) produced a similar extent of BP lowering at 200 mg/kg/day to the mixture fed at 20 mg/kg/day. This showed that the specific activity of the test mixture was higher than the Myopure although their in vitro bioactivities were similar. Thus, the process used to produce the products in the mixture yielded a product of superior bioavailability to Myopure.
Example 6. In vivo testing protocol in spontaneous hypertensive rat study 2
The component of the mixture responsible for the in vivo bioactivity observed in SH rats Study 1 was investigated in a subsequent SH rat feeding study (Study 2). In an equivalent study protocol to Study 1, PO 147 was tested alone in the Spontaneous Hypertensive rat model, i.e., by dietary intervention over 20 weeks of feeding at 200 mg/kg/day. Rats were randomised into 2 treatment groups (control, PO 147 at 200 mg/kg. Tailcuff pressures and body weights were monitored every 14 days. The results (Figure 2) suggest that PO 147 was not responsible for the anti-hypertensive effect
observed in Study 1 even though PO 147 exhibited the highest specific ACE inhibitory activity by in vitro assay.
Example 7. Inhibition kinetics of angiotensin converting enzyme
Assay for determination of Angiotensin converting enzyme inhibition
The HPLC-based method described was adapted from that of Cushman and Cheung (1971). In brief, hippuric acid (HA) is released from a substrate hippuryl-L- histidyl-L-leucine (HHL) in the presence of Angiotensin I-converting enzyme (ACE) and HA is isolated by extraction into ethyl acetate and measured by absorbance at 228 nm. The concentration of the HA released from HHL is directly related to ACE activity or its inhibition. In the adapted method, the concentration of HA and HHL was quantified by HPLC.
Hippuryl-L-histidyl-L-leucine (4 mM, St. Louis, MO, USA) and angiotensin I- converting enzyme (25 μL, 0.05 unit/mL, rabbit lung, St. Louis, MO, USA) were dissolved in reaction buffer (0.1 M dipotassium hydrogen phosphate, 0.3 M NaCl, pH 8.3). HHL (50 μL, St. Louis, MO, USA) was prepared in 4 different concentrations (4, 2, 1 and 0.5 mM). Test inhibitor samples were dissolved in MQ water and tested each at 0, 0.1, 0.5, 1.0 and 2.0 mg/mL for each concentration of substrate. The reaction mixture was incubated at 37°C for 30 min using an Eppendorf Thermomixer (Brinkmann Instruments, New York, USA) with continuous agitation (500 rpm) before inactivation of the enzyme by addition of 1 M HCl (50 μL). By omission of enzyme, the HHL concentration corresponding to zero enzyme activity (i.e., 100% inhibition) was determined and used to calculate the 5 inhibition of test samples. Inhibition was expressed as the percentage of inhibition of ACE activity compared with the control. Data were analysed using MS Excel XP and Prism (V4.0, GraphPad Software Inc., CA, USA).
HA and HHL analysis was performed by HPLC (ThermoFinnigan HPLC system, with diode-array detection, a MS pump, and Xcalibur Version 1.4 SRl software, ThermoFinnigan USA). Samples (10 μL) were injected onto C18 reverse phase column (Vydac 238 EV52, monomeric column, 2.1 x 250 mm, 5 μm). HA and HHL were detected at 228 nm. Column temperature was 350C. Gradient elution using solvent systems: (A) 0.08% TFA (St. Louis, MO, USA) in acetonitrile (HPLC-grade), and (B) 0.1% TFA in Milli-Q water, at 150 μl/min flow rate (0 to 5 min at 10% A, increase to 18% A at 8 min and to 90% A at 12 min, hold at 90% A for 2 min and then return to 10% A over 1 min and re-equilibrate before next injection). The concentration
of HA produced from enzyme reaction was quantified by comparison with a calibration curve using fresh standards of HA in water, over the range 1 to 250 μM.
Sample preparation by solid phase extraction (SPE)
Test samples were fractionated using solid phase extraction cartridge media in order to isolate the active peptide fraction and eliminate salts. Samples were dissolved in MQ water 0.1 to 0.5 g total solids loaded per SPE column (Strata-X reversed phase polymeric sorbent, 500 mg/6 ml, particle size 33 μm, pore size 85 A, surface area 800 m /g, Phenomenex Australia). A 12-position SPE vacuum manifold set (AHO-60230) was used for loading, washing and elution cycles (Phenomenex Australia).
SPE columns were conditioned with 5 ml methanol and equilibrated with 5 ml MQ water. Sample (5 ml) was loaded onto the column and washed with 5 ml MQ water. Void, wash and samples eluted into 5 ml of 10%, 30%, 50% or 100% acetonitrile were collected after drying under vacuum at 350C, before testing ACE inhibition activity.
Results
In order to understand the lack of correlation of in vitro data with the in vivo result, the competitive kinetics of inhibition of components of the mixture were studied (Figure 3). The active fractions of leads tested in SHR Study 1 were evaluated in terms of kinetic mode of enzyme inhibition by in vitro assay. The results show that the active fraction of PO 148 (as isolated by Cl 8 Solid Phase Extraction), exhibits competitive inhibition kinetics whereas active fractions of PO 147 (IEO) and P0052 (IE-) exhibit either uncompetitive or non-competitive inhibition kinetics respectively. These results support that the PO 148 component of the mixture tested in Study 1, which was recovered by cation exchange (IE+) fractionation, was most likely responsible for in vivo bioactivity. Furthermore, active fractions recovered by SPE of the IE+, but not IEO or IE- fractions of sheep whey and soy protein hydrolysates using a similar processing method (i.e., enzyme sequence), also exhibited competitive inhibition kinetics (Figure 3e and 3f). These results suggest that in some instances the recovery of the cationic fraction of peptides, following enzymatic hydrolysis using the enzyme method described in this invention, facilitates the identification of peptide fractions having in vivo bioactivity.
Example 8. Anti-T helper Cell type 1-mediated inflammation activity
Assay protocol
A ThI response in a human Peripheral Blood Mononuclear Cell (PMBC) culture system was generated by the addition of interleukin 7 (IL7), for homeostatic proliferation and survival of naϊve T-cells (Rathmell et al., 2001); and interleukin 12 (IL12) to promote the stimulation of naϊve T- cells to mature into ThI cells. This mimics, in part, the cytokine environment created by antigen presenting cells (APCs). The stimulation of naϊve T- cells to mature into ThI cells causes the production of ThI associated cytokines including IFN-γ (Gutcher and Becher, 2007).
Anti-inflammatory effects of a food extract, protein, or peptide were demonstrated by introducing the test substance into a culture containing PBMC, IL- 12 and IL-7 and monitoring levels of IFN-γ. A decrease in the levels of IFN-γ relative to a control culture, where the extract, protein, or peptide was not present, was taken as indicating an anti-inflammatory effect while an increase in the level of IFN-γ relative to control was taken to indicate a pro-inflammatory response.
Results
A small selection of substrates yielded peptide products with significant capacity for inhibition of T Helper cell Type 1-mediated inflammation (Table 6). Substrates included bovine whey protein after high pressure denaturation and several sources of yeast protein including commercial hydro lysates (i.e., Vegemite) and both Brewers and Bakers yeast sources. In vitro activity was significantly associated with IE+ chromatographic fractions and enzyme sequence codes 1, 2 or 4 were represented. Table 6. Summary of inhibition of T Helper Cell Type 1 receptor inhibition bioactivity of food protein-derived peptide fractions generated using systematic method of hydrolysis and chromatographic fractionation.
Assay protocol
For use in these assays, κ-casein was reduced and carboxymethylated as previously described (Bennett et al., 2009). Our model target protein, RCM-K-CN, which forms amyloid fibrils under physiological conditions, was used in a primary high throughput microtitre plate screen for potential inhibitors of amyloid formation (Carver et al., 2010). RCM-K-CN was incubated at 37°C in 50 mM phosphate buffer, pH 7.4 at 0.5 mg/mL. Screened samples were prepared by weighing out appropriate quantities and diluted to double final concentration in the assay using MiIIiQ water as solvent for peptide samples and 10% ethanol for plant samples.
All samples in the assay were prepared in duplicate and incubated with 10 μM ThT. The plates were sealed to prevent evaporation and the fluorescence levels measured with a Fluostar Optima plate reader (BMG Labtechnologies, Melbourne, Australia) with a 440/490 nm excitation/emission filter set over 1000 mins. As ThT fluorescence is temperature dependent and RCM-K-CN binds a small amount of ThT in its native state, the first 45 mins of the assay show a slight decrease in ThT fluorescence intensity as the samples equilibrate to 37°C. Following each assay the percentage inhibition after 1000 mins (i.e. the difference in the change in ThT fluorescence between the sample with and without added tested samples after 1000 mins incubation, expressed as a percentage - see equation below) was calculated for each sample and is reported in the results. The change in ThT fluorescence in the absence of RCM-K-CN was negligible for most samples. For those in which there was a small increase in ThT fluorescence in the absence of the RCM-K-CN, this has been taken into account in the calculations of the Inhibition percentage (IP).
% inhibition = 100 * (ΔI - ΔL)
ΔI
Where: ΔI and ΔIS represents the change in ThT fluorescence after 1000 mins for RCM-K-CN in the absence and presence of the tested sample respectively.
In the concentration-dependent studies, the samples were used at a number of concentrations and the percent inhibition data were used to calculate the IC50 for that tested samples (i.e. the concentration of solids able to inhibit the increase in ThT fluorescence by 50%) using PRISM software.
Results
A selection of substrates yielded peptide products with significant capacity for inhibition of RCM-kCn fibril assembly (Table 7). Substrates included several bovine and non-bovine dairy sources, sheep wool, chicken feather and millet. The application of the same process for millet P0263 yielded anti-fibril fractions also from Brewers spent grain and sorghum. In vitro activity was significantly associated with IEO chromatographic fractions and several enzyme sequence codes were represented. Activity in millet, sorghum and spent grain was elicited following 1-NIE processing.
Table 7. Summary of inhibition of reduced carboxymethylated kappa casein fibril assembly bioactivity of food protein-derived peptide fractions generated using systematic method of hydrolysis and chromatographic fractionation.
Assay protocol
Beta-Amyloid (1-42), Aβl-42, was purchased from Anaspec Company (San Jose, CA, USA) and then dissolved with 60 μL 1.0% NH4OH. MiIIiQ water was added to make a 250 μM stock solution, which was aliquoted and stored at - 80 0C until use.
Amyloid fibril formation by Aβl-42 was monitored using an adapted in situ ThT binding assay similar to that described above for RCM-K-CN. 25 μM Aβl-42 in 50 mM phosphate buffer (pH 7.4) with 100 mM NaCl was incubated at 37°C in black μclear 96-microwell plates (Greiner Bio-One, Stonehouse, UK) either in the presence or absence of tested samples. The percent protection afforded by each sample was calculated from the ThT fluorescence data at 200 mins by the same equation as used for the RCM-K-CN ThT assay (see above).
Results
Bioactivity of a selection of leads from Table 7 were tested in the Amyloid beta
1-42 fibril inhibition assay and bioactivity confirmed. A peptide and analogues identified in P0263 exhibited anti-fibril activity (Table 8).
Table 8. Summary of inhibition of Amyloid beta 1-42 peptide fibril assembly bioactivity of food protein-derived peptide fractions generated using systematic method of hydrolysis and chromatographic fractionation.
Example 11. Oligomer inhibition activity by GFP-Ab yeast assay
The Saccharomyces cerevisiae assay system employs an Aβ42-MRF fusion with functional MRF being required for growth of yeast (Bagrianstev et al., 2006). The
Aβ42-MRF fusion readily aggregates into non-functional high n-oligomers due to
Aβ42-induced oligomerisation. However, several compounds that decrease the oligomerisation, allow growth. Growth assays are convenient and can be performed on solid or liquid media. Our system is a hybrid of the above two in that it uses a GFP-Aβ fusion in yeast. We have previously used it to examine how GFP-Aβ affects yeast, finding a growth stress and a heat shock response (Caine et al., 2007). This effect appears relevant to AD, where elevated levels of heat shock proteins are observed in AD brains, suggesting that yeast may be a relevant model for AD pathogenesis.
Assay protocol
In 5". cerevisiae, plasmids pASIN.GFP and pAS IN. GFP-Aβ direct the constitutive synthesis of GFP and GFP-Aβ, respectively. Standard yeast strains transformed with these plasmids have been previously described (Bayly et al., 2001). Cells were spread at 107 cells per plate of solidified media and incubated for 16 hours. Plates of 90 mm diameter contained 20 ml solidified media. Cells were re-suspended from the surface of the plate into water immediately before flow cytometry analyses.
LCYl [pASlN.GFP-Aβ] and LCYl [pASIN.GFP] cells were grown in solidified minimal media (with tryptophan but lacking leucine) supplemented with folinic acid at 50, 100, 200, and 300 μg/ml concentrations. Propidium iodide (PI) was used to identify dead cells. GFP fluorescence was assessed using a flow cytometer (FACSCalibur, BD Biosciences). Data were analyzed using CellQuest analysis software. Cell population gated on a forward and side scatter dot plot was analyzed for PI staining. GFP fluorescence was estimated in the population of Pi-negative (live) cells. Fifteen thousand cells per sample were analyzed. Results
Bioactivity of a selection of leads from Table 7 were also tested in the yeast expression system of GDP-tagged amyloid beta 1-42. In this assay fluorescence increases >10% represent significant anti-fibril activity and the assay also confirms cellular uptake of samples associated with positive results. As for previous fibril- specific assays, millet and related grains following 1-NIE processing exhibited significant anti-fibril assay in this cell system. Some additional bioactive peptides were identified from dairy and Spirulina. Bioactivity was associated with IEO fractions indicating that low net charge was required for cell uptake (Table 9).
Table 9. Summary of inhibition of Aβ 1-42 oligomerisation as indicated by increase in GFP fluorescence, by food protein-derived peptide fractions generated using systematic method of hydrolysis and chromatographic fractionation.
Assay protocol
Dried plant samples were dispersed in 10% ethanol at approximately 50 mg/mL total solids by vortexing and extracted for 30 mins using gentle agitation, at room temperature. Supernatants containing extractable solids were freeze dried before reconstitution at 20 mg/mL in 10% ethanol. The stock solution was diluted by 1/100 into sodium acetate buffer (0.1 M, pH 4.5) to a final concentration of 200 μg/mLH. A working sample aliquot (25 μl) was pre-incubated (15 mins at room temperature) with BACEl enzyme (25 μL at 4 μg/mL, Calbiochem) before adding the fluorescent substrate (50 μL at 25 μM, Calbiochem) and commencing monitoring of the reaction. The enzyme inhibition assay was adapted to a high-throughput format using 96-well plate format and microplate fluorescence reader (Biotek FL600, Bio-Tek Instruments Inc, VT, USA), monitoring for 2 hours at room temperature, at excitation and emission wavelength settings of 360 and 485 nm, respectively. Enzyme activity was detected as a linear increase in florescence over the 2 hour monitoring timeframe, and inhibition was measured as the percentage reduction in the fluorescence increase, compared to the
control reaction. For dose response experiments, the concentration of extracts was the only variable altered, with all other conditions remaining constant.
Results
Capacity for inhibition of beta secretase was associated with protein substrates from bovine dairy and egg protein sources. In addition, a peptides product prepared from a probiotic cell biomass was bioactive following high pressure denaturation and hydrolysis (3 -IEO) (Table 10).
Table 10. Summary of inhibition of Beta Secretase Type 1 enzyme bioactivity of food protein-derived peptide fractions generated using systematic method of hydrolysis and chromatographic fractionation.
Example 13. Inhibition of receptor for advanced glycation endproduct-mediated inflammation
Assay protocol
Cell maintenance
RAW264.7 cells (obtained from Ian Cassidy, University of Queensland, Australia) and Ni l microglia (obtained from the University of Tublingen, Germany) were grown in 175cm2 cell culture flasks on Dulbecco's Modified Eagle's Medium (DMEM) containing 5% fetal calf serum (FCS), supplemented with penicillin (200 U/ml), streptomycin (200 μg/ml) and Fungizone (2.6 μg/ml). Both cell lines were maintained at 37°C in a humid environment containing 5% CO2. Activation of macrophages and microglia with LPS and Interferon-y
After cells had grown to confluence in culture flasks, they were removed using a rubber cell scraper. Use of trypsin was avoided as it can catalyse the removal of membrane -bound receptors. Cells were concentrated by centrifugation for 3 min at 900
rpm, resuspended in a small volume of fresh DMEM (5% FCS), cell densities estimated using a Neubauer counting chamber and cell densities adjusted to 106 cells/ml. Cells (100 μl) were dispensed into the 60 inner wells of 96-well plates. Sterile distilled water was added to the outer row of wells. Plates were incubated at 37°C for 24 hours with 5% FCS DMEM to allow growth to confluence. The media was removed by aspiration and cell were the grown in 0.1% FCS containing media for 18 hours.
Samples to be tested were dissolved in DMSO, 95% ethanol or ddH2O to concentrations of 100 mg/ml. Dilutions were then made in media from these concentrates, so that the maximum solvent content did not exceed 0.05% of the final well volume. All stock solutions were stored at -200C and dilutions in media were stored at 4°C for no longer than one week.
After the cells had been in media for 18 hours, the media was removed by aspiration. For assays with extracts, the dilutions in media were added one hour prior to addition of the activation mixture containing 25 μg/ml LPS and 10 U/ml IFN-γ (Shanmugam et al, 2008, Berbaum et al, 2008). Plates were incubated at 37°C (5% CO2) for 24 hours. Every plate contained three wells that only contained media as a negative control, while 10 μg/ml LPS was used as a positive control. Vehicle controls were initially present, where all solvents used were tested alone at 0.05% of total volume, but did not have a significant effect on cells in terms of activating ability or effect on viability.
Nitric oxide determination in cell culture supernatant the Griess reagent
Nitric oxide production was monitored by measuring the concentration of nitrite in the media using the 'Griess reagent' (Fox et al., 1982). Conditioned media (50 μl) from each well was transferred to a fresh 96-well plate and 25 μl of Reagent 1 (1% w/v sulfanilamide in ddH2O) and 25 μl of Reagent 2 (0.1% w/v naphthyethylene-diamine in 5% HCl) were added and the absorbance at 540nm determined using a plate reader (Multiskan Ascent with Ascent software v2.4, Labsystems). Determination of TNF in cell culture supernatant by ELISA
The concentration of TNF, following 24 hours of incubation of cells with LPS was determined by a Sandwich Enzyme -Linked Immunosorbent Assay (ELISA), according to the manufacturer's manual (Peprotech). Briefly, capture antibody was used at a concentration of 1 μg/ml in PBS (1.9 mM NaH2PO4, 8.1 mM Na2HPO4, 154 mM NaCl) (pH 7.4). Serial dilutions of TNF standard from 0 to 10000 pg/ml in diluent
(0.05% Tween-20, 0.1% BSA in PBS) were used as internal standard. TNF was detected with a biotinylated second antibody and an Avidin peroxidase conjugate with ABTS as detection reagent. Colour was determined at 405nm in a 96 well plate reader. Cell viability assays
Cell viability was assessed using MTT (3-(4,5-dimethylthiazol-2-yl)2,5- diphenyl tetrazolium bromide) which measures the level of energy production and respiration in a cell (Takahashi et al., 2002). DMEM (50 μl) containing lmg/ml MTT was added to each well and incubated for 1 hour at 37°C (5%CO2). Media was then removed and 100 μl of 95% ethanol added. Following shaking for at least 30 minutes, the absorbance at 595 nm was measured. Cell viability was also assessed using Neutral Red uptake (Borden & Leonhardt, 1977). Following removal of media of 50 μl of DMEM containing 25 μg/ml Neutral Red was added to the wells and incubated for 1 hour at 37°C (5% CO2). The media was then removed and 100 μl of the cell lysis solution (50% ethanol, 10% acetic acid) added to each well. Plates were then shaken for 30 minutes and the absorbance at 540 nm was measures with a 96 well plate reader.
Results
Substrates from fish, soy and probiotic biomass yielded peptide products with significant capacity for inhibition RAW macrophage inflammation (Table 11). The anti-inflammatory activity of P0263 was thought to be related to its anti-fibril activity as demonstrated previously. In vitro activity was significantly associated with IEO chromatographic fractions and enzyme sequence codes 1-3 were represented.
Bioactivity associated with IEO fractions may indicate cell uptake but anti- inflammatory effects were also possible by inhibition of extra-cellular processes IE- and IE+ fractions.
Table 11. Inhibition of RAW macrophage inflammation in selected food protein- derived peptide fractions.
Example 14. Anti-fibril activity of BM0263 from button mushroom
Materials and methods
Sample preparation
BM0263 was prepared according to the method applied for millet 'P0263' as per Table 8, with the exception that the button mushroom was processed without prior
concentration of protein fraction and dispersed initially at a stock concentration of 10% total solids on a dry weight basis, before addition of enzymes. BM0263-spe40 sub- fraction was prepared by recovering the fraction that eluted from C18 Solid Phase Extraction cartridges in 40% acetonitrile after elution of the non-binding fraction with water.
RCM-kCn fibril inhibition assay
Performed as described previously in Example 9. TEM imaging
Sample concentrations were optimised in order to permit visualisation of fibrils without background interference from inhibitor. The reduction of three dimensions of volume to a two-dimensional area rendered changes in extent of fibrillisation difficult to assess, requiring large excess of inhibitor to observe effects. Amyloid beta 1-42 (Ab 1-42, Rpeptides, USA ) was dissolved in DMSO (1 mg/ml) and immediately stored in aliquots (100 μl) at -180C. An aliquot of Ab 1-42 was diluted by 1/10 in water producing a stock solution of 0.1 mg/ml in 10% DMSO. The mushroom product stock solution was 10 mg/ml in water. Ab 1-42 and mushrooms stock solutions were mixed 1 : 1 (v/v) and divided in half with one set of samples (including Ab 1-42 only controls) incubated at -180C and the other set of samples incubated at 370C, each for 48 hr. The final concentrations were 0.05 and 10 mg/ml for Ab 1-42 and mushroom solids, in 5% DMSO.
Carbon-coated 300-mesh copper grids were glow-discharged in nitrogen to render the carbon film hydrophilic. A sample aliquot (4 μl) was pipetted onto each grid with excess liquid drawn off using filter paper, after 30 seconds adsorption time, before staining with 2% aqueous potassium phosphotungstate at pH 7.2, for 10 seconds. Grids were air-dried pending analysis. The samples were examined using a Tecnai 12 Transmission Electron Microscope (FEI, Eindhoven, The Netherlands) at an operating voltage of 120 KV. Images were recorded using a Megaview III CCD camera and AnalySIS camera control software (Olympus, Tokyo, Japan). Each grid was systematically examined and imaged to reflect a representative view of the sample.
Results
The 'P0263' analogue prepared from button mushroom exhibited significant anti-fibril activity in the RCM-kCn assay and this activity was supported by the
suppression of progression of self-assembly of human Ab42 peptide, as monitored by TEM (Table 12; Figure 4).
Table 12. Summary of inhibition of reduced carboxymethylated kappa casein fibril assembly bioactivity of food protein-derived peptide fractions, generated using systematic method of enzyme hydrolysis and chromatographic fractionation.
Example 15. Dissolution of Ab42 fibrils by P0263 and BM0263
Materials and methods
Dissolution of fibrillar Aβ42 by SPE40 fractions of millet and button mushroom
Freshly prepared Aβ42 was dissolved in MQ water and sonicated for 10 min and then placed in 370C oven for 52 hr before being used for dissolution study. P0263- SPE40 (from Panorama millet) and BM0263-SPE40 (from Button mushroom were dissolved in MQ water, respectively. Equal volumes of Aβ42 and P0263-SPE40 or BM0263-SPE40 (100 μl each) and 30 μl 20 μM ThT were added to a 96 microplate (OptiPlate-96F, PerkinElmer Inc., MA, USA), each in triplicate. The final concentrations for fibrillar Aβ42 was 0.043 mg/ml, and for PP0263SPE40 or BM0263SPE40 were 0.17 mg/ml, respectively. They were incubated at 370C for 66 hr with fluorescence intensity readings at 10 min intervals (Varioskan Flash, Thermo Scientific, USA and 442/482 nm excitation and Emission wavelengths, respectively.
Results
The extent of preformed fibrillization of Aβ42 was reflected in the starting level of ThT fluorescence with the growth of fluorescence in the Aβ42 controls indicating clear capacity for further fibril growth (Figure 5a). In the presence of either P0263-
SPE40 (Figure 5a) or BM0263-SPE40 (Figure 5b), ThT fluorescence was not only suppressed completely but a downward trend in fluorescence was evident over the 66 hr incubation. These trends suggested that the inhibitory factors present in the millet and mushroom products were able to both prevent assembly of new fibrils and also to dissolve pre-existing fibrils. The downward trend was greater for the mushroom compared with the millet-derived product, when compared at the same level of sample solids indicating higher specific activity of the mushroom compared with the millet product. Example 16. Regulation of toxicity of amyloid beta peptide by SPE fractions of dairy hydrolysate fraction P0147
Materials and methods
Preparation of PO 147 SPE fractions
PO 147 hydrolysate was prepared from bovine whey protein isolate using confidential project methods and contained 77.6% protein (w/w). P0147 was sub- fractionated using Cl 8 solid phase cartridges (Phenomenex, California, USA). The void and unbound species (LW) were eluted with water and bound fractions sequentially eluted with 40% and 100% acetonitrile (Aj ax Fine Chem, NSW, Australia, SPE40, and SPElOO respectively).
Reverse phase HPLC profiling
Fractions were analysed by reverse phase HPLC (Jupiter 5μ C18 300A, 25O x
4.6, Phenomenex, California, USA) connected to Waters Alliance HPLC with Photo
Diode array Detector (Waters, Massachusetts, USA). A gradient elution was employed with mobile phase A (0.1% TFA in water) and B (0.1% TFA in 95% acetonitrile) at a flow rate of 1.0 ml/min over 60 mins.
Preparation ofAβ solutions
Synthetic human Aβ42 (Aβ) was purchased from the W. M. Keck Laboratory (Yale University, New Haven, CT). Solutions of Aβ were prepared according to the method of Bharadwaj et al. (2008) with some modifications. Aβ was dissolved in l,l,l,3,3,3-hexafluoro-2-propanol (HFIP) and incubated overnight at RT. The HFIP solution was centrifuged at 14000 rpm for 10 min and the supernatant removed. The HFIP was then evaporated and the resulting peptide film dissolved in sterile double- distilled water. The solution was sonicated on ice for 5 min and centrifuged for 10 min
at 14000 rpm. The supernatant contained soluble oligomers and was used for the toxicity experiments. The Aβ peptide concentration was determined by measuring absorbance at 214 nm. The final concentration was calculated using the formula Aβ (M) = Abs214 x DF / 75887. All solvents used for the preparation of Aβ solutions were filtered using 0.2 μm filters and the entire procedure was performed in laminar air flow hoods.
In situ fluorescent RCM kappa-casein assay
Inhibition of fibril assembly was monitored using reduced and carboxymethylated-kappa casein (RCM-kCn, 0.5 mg/ml) prepared according to
Schecter et al, 1973. The RCM-kCn was used as a model for protein fibril self assembly as follows. RCM-kCn (0.5 mg/mL) was incubated with test peptide samples for 24 h at 370C in black Clear 96-microwell plates that were sealed to prevent evaporation. ThT (Thioflavin T) was added to a final concentration of 10 μM. The ThT fluorescence intensity of each sample was recorded every 5 min using a FLUOstar
OPTIMA plate reader (BMG Lab technologies) with 440-/490-nm excitation/emission filters set. Percentage fibril inhibition (Fi) was calculated as follows: Fi (%) = 100 *
(dl-c - dl-s )/dI-c , where dl_c and dl_s represent the change in ThT fluorescence in the absence (control) and presence of sample, respectively. Fibril inhibition (Fi) was calculated as the percentage change in ThT fluorescence in the absence and presence of sample, after correction for any background fluorescence of the sample.
Yeast cell viability assay
Aβ42 toxicity assay in yeast was done according to the method of Bharadwaj et al. (2008). The prototrophic yeast strain Candida glabrata ATCC 90030 was used in this study. Cultures of yeast cells were grown in YEPD (1% yeast extract; 2% peptone,
2% dextrose), to achieve exponential growth phase. These cultures, containing -10 yeast cells/ml, were diluted to ~5 x 10 yeast cells/ml in sterile, pure water. Cells were then aliquoted into 96-well microtitre plates for peptide treatments. Peptide preparations were added to the diluted cell suspension to required concentrations. The final volume in each well was made up to 125 μl. The microtitre plate was then sealed with gas permeable membrane (Diversified Biotech Inc.) and incubated at 300C constantly shaken at 150 rpm for 20 h. Cell survival was determined by plating aliquots of peptide treated cell suspensions onto YEPD agar plates to measure the number of colony- forming units (cfu).
Circular dichroism spectroscopy
Aβ42 peptide solutions pre-incubated with different concentrations of PO 147 were analysed by Jasco J-810 CD Spectropolarimeter (JASCO Inc., Easton, MD, USA) with computerised data collection. Ab 1-42 Oligomer solution was prepared as described in the methods. Oligomeric Abl-42 (0.05mg/ml) was incubated with P0147 sub-fractions spe40 and spelOO, at 0.005, 0.05 & 0.25 mg/ml, respectively in MiIIiQ water. The mean residue ellipticities of samples were recorded across the far UV range of 190-260 nm wavelength using a 0.1 cm path-length quartz cuvette, at room temperature, monitoring at 0.1 nm intervals. The acquisition parameters were 100 nm/min with 1 sec response times, 1.0 nm bandwidth, and 0.1 nm data pitch, and data sets were averaged over 3 scans. Spectra of P0147 fractions alone at the appropriate experimental concentration were subtracted from respective profiles of Ab 1-42 +P0147, but were otherwise unsmoothed. The instrument was calibrated with deionised water (MiIIiQ).
SDS-PAGE electrophoresis and Western Blot Analysis
Aβ42 peptide solutions pre-incubated with different concentrations of PO 147 fractions. The samples were fractionated on a 4-12% Bis-Tris NuPage gel in a MES buffering system and visualized by 6E10 immunoblotting followed by TMB development.
Results
ThT -binding assay (Figure 7) and yeast toxicity results (Figure 8) revealed interesting dose-dependent capacity for modulation of Aβ fibril morphology and toxicity, respectively, by SPE40 and SPElOO (see Reverse Phase HPLC profiles of respective hydrolysate fractions, Figure 6), apparently driving self-assembly progressively from relatively more toxic to less toxic forms of Aβ42. The suppression of ThT binding by dairy peptides correlated with: loss of beta sheet absorbance by CD (Figure 9); suppression of oligomeric Aβ42 by Western blot with 6E10 antibody
(Figure 10) and disappearance of macroscopic fibril structures by TEM (Figure 11).
The modulation of Aβ42 self-assembly by dairy peptides, eliciting either potentiation or suppression of amyloid self-assembly, can assist in understanding the determinants of toxicity of self-assembled forms of Aβ42.
Example 17. Anti-inflammatory activity of Vegemite, Brewers and Bakers yeast products in whole blood
Materials and methods
Preparation of low molecular weight yeast fractions by hydrolysis
Peptide hydrolysates of brewer's and baker's yeasts were prepared as follows.
Dried Brewers yeast (Lotus Foods Pty Ltd, Cheltenham, Victoria, Australia) and dried Bakers yeast (Lowan Whole Foods, Glendenning, New South Wales, Australia) were dissolved or suspended at 10% total protein (w/w) in 10 mM tri-ethanolamine, 10% EtOH, pH 7.4 and maintained at pH 7.4 throughout the hydrolysis process. After rehydration, Glutaminase was added to a final concentration of 0.5% (w/w) and incubated with agitation at 500C for 1 hour. The enzymes Alcalase (0.5%, w/w), Corolase (0.5%, w/w) and Flavourzyme (0.5%, w/w) were subsequently introduced sequentially at 1 hr intervals at 500C. The final enzyme Trypsin (0.5%, w/w) was introduced to the mixture and incubated at 37°C for 17 hours (overnight). The enzymes were inactivated heating at 900C for 30 min, and the product cooled to 220C for at least 15 mins. The hydrolysates were dialysed and the permeate (regenerated cellulose membrane, 6-8 KDa MWCO) recovered and freeze dried.
Vegemite™ (Kraft Foods, Port Melbourne, Victoria, Australia) and Marmite™ (Australian Health and Nutrition Association Ltd, Berkley Vale, NSW, Australia) were obtained from local retail suppliers and Epicor® was purchased on-line (Vitamin research products, Carson City, USA).
Fractionation by solid phase extraction (SPE)
SPE fractions of the hydrolysate products and the yeast derived foods were obtained by dispersing the samples in water at a concentration of 100 mg/mL then centrifuging to remove insoluble matter. Supernatants were fractionated using Strata-X
33 μm polymeric reverse phase cartridges (500 mg/6 ml, Phenomenex). After washing with methanol and re-equilibrating with water, 5.0 ml of dissolved sample (100 mg/mL) was loaded and non-binding material eluted with a further 5.0 ml of water (designated wash sample). Bound fractions were subsequently eluted with two 5.0 ml aliquots of aqueous acetonitrile at increasing proportions of solvent, typically, 40 and
100%, under vacuum and designated 'SPE40, SPElOO for fractions eluted with 40% or
100% acetonitrile, respectively. For some of the work reported here, the 40% and
100% fractions were pooled then dried (designated 'SPE').
Whole blood Inflammation assay
An assay system utilising diluted blood was adapted from the protocol of Matalka (2003). Test samples were dispersed in 10% ethanol and filter sterilised by passing through 0.22 μm membranes then diluted in RPMI 1640 supplemented with 2 mM Glutamine, 100 U/mL Penicillin and 100 ug/mL streptomycin. Blood was obtained from healthy volunteers (into heparinised tubes) and diluted 1+9 with supplemented RPMI 1640 as above. An inflammatory state was initiated by the addition of 1 ug/mL Lipopolysaccharide (LPS) and 5 ug/mL phytohemeagglutinin (PHA). Diluted blood, LPS, PHA, and test compounds were incubated together in 24 well plates (total volume per well 2 mL) incubated for 2 or 3 days at 37°C, in a 5 % CO2 atmosphere.
Each test compound / concentration point was tested in two culture wells, each well being assayed in triplicate. Interleukin 10 (IL-10, 250 pg/mL) and Hydrocortisone (HC, 200 ng/mL) were used as a positive controls. Supernatants were removed at the conclusion of the culture period and stored at -800C until tested. Supernatants were tested for IFN-γ by ELISA using the Human IFN- γ DuoSet; DY28E (R&D systems, USA) as per instructions with a standard curve from 5000 to 5 pg/ml prepared by serial 1:2 dilutions of the supplied standard. Results for ELISAs were read at absorbance wavelengths 460 nm and 590 nm in an FL600 Fluorescence Microplate Reader (BioTek, USA) and the KC4 software (version 3.1, BioTek, USA).
Results
As distinct from a previous method of preparation of Brewers and bakers yeast hydrolysates (P0613, P0713), the revised method did not involve chromatographic fractionation and so the hydrolysate was not diluted in salt required for elution from the ion-exchange resin.
Basic compositional data obtained for the two yeast hydrolysate products were: Baker's yeast: BA0263 8.6%N 41.7%C 7.6%H 6.8% Ash.
Brewer's yeast: BR0263 8.5%N 41.4%C 7.6%H 8.1% Ash.
The assay was also revised from that used to test the P0613 and P0713 products.
In this assay, LPS activates the Toll Like Receptor 4 present on macrophages and monocytes and PHA activates phosphorylation of mitogen activated protein kinases (MAPK), stimulating the release of inflammatory cytokines including Tumour necrosis Factor-alpha (TNF-a) and Interferon -gamma (IFN-γ). Using both PHA and LPS activates the proliferation of both T-cells and B-cells respectively in assays used to investigate inflammation and immunomodulatory effects of compounds.
When tested without fractionation, neither Vegemite™ nor EpiCor® effected the production of IFN-γ in the assay (Figure 12b). In contrast, the SPE fractions generated a strong effect with considerable suppression of IFN-γ production (Figure 12a and 12b). The level of suppression was similar in magnitude to both positive controls used in the test; hydrocortisone and Interlukin-10. It is noted that there was some donor to donor variation in the response. The EpiCor® SPE fractions showed the strongest and most consistent effect followed by the Brewer's 0263 SPE fraction.
Dose response curves were evaluated for the total SPE fractions of each of the four samples (Figure 13). Each of the fractions exhibited a dose response effect with almost complete inhibition of IFN-γ production at 2000 μg/mL. The differences between samples were most pronounced at 20 μg/mL. The SPE fractions of unadulterated Vegemite, and processed forms of Brewers and Bakers yeast exhibited comparable, although slightly inferior specific activity to Epicor suggesting that the processing methods applied to Brewers and Bakers yeast recovered bioactive components of similar activity to those in Epicor.
It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
All publications discussed and/or referenced herein are incorporated herein in their entirety.
The present application claims priority from AU 2009903698 and AU 2009903699 filed 7 August 2009, the entire contents of which are incorporated herein by reference.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.
REFERENCES
Bagrianstev et al. (2006) Methods Enzymol, 412:33-48.
Bayly et al. (2001) FEMS Microbiol Lett, 204:387-390.
Bennett et al. (2009) Australian Journal of Dairy Technology, 64: 117-121. Berbaum et al. (2008) Cytokine, 41 : 198-203.
Bharadwaj et al. (2008) J Alzheimers Dis, 13: 147-150.
Borden and Leonhardt (1977) J Lab Clin Med, 89:1036-1042.
Caine et al. (2007) FEMS Yeast Res, 7: 1230-1236.
Carver et al. (2010) Bioorg Med Chem, 18:222-228.
Cushman and Cheung (1971). Biochem. Pharmacol, 20: 1637-1648.
Del Carmen Caro et al. (1998) Life Sci, 62:51-57.
Fox et al. (1982) J Assoc Off Anal Chem, 65:690-695.
Gutcher and Becher (2007) J Clin Invest, 117: 1119-1127.
Harjanne (1984) Clin Chem. 30:901-902.
Leifert et al. (2009) Methods MoI Biol, 552: 131-141.
Matalka (2003) Cytokine, 21: 187-194.
Rathmell et al. (2001) J Immunol, 167:6869-6876.
Shanmugam et al. (2008) MoI Nutr Food Res, 52:427-438.
Schechter et al. (1973) Biochem, 12:3407-3413
Takahashi et al. (2002) Neurochem Int, 40:441-448.
Vanderheiden et al. (1970) Appl Microbiol, 19:875.
Claims
1. A process for obtaining a peptide fraction, the process comprising:
i) contacting a protein substrate with a series of enzymes selected from:
a) glutaminase, subtilisin, oryzin, leucyl aminopeptidase, and trypsin, b) glutaminase, oryzin, subtilisin, leucyl aminopeptidase, and trypsin, c) glutaminase, subtilisin, leucyl aminopeptidase, oryzin, and trypsin, d) glutaminase, oryzin, leucyl aminopeptidase, subtilisin, and trypsin, e) glutaminase, leucyl aminopeptidase, oryzin, subtilisin, and trypsin, and f) glutaminase, leucyl aminopeptidase, subtilisin, oryzin, and trypsin, ii) selecting peptides obtained from step i) which are less than about 11 kDa.
2. A process for obtaining a peptide fraction, the process comprising:
i) contacting a protein substrate with a series of enzymes selected from:
a) trypsin, subtilisin, oryzin, leucyl aminopeptidase, and glutaminase, b) trypsin, subtilisin, leucyl aminopeptidase, oryzin, and glutaminase, c) trypsin, oryzin, subtilisin, leucyl aminopeptidase, and glutaminase, d) trypsin, oryzin, leucyl aminopeptidase, subtilisin, and glutaminase, e) trypsin, leucyl aminopeptidase, oryzin, subtilisin, and glutaminase, and f) trypsin, leucyl aminopeptidase, subtilisin, oryzin, and glutaminase, ii) selecting peptides obtained from step i) which are less than about 11 kDa.
3. The process of claim 1, wherein step i) comprises contacting the protein substrate with a series of enzymes selected from:
a) glutaminase, subtilisin, oryzin, leucyl aminopeptidase, and trypsin, b) glutaminase, oryzin, subtilisin, leucyl aminopeptidase, and trypsin, and c) glutaminase, leucyl aminopeptidase, oryzin, subtilisin, and trypsin.
4. The process of any one of claims 1 to 3, wherein the process further comprises: iii) separating the peptides which are less than about 11 kDa into one or more of cation, anion and/or neutral peptide fractions.
5. The process of claim 4, wherein the peptides are separated into one or more of cation, anion and/or neutral peptide fractions by ion-exchange chromatography.
6. The process of claim 5, wherein the ion-exchange chromatography is performed using cation and anion exchange columns in series.
7. The process of claim 5 or claim 6, wherein the ion-exchange chromatography is performed at about pH 6.0 to about 8.0.
8. The method of claim 7, wherein the ion-exchange chromatography is performed at about pH 7.4
9. The process of any one of claims 1 to 8, wherein the step ii) is performed by dialysis, membrane filtration or size-exclusion chromatography.
10. The process of any one of claims 1 to 9, wherein the protein substrate is a protein-rich extract.
11. The process of claim 10, wherein the protein-rich extract is a milk extract, meat extract, plant extract, yeast extract and/or bacterial extract.
12. The process of any one of claims 1 to 11, wherein the protein substrate has been high pressure treated prior to contacting the protein substrate with the series of enzymes.
13. The process of any one of claims 1 to 12, wherein the process further comprises isolating one or more peptides from the peptide fraction.
14. The process of any one of claims 1 to 13 further comprising testing the peptide fraction and/or isolated peptide for biological activity.
15. A peptide fraction obtained by the process of any one of claims 1 to 14.
16. The peptide fraction of claim 15 which is a cation peptide fraction at about pH
7.4.
17. A composition comprising the peptide fraction of claim 15 or claim 16.
18. Use of the peptide fraction of claim 15 or claim 16 or the composition of claim 17 in the manufacture of a food or drink product.
19. The use of claim 18, wherein the food or drink product is a nutritional supplement.
20. A food or drink product comprising the peptide fraction of claim 15 or claim 16 or the composition of claim 17.
21. Use of the peptide fraction of claim 15 or claim 16 or the composition of claim 17 in the manufacture of a medicament for the treatment or prevention of disease in a subject.
22. A method for the treatment or prevention of disease in a subject, the method comprising administering to the subject the peptide fraction of claim 15 or claim 16 or the composition of claim 17.
23. The use of claim 21 or method of claim 22, wherein the disease is selected from cardiovascular disease, cancer, inflammatory or autoimmune disease, and/or a neurological disorder.
24. The use or method of claim 23, wherein the cardiovascular disease is hypertension, atherosclerosis and/or arteriosclerosis.
25. The use or method of claim 23, wherein the cancer is selected from carcinoma, lymphoma, blastoma, sarcoma, and leukemia.
26. The use or method of claim 23, wherein the inflammatory or autoimmune disease is selected from asthma, rheumatoid arthritis, inflammatory bowel disease, psoriasis and multiple sclerosis.
27. The use or method of claim 23, wherein the neurological disorder is selected from Alzheimer's disease, Parkinson's disease, dementia, Huntington's disease, Shy- Drager syndrome, progressive supranuclear palsy, Lewy body disease and amyotrophic lateral sclerosis.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009903699A AU2009903699A0 (en) | 2009-08-07 | Process for obtaining peptide fractions | |
AU2009903698 | 2009-08-07 | ||
AU2009903698A AU2009903698A0 (en) | 2009-08-07 | Process for obtaining peptide fractions | |
AU2009903699 | 2009-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011014925A1 true WO2011014925A1 (en) | 2011-02-10 |
Family
ID=43543825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2010/000994 WO2011014925A1 (en) | 2009-08-07 | 2010-08-06 | Process for obtaining peptide fractions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011014925A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2725105A1 (en) * | 2011-06-24 | 2014-04-30 | Calpis Co., Ltd. | Enzymatic production method for brain-function-improving peptides |
CN104736552A (en) * | 2012-08-24 | 2015-06-24 | 庆熙大学校产学协力团 | Pharmaceutical composition comprising, as active ingredients, peptides which exhibit inhibitory activity against angiotensin-I converting enzyme for preventing or treating cardiovascular diseases |
US10226422B2 (en) | 2013-01-23 | 2019-03-12 | Bottled Science Limited | Skin enhancing beverage composition |
CN111154823A (en) * | 2020-01-13 | 2020-05-15 | 山西原生肽科技有限公司 | Millet active peptide and preparation method and application thereof |
US20210045419A1 (en) * | 2018-02-20 | 2021-02-18 | University Of Manitoba | Food Protein-Derived Peptides as Bitter Taste Blockers |
CN113943346A (en) * | 2021-10-14 | 2022-01-18 | 中国科学院海洋研究所 | Spirulina antihypertensive peptide and application thereof |
-
2010
- 2010-08-06 WO PCT/AU2010/000994 patent/WO2011014925A1/en active Application Filing
Non-Patent Citations (3)
Title |
---|
CLEMENTE, A.: "Enzymatic Protein Hydrolysates in Human Nutrition", TRENDS IN FOOD SCIENCE & TECHNOLOGY, vol. 11, 2000, pages 254 - 262, XP055296932 * |
RAGHUNATH M. ET AL.: "Release ofPeptides & Amino Acids from Dietary Proteins during Sequential Enzymatic Digestion in vitro with Pepsin, Pancreatin + Trypsin & Erepsin", FOOD CHEMISTRY, vol. 15, 1984, pages 285 - 306 * |
WANG S ET AL.: "Neuroprotective Activities of Enzymatically Hydrolysed Peptides from Porcine Hyde Gelatin", INT J CLIN EXP MED, vol. 1, 2008, pages 283 - 293 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2725105A1 (en) * | 2011-06-24 | 2014-04-30 | Calpis Co., Ltd. | Enzymatic production method for brain-function-improving peptides |
EP2725105A4 (en) * | 2011-06-24 | 2015-02-25 | Calpis Co Ltd | Enzymatic production method for brain-function-improving peptides |
CN104736552A (en) * | 2012-08-24 | 2015-06-24 | 庆熙大学校产学协力团 | Pharmaceutical composition comprising, as active ingredients, peptides which exhibit inhibitory activity against angiotensin-I converting enzyme for preventing or treating cardiovascular diseases |
CN104736552B (en) * | 2012-08-24 | 2018-04-06 | 庆熙大学校产学协力团 | For prevent or treat angiocardiopathy, comprising pharmaceutical composition of the peptide as active component that inhibitory activity is shown to angiotensin i-converting enzyme |
US10226422B2 (en) | 2013-01-23 | 2019-03-12 | Bottled Science Limited | Skin enhancing beverage composition |
US20210045419A1 (en) * | 2018-02-20 | 2021-02-18 | University Of Manitoba | Food Protein-Derived Peptides as Bitter Taste Blockers |
CN111154823A (en) * | 2020-01-13 | 2020-05-15 | 山西原生肽科技有限公司 | Millet active peptide and preparation method and application thereof |
CN113943346A (en) * | 2021-10-14 | 2022-01-18 | 中国科学院海洋研究所 | Spirulina antihypertensive peptide and application thereof |
CN113943346B (en) * | 2021-10-14 | 2023-07-04 | 中国科学院海洋研究所 | Antihypertensive peptide of spirulina and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bhandari et al. | A review on bioactive peptides: Physiological functions, bioavailability and safety | |
Sánchez et al. | Bioactive peptides: A review | |
Kaur et al. | Recently isolated food-derived antihypertensive hydrolysates and peptides: A review | |
Santiago‐López et al. | Food‐derived immunomodulatory peptides | |
Connolly et al. | Characterisation of the in vitro bioactive properties of alkaline and enzyme extracted brewers' spent grain protein hydrolysates | |
Capriotti et al. | Identification of potential bioactive peptides generated by simulated gastrointestinal digestion of soybean seeds and soy milk proteins | |
Saleh et al. | Recent research in antihypertensive activity of food protein-derived hydrolyzates and peptides | |
Liu et al. | Purification and identification of an ACE inhibitory peptide from walnut protein | |
Hayes et al. | Boarfish protein recovery using the pH-shift process and generation of protein hydrolysates with ACE-I and antihypertensive bioactivities in spontaneously hypertensive rats | |
Jacquot et al. | Proliferative effects of synthetic peptides from β-lactoglobulin and α-lactalbumin on murine splenocytes | |
CN101305017B (en) | Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same | |
Jrad et al. | Antioxidant activity of camel milk casein before and after in vitro simulated enzymatic digestion | |
WO2011014925A1 (en) | Process for obtaining peptide fractions | |
Ozuna et al. | Cucurbitaceae seed protein hydrolysates as a potential source of bioactive peptides with functional properties | |
MX2022005412A (en) | Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins. | |
Voss et al. | Impact of thermal treatment and hydrolysis by Alcalase and Cynara cardunculus enzymes on the functional and nutritional value of Okara | |
WO2011152330A1 (en) | Soybean protein hydrolysate-containing antioxidant and use thereof | |
Eckert et al. | Biologically active peptides derived from egg proteins | |
Murtaza et al. | Conventional and novel technologies in the production of dairy bioactive peptides | |
Tapal et al. | In vitro human gastro-intestinal enzyme digestibility of globulin isolate from oil palm (Elaeis guineensis var. tenera) kernel meal and the bioactivity of the digest | |
Singh et al. | Peptide enriched functional food adjunct from soy whey: a statistical optimization study | |
Sansi et al. | In vitro biosafety and bioactivity assessment of the goat milk protein derived hydrolysates peptides | |
Xu et al. | Isolation, identification, and characterization of corn-derived antioxidant peptides from corn fermented milk by Limosilactobacillus fermentum | |
JP2004155751A (en) | Peptide useful for oral immunonutritional therapy in bioinvasion | |
Patil et al. | Biofunctional properties of milk protein derived bioactive peptides-A review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10805890 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10805890 Country of ref document: EP Kind code of ref document: A1 |